Niraparib Maintenance Therapy in Platinum-Sensitive,

New England Journal of Medicine
375, 2154-2164
DOI: 10.1056/nejmoa1611310

Citation Report

#	Article	IF	Citations
1	Biomarkers come of age: PD1 in the frontline and cell cycle therapy swells the ranks of personalised therapy in the European Society of Medical Oncology (ESMO) congress, Copenhagen, 7â€“10 October 2016. Ecancermedicalscience, 2016, 10, 703.	0.6	0
2	Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment. International Journal of Molecular Sciences, 2016, 17, 2113.	1.8	165
3	Pharmacokinetic problems in peritoneal drug administration: an update after 20 years. Pleura and Peritoneum, 2016, 1, 183-191.	0.5	12
4	PARP Inhibitors in Ovarian Cancer Treatment. New England Journal of Medicine, 2016, 375, 2197-2198.	13.9	9
5	Annual Congress of the European Society for Medical Oncology (ESMO): Copenhagen, Denmark; 7â€“11 October 2016. Targeted Oncology, 2016, 11, 705-709.	1.7	0
6	Biomarkers of Response and Resistance to DNA Repair Targeted Therapies. Clinical Cancer Research, 2016, 22, 5651-5660.	3.2	116
7	Individualized Medicine in Ovarian Cancer: Are We There Yet?. Gynecologic Oncology, 2017, 144, 229-231.	0.6	0
8	A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers. Gynecologic Oncology, 2017, 144, 486-490.	0.6	47
10	PARP Inhibitors in Reproductive System Cancers: Current Use and Developments. Drugs, 2017, 77, 113-130.	4.9	44
11	Upregulation of the long non-coding RNA SPRY4-IT1 indicates a poor prognosis and promotes tumorigenesis in ovarian cancer. Biomedicine and Pharmacotherapy, 2017, 88, 529-534.	2.5	42
12	Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization. Clinical Cancer Research, 2017, 23, 4086-4094.	3.2	114
13	Niraparib in Recurrent Ovarian Cancer. New England Journal of Medicine, 2017, 376, 801-802.	13.9	19
14	Epidemiology and treatment patterns of epithelial ovarian cancer. Expert Review of Anticancer Therapy, 2017, 17, 427-437.	1.1	93
15	PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clinical Cancer Research, 2017, 23, 3711-3720.	3.2	710
16	Implementing Genome-Driven Oncology. Cell, 2017, 168, 584-599.	13.5	405
17	Poly(ADP-ribose) polymerase (PARP) inhibitors as treatment versus maintenance in ovarian carcinoma. Gynecologic Oncology, 2017, 146, 11-15.	0.6	2
18	PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the clinic. Critical Reviews in Oncology/Hematology, 2017, 114, 153-165.	2.0	37
19	Therapeutic targeting and patient selection for cancers with homologous recombination defects. Expert Opinion on Drug Discovery, 2017, 12, 565-581.	2.5	32

#	Article	IF	Citations
20	A new standard of care or just another option for patients with relapsed ovarian cancer?. Lancet Oncology, The, 2017, 18, 701-702.	5.1	0
21	Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes. Nature Genetics, 2017, 49, 856-865.	9.4	220
22	PARP inhibitors in ovarian cancer: evidence, experience and clinical potential. Therapeutic Advances in Medical Oncology, 2017, 9, 253-267.	1.4	78
23	Next-Generation Sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations. Journal of Neuro-Oncology, 2017, 133, 469-476.	1.4	25
24	Emerging therapies for breast cancer. Journal of Hematology and Oncology, 2017, 10, 98.	6.9	60
25	The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer. Expert Opinion on Drug Safety, 2017, 16, 687-696.	1.0	9
26	The role of biomarkers in the management of epithelial ovarian cancer. Expert Review of Molecular Diagnostics, 2017, 17, 577-591.	1.5	102
27	Ovarian cancer stem cells more questions than answers. Seminars in Cancer Biology, 2017, 44, 67-71.	4.3	128
28	Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2017, 18, 75-87.	5.1	975
29	Progress in PARP inhibitors beyond BRCA mutant recurrent ovarian cancer?. Lancet Oncology, The, 2017, 18, 8-9.	5.1	12
30	Genomic profiling of gynecologic cancers and implications for clinical practice. Current Opinion in Obstetrics and Gynecology, 2017, 29, 18-25.	0.9	5
31	Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance. International Journal of Clinical Oncology, 2017, 22, 611-618.	1.0	10
32	Drugging the Cancers Addicted to DNA Repair. Journal of the National Cancer Institute, 2017, 109, .	3.0	114
33	Targeting ATR in cancer medicine. Current Problems in Cancer, 2017, 41, 302-315.	1.0	43
34	Updates and current challenges in microRNA research for personalized medicine in ovarian cancer. Expert Opinion on Biological Therapy, 2017, 17, 927-943.	1.4	18
35	Targeting DNA damage response systems to impact cancer care. Current Problems in Cancer, 2017, 41, 247-250.	1.0	2
36	Treatment strategies for DNA repair-deficient prostate cancer. Expert Review of Clinical Pharmacology, 2017, 10, 889-898.	1.3	26
37	Pathogenesis and heterogeneity of ovarian cancer. Current Opinion in Obstetrics and Gynecology, 2017, 29, 26-34.	0.9	223

#	Article	IF	Citations
38	Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discovery, 2017, 7, 984-998.	7.7	310
39	Unravelling the biology of SCLC: implications for therapy. Nature Reviews Clinical Oncology, 2017, 14, 549-561.	12.5	336
40	MicroRNAâ€135aâ€3p as a promising biomarker and nucleic acid therapeutic agent for ovarian cancer. Cancer Science, 2017, 108, 886-896.	1.7	32
41	The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies. Cancer, 2017, 123, 1912-1924.	2.0	52
42	Development of PARP inhibitors in gynecological malignancies. Current Problems in Cancer, 2017, 41, 273-286.	1.0	13
44	Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. Clinical Cancer Research, 2017, 23, 4066-4076.	3.2	87
45	Using genetics to predict patient response to platinum-based chemotherapy. Expert Review of Precision Medicine and Drug Development, 2017, 2, 21-32.	0.4	7
46	Niraparib for the treatment of ovarian cancer. Expert Opinion on Pharmacotherapy, 2017, 18, 631-640.	0.9	35
47	PARP inhibitors: Synthetic lethality in the clinic. Science, 2017, 355, 1152-1158.	6.0	1,826
48	Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer. Investigational New Drugs, 2017, 35, 751-765.	1.2	24
49	The European Society for Medical Oncology (ESMO) Congress 2016: Highlights and summary of selected abstracts in gynecologic cancers. Gynecologic Oncology, 2017, 144, 8-10.	0.6	0
50	Targeted Therapies for Ovarian Cancer. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2017, 41, 139-152.	1.4	95
51	BRCA mutation genetic testing implications in the United States. Breast, 2017, 31, 224-232.	0.9	41
52	Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. Nature Reviews Clinical Oncology, 2017, 14, 284-296.	12.5	131
53	PARP inhibition â€" moving beyond BRCA-mutated disease. Nature Reviews Clinical Oncology, 2017, 14, 71-71.	12.5	2
54	Update on relapsed ovarian cancer treatment: from new consensus to daily clinical practice. Future Oncology, 2017, 13, 3-9.	1.1	10
55	Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer. Gynecologic Oncology, 2017, 147, 509-513.	0.6	32
56	Incorporating Biomarker Stratification into STAMPEDE: an Adaptive Multi-arm, Multi-stage Trial Platform. Clinical Oncology, 2017, 29, 778-786.	0.6	13

#	Article	IF	Citations
57	Optimizing treatment in recurrent epithelial ovarian cancer. Expert Review of Anticancer Therapy, 2017, 17, 1147-1158.	1.1	107
58	Niraparib in ovarian cancer: results to date and clinical potential. Therapeutic Advances in Medical Oncology, 2017, 9, 579-588.	1.4	29
59	Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer. Cancer Science, 2017, 108, 2213-2220.	1.7	22
60	Clear Cell Ovarian Cancer: Optimum Management and Prognosis Remain Hazy. Gynecologic Oncology, 2017, 147, 237-239.	0.6	3
61	Targeted Therapies in the Management of Ovarian Cancer: A Focus on Older Patients. Drugs and Aging, 2017, 34, 821-831.	1.3	4
62	Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2017, 18, 1637-1651.	5.1	233
63	Searching for new biomarkers in ovarian cancer patients: Rationale and design of a retrospective study under the Mermaid III project. Contemporary Clinical Trials Communications, 2017, 8, 167-174.	0.5	14
64	Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer. European Journal of Cancer, 2017, 86, 5-14.	1.3	49
65	The Role of Hereditary Factors in Ovarian Carcinoma. Clinical Obstetrics and Gynecology, 2017, 60, 728-737.	0.6	1
66	Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients. Seminars in Oncology, 2017, 44, 187-197.	0.8	76
67	Genetic epidemiology of ovarian cancer and prospects for polygenic risk prediction. Gynecologic Oncology, 2017, 147, 705-713.	0.6	69
68	PARP inhibitors: Clinical utility and possibilities of overcoming resistance. Gynecologic Oncology, 2017, 147, 695-704.	0.6	172
69	Reversion Mutations with Clinical Use of PARP Inhibitors: Many Genes, Many Versions. Cancer Discovery, 2017, 7, 937-939.	7.7	33
70	Co-targeting c-Met and DNA double-strand breaks (DSBs): Therapeutic strategies in BRCA-mutated gastric carcinomas. Biochimie, 2017, 142, 135-143.	1.3	10
71	PARP inhibitors for targeted treatment in ovarian cancer. Lancet, The, 2017, 390, 1929-1930.	6.3	30
72	Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2017, 390, 1949-1961.	6.3	1,261
73	Missed therapeutic and prevention opportunities in women with BRCAâ€mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature. Ca-A Cancer Journal for Clinicians, 2017, 67, 493-506.	157.7	58
74	PARP-1 serves as a novel molecular marker for hepatocellular carcinoma in a Southern Chinese Zhuang population. Tumor Biology, 2017, 39, 101042831770691.	0.8	14

#	Article	IF	Citations
75	Emerging Therapies in the Management of High-Grade Serous Ovarian Carcinoma: a Focus on PARP Inhibitors. Current Obstetrics and Gynecology Reports, 2017, 6, 207-218.	0.3	1
76	Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2017, 18, 1274-1284.	5.1	1,376
77	Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinumâ€free interval: Myth or reality?. Cancer, 2017, 123, 3450-3459.	2.0	48
79	To promote maintenance or treatment, is that the question?. Lancet Oncology, The, 2017, 18, 1151-1152.	5.1	1
80	The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna. ESMO Open, 2017, 2, e000166.	2.0	4
81	Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition. Cancer Chemotherapy and Pharmacology, 2017, 80, 861-867.	1.1	49
82	Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, e1137-e1141.	0.9	8
83	Phase 1 doseâ€escalation study of singleâ€agent veliparib in Japanese patients with advanced solid tumors. Cancer Science, 2017, 108, 1834-1842.	1.7	23
84	Veliparib Monotherapy to Patients With BRCA Germ Line Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer: A Phase I/II Study. International Journal of Gynecological Cancer, 2017, 27, 1842-1849.	1.2	33
85	CDK6 protects epithelial ovarian cancer from platinumâ€induced death via FOXO3 regulation. EMBO Molecular Medicine, 2017, 9, 1415-1433.	3.3	61
87	BRCA mutation in ovarian cancer: testing, implications and treatment considerations. Therapeutic Advances in Medical Oncology, 2017, 9, 519-531.	1.4	96
88	Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors. Clinical Cancer Research, 2017, 23, 6400-6410.	3.2	59
91	Characterization, Detection, and Treatment Approaches for Homologous Recombination Deficiency in Cancer. Trends in Molecular Medicine, 2017, 23, 1121-1137.	3.5	48
92	Metronomic cyclophosphamideâ€induced longâ€term remission after recurrent highâ€grade serous ovarian cancer: A case study. Molecular and Clinical Oncology, 2017, 7, 1130-1134.	0.4	3
93	Treatment of Recurrent Epithelial Ovarian Cancer. Comprehensive Gynecology and Obstetrics, 2017, , 243-265.	0.0	0
94	The immunopeptidomic landscape of ovarian carcinomas. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E9942-E9951.	3.3	152
96	Monogenic Diseases of DNA Repair. New England Journal of Medicine, 2017, 377, 1868-1876.	13.9	49
97	Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer. Taiwanese Journal of Obstetrics and Gynecology, 2017, 56, 713-714.	0.5	16

#	Article	IF	Citations
98	Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer. Annals of Surgical Oncology, 2017, 24, 3116-3123.	0.7	17
102	Niraparib: First Global Approval. Drugs, 2017, 77, 1029-1034.	4.9	126
103	Spotlight on landmark oncology trials: the latest evidence and novel trial designs. BMC Medicine, 2017, 15, 111.	2.3	3
104	Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature. Gynecologic Oncology Research and Practice, 2017, 4, 4.	3.6	106
105	Relevance of DNA damage repair in the management of prostate cancer. Current Problems in Cancer, 2017, 41, 287-301.	1.0	16
108	DNA Repair Defects for Therapy in Ovarian Cancer: The BRCA1/2 and PARP Inhibitor Story. Indian Journal of Gynecologic Oncology, 2017, 15, 65-75.	0.1	0
109	Germline Testing for Predisposition to Ovarian/Breast Cancer Should be Routinely Recommended in all Patients with Invasive Epithelial Ovarian Cancer. Indian Journal of Gynecologic Oncology, 2017, 15, 27-30.	0.1	0
110	How can molecular abnormalities influence our clinical approach. Annals of Oncology, 2017, 28, viii16-viii24.	0.6	37
111	New treatments in ovarian cancer. Annals of Oncology, 2017, 28, viii57-viii60.	0.6	45
112	Treatment of recurrent ovarian cancer. Annals of Oncology, 2017, 28, viii51-viii56.	0.6	200
113	Front-line therapy of advanced ovarian cancer: new approaches. Annals of Oncology, 2017, 28, viii46-viii50.	0.6	41
114	Recent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer. F1000Research, 2017, 6, 84.	0.8	16
115	Synthetic lethality between the cohesin subunits STAG1 and STAG2 in diverse cancer contexts. ELife, 2017, 6, .	2.8	94
116	Major clinical research advances in gynecologic cancer in 2016: 10-year special edition. Journal of Gynecologic Oncology, 2017, 28, e45.	1.0	24
117	Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer. OncoTargets and Therapy, 2017, Volume 10, 3029-3037.	1.0	49
118	Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials. Drug Design, Development and Therapy, 2017, Volume 11, 3009-3017.	2.0	78
120	PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs. International Journal of Molecular Sciences, 2017, 18, 2111.	1.8	53
121	Molecular Basis of PARP Inhibition and Future Opportunities in Ovarian Cancer Therapy. , 2017, , 129-150.		0

#	Article	IF	Citations
122	Radiation Treatment in Women with Ovarian Cancer: Past, Present, and Future. Frontiers in Oncology, 2017, 7, 177.	1.3	59
123	Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors. Cancers, 2017, 9, 109.	1.7	36
124	The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer. International Journal of Molecular Sciences, 2017, 18, 210.	1.8	20
125	Current status of poly(ADP-ribose) polymerase inhibitors and future directions. OncoTargets and Therapy, 2017, Volume 10, 5195-5208.	1.0	96
126	Systemic Therapy for Recurrent Epithelial Ovarian Cancer: A Clinical Practice Guideline. Current Oncology, 2017, 24, 540-546.	0.9	13
127	Role and clinical application of next-generation sequencing (NGS) for ovarian cancer. Journal of Gynecologic Oncology, 2017, 28, e51.	1.0	3
128	Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer. OncoTargets and Therapy, 2017, Volume 10, 2539-2551.	1.0	45
129	Emerging treatment options for ovarian cancer: focus on rucaparib . International Journal of Women's Health, 2017, Volume 9, 913-924.	1.1	19
130	Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer. PLoS ONE, 2017, 12, e0174300.	1.1	11
131	Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?. Gynecologic Oncology Research and Practice, 2017, 4, 13.	3.6	26
132	PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers. Gynecologic Oncology Research and Practice, 2017, 4, 18.	3.6	42
133	Germline Testing for Predisposition to Breast/Ovarian Cancer Should Only be Offered to Selected Patients with Epithelial Ovarian Cancer. Indian Journal of Gynecologic Oncology, 2017, 15, 31-36.	0.1	0
134	Using genetics to develop new treatment possibilities for ovarian cancer. International Journal of Endocrine Oncology, 2017, 4, 59-62.	0.4	0
135	Olaparib and somatic BRCA mutations. Oncotarget, 2017, 8, 43598-43599.	0.8	11
136	Homologous Recombination Deficiency in Breast Cancer: A Clinical Review. JCO Precision Oncology, 2017, 1, 1-13.	1.5	50
137	Maintenance Poly (ADP-ribose) Polymerase Inhibitor Therapy for Ovarian Cancer: Precision Oncology or One Size Fits All?. Journal of Clinical Oncology, 2017, 35, 3999-4002.	0.8	14
138	Understanding Exceptional Responses to Poly (ADP-ribose) Polymerase Inhibition in Sporadic Ovarian Cancer. Journal of Clinical Oncology, 2017, 35, 1151-1153.	0.8	2
139	Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies. Oncotarget, 2017, 8, 69105-69124.	0.8	101

#	Article	IF	Citations
140	A Genomically Characterized Collection of High-Grade Serous Ovarian Cancer Xenografts for Preclinical Testing. American Journal of Pathology, 2018, 188, 1120-1131.	1.9	23
141	The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others. Biomedicine and Pharmacotherapy, 2018, 99, 552-560.	2.5	32
142	Antiangiogenic therapies in ovarian cancer. Memo - Magazine of European Medical Oncology, 2018, 11, 18-26.	0.3	1
143	Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers. Current Treatment Options in Cardiovascular Medicine, 2018, 20, 18.	0.4	6
144	Use of Targeted Therapeutics in Epithelial Ovarian Cancer: A Review of Current Literature and Future Directions. Clinical Therapeutics, 2018, 40, 361-371.	1.1	41
145	Rucaparib: a new treatment option for ovarian cancer. Expert Opinion on Pharmacotherapy, 2018, 19, 765-771.	0.9	7
146	Representation of obese participants in obesity-related cancer randomized trials. Annals of Oncology, 2018, 29, 1582-1587.	0.6	20
147	Increased oxidative stress mediates the antitumor effect of PARP inhibition in ovarian cancer. Redox Biology, 2018, 17, 99-111.	3.9	58
148	Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas. Cell Reports, 2018, 23, 100-111.	2.9	60
149	Pharmacokinetic drug evaluation of niraparib for the treatment of ovarian cancer. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 543-550.	1.5	10
150	APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency. Molecular Cancer Therapeutics, 2018, 17, 1167-1176.	1.9	13
151	PARP inhibitors and breast cancer: highlights and hang-ups. Expert Review of Precision Medicine and Drug Development, 2018, 3, 83-94.	0.4	4
152	The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities. Gynecologic Oncology, 2018, 149, 214-220.	0.6	53
153	Comparison of Practice Guidelines, BRCAPRO, and Genetic Counselor Estimates to Identify Germline BRCA1 and BRCA2 Mutations in Pancreatic Cancer. Journal of Genetic Counseling, 2018, 27, 988-995.	0.9	6
154	Acquired resistance of phosphatase and tensin homologâ€deficient cells to poly(ADPâ€ribose) polymerase inhibitor and Araâ€C mediated by 53BP1 loss and SAMHD1 overexpression. Cancer Science, 2018, 109, 821-831.	1.7	19
155	The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer. Cancer Chemotherapy and Pharmacology, 2018, 81, 497-503.	1.1	20
156	Management of the toxicities of common targeted therapeutics for gynecologic cancers. Gynecologic Oncology, 2018, 148, 591-600.	0.6	23
158	Management of QT prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for different drugs. Cancer Treatment Reviews, 2018, 63, 135-143.	3.4	56

#	Article	IF	Citations
159	TRACERx: Tracking tumor evolution to impact the course of lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 1199-1202.	0.4	14
160	Rucaparib for the treatment of ovarian cancer. Expert Opinion on Orphan Drugs, 2018, 6, 151-161.	0.5	0
161	Targeting DNA repair: the genome as a potential biomarker. Journal of Pathology, 2018, 244, 586-597.	2.1	41
162	Gynaecological neoplasms in common familial syndromes (Lynch and HBOC). Pathology, 2018, 50, 222-237.	0.3	23
163	Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer. Current Opinion in Obstetrics and Gynecology, 2018, 30, 7-16.	0.9	14
164	Advances in ovarian cancer therapy. Cancer Chemotherapy and Pharmacology, 2018, 81, 17-38.	1.1	393
165	The development of PARP as a successful target for cancer therapy. Expert Review of Anticancer Therapy, 2018, 18, 161-175.	1.1	16
166	Proteomic Analysis of the Downstream Signaling Network of PARP1. Biochemistry, 2018, 57, 429-440.	1.2	31
167	Multicenter Clinicopathological Study of High-Grade Serous Carcinoma Presenting as Primary Peritoneal Carcinoma. International Journal of Gynecological Cancer, 2018, 28, 657-665.	1.2	7
168	Reprogramming T-cells for adoptive immunotherapy of ovarian cancer. Expert Opinion on Biological Therapy, 2018, 18, 359-367.	1.4	5
169	High-grade Endometrioid Carcinoma of the Ovary. American Journal of Surgical Pathology, 2018, 42, 534-544.	2.1	34
170	Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer. Women's Health, 2018, 14, 174550571775069.	0.7	7
171	CCL2/CCL5 secreted by the stroma induce IL-6/PYK2 dependent chemoresistance in ovarian cancer. Molecular Cancer, 2018, 17, 47.	7.9	59
172	A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis. Gynecologic Oncology, 2018, 150, 23-30.	0.6	69
173	The Chemoprevention of Ovarian Cancer: the Need and the Options. Current Pharmacology Reports, 2018, 4, 250-260.	1.5	12
174	Genomic scar signatures associated with homologous recombination deficiency predict adverse clinical outcomes in patients with ovarian clear cell carcinoma. Journal of Molecular Medicine, 2018, 96, 527-536.	1.7	18
175	Expanding the pipeline. The 2018 Society of Gynecologic Oncology presidential address.. Gynecologic Oncology, 2018, 149, 435-438.	0.6	1
176	Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer. Cancer Treatment Reviews, 2018, 66, 7-14.	3.4	51

#	Article	IF	Citations
177	PARP inhibitors for homologous recombination-deficient prostate cancer. Expert Opinion on Emerging Drugs, 2018, 23, 123-133.	1.0	24
178	miR200-regulated CXCL12Î² promotes fibroblast heterogeneity and immunosuppression in ovarian cancers. Nature Communications, 2018, 9, 1056.	5.8	188
179	Transcriptional control of the MUC16 promoter facilitates follicle-stimulating hormone peptide-conjugated shRNA nanoparticle-mediated inhibition of ovarian carcinoma in vivo. Drug Delivery, 2018, 25, 797-806.	2.5	10
181	PARP (Poly(ADP-Ribose) Polymerase) Inhibitors in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis of Randomized Controlled Trials. Oncology Research and Treatment, 2018, 41, 226-234.	0.8	10
183	Helicase POLQ-like (HELQ) as a novel indicator of platinum-based chemoresistance for epithelial ovarian cancer. Gynecologic Oncology, 2018, 149, 341-349.	0.6	12
185	The Current Landscape of PARP Inhibitors in Ovarian Cancer. Current Obstetrics and Gynecology Reports, 2018, 7, 20-27.	0.3	2
186	BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. Cancer Cell, 2018, 33, 401-416.e8.	7.7	215
187	An Overview of Immune Checkpoint Inhibitors in Gynecologic Cancers. Clinical Therapeutics, 2018, 40, 372-388.	1.1	17
188	A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours. British Journal of Cancer, 2018, 118, 938-946.	2.9	29
189	Emerging growth factor receptor antagonists for ovarian cancer treatment. Expert Opinion on Emerging Drugs, 2018, 23, 1-16.	1.0	2
190	Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients. Cancer Chemotherapy and Pharmacology, 2018, 81, 39-46.	1.1	25
191	Location of Mutation in BRCA2 Gene and Survival in Patients with Ovarian Cancer. Clinical Cancer Research, 2018, 24, 326-333.	3.2	40
192	Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status. Cancer Treatment and Research Communications, 2018, 14, 7-12.	0.7	16
193	Cell-Cycle and DNA-Damage Response Pathway Is Involved in Leptomeningeal Metastasis of Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2018, 24, 209-216.	3.2	47
195	Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clinical and Translational Oncology, 2018, 20, 274-285.	1.2	5
196	Development of Peritoneal Carcinomatosis in Epithelial Ovarian Cancer: A Review. Journal of Histochemistry and Cytochemistry, 2018, 66, 67-83.	1.3	92
197	Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma. Gynecologic Oncology, 2018, 148, 281-285.	0.6	52
198	PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. Oncogene, 2018, 37, 341-351.	2.6	98

#	Article	IF	Citations
199	Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. Clinical Cancer Research, 2018, 24, 777-783.	3.2	171
200	Drug development in the era of precision medicine. Nature Reviews Drug Discovery, 2018, 17, 183-196.	21.5	294
201	Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients. Gynecologic Oncology, 2018, 148, 79-85.	0.6	29
202	Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology. Annual Review of Medicine, 2018, 69, 319-331.	5.0	61
203	Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. Cancer Discovery, 2018, 8, 49-58.	7.7	275
204	Prevalence of Homologous Recombinationâ€"Related Gene Mutations Across Multiple Cancer Types. JCO Precision Oncology, 2018, 2018, 1-13.	1.5	215
205	A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models. Oncotarget, 2018, 9, 37080-37096.	0.8	108
206	Moving From Mutation to Actionability. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 495-503.	1.8	4
207	The Winds of Change: Emerging Therapeutics in Prostate Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 382-390.	1.8	2
208	Low ATM expression and progression-free and overall survival in advanced gastric cancer patients treated with first-line XELOX chemotherapy. Journal of Gastrointestinal Oncology, 2018, 9, 1198-1206.	0.6	6
209	Ovarian Cancer Overview: Molecular Biology and Its Potential Clinical Application. , 0, , .		1
210	Precision Trial Drawer, a Computational Tool to Assist Planning of Genomics-Driven Trials in Oncology. JCO Precision Oncology, 2018, 2, 1-16.	1.5	2
211	Inherited gynaecological cancers. Current Opinion in Oncology, 2018, 30, 317-322.	1.1	0
213	Reversal of Bowel Obstruction With Platinum-Based Chemotherapy and Olaparib in Recurrent, Short Platinum-Free Interval, RAD51C Germline Mutationâ€"Associated Ovarian Cancer. JCO Precision Oncology, 2018, 2, 1-8.	1.5	5
214	PIPAC-OV3: A multicenter, open-label, randomized, two-arm phase III trial of the effect on progression-free survival of cisplatin and doxorubicin as Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) vs. chemotherapy alone in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. Pleura and Peritoneum, 2018, 3, 20180114.	0.5	27
215	Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines. Cell Reports, 2018, 25, 2617-2633.	2.9	74
216	Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 1219-1228.	0.5	30
217	Clinical Utility of Poly (ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer. Journal of Cancer Science & Therapy, 2018, 10, .	1.7	0

#	Article	IF	Citations
218	Targeted treatment of advanced ovarian cancer: spotlight on rucaparib. Therapeutics and Clinical Risk Management, 2018, Volume 14, 2189-2201.	0.9	8
219	PARPâ€1 regulates DNA repair factor availability. EMBO Molecular Medicine, 2018, 10, .	3.3	52
220	Non-Coding Variants in BRCA1 and BRCA2 Genes: Potential Impact on Breast and Ovarian Cancer Predisposition. Cancers, 2018, 10, 453.	1.7	14
221	Management and Treatment of Recurrent Epithelial Ovarian Cancer. Hematology/Oncology Clinics of North America, 2018, 32, 965-982.	0.9	40
222	Living Through Ovarian Cancer Treatment. Hematology/Oncology Clinics of North America, 2018, 32, 1073-1085.	0.9	4
223	Currently Approved Poly (Adenosine Diphosphate-Ribose) Inhibitors in Ovarian Cancer: Current Status and Future Directions. Clinical Cancer Drugs, 2018, 5, 3-12.	0.3	0
224	Epithelial Tumors of the Ovary. , 2018, , 1-128.		0
225	Implementing a comprehensive translational oncology platform: from molecular testing to actionability. Journal of Translational Medicine, 2018, 16, 358.	1.8	35
226	Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors. Cancers, 2018, 10, 487.	1.7	154
228	Development of PARP and Immune-Checkpoint Inhibitor Combinations. Cancer Research, 2018, 78, 6717-6725.	0.4	155
229	Current Clinical Application and Response Prediction Biomarkers of PARP Inhibitors. Current Pharmacogenomics and Personalized Medicine, 2018, 16, 108-117.	0.2	0
230	PARP Inhibitors in Ovarian Cancer. Recent Patents on Anti-Cancer Drug Discovery, 2018, 13, 392-410.	0.8	102
231	Are we ready for routine precision medicine? Highlights from the Milan Summit on Precision Medicine, Milan, Italy, 8â€“9 February 2018. Ecancermedicalscience, 2018, 12, 817.	0.6	3
232	PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer. Cell Reports, 2018, 25, 2972-2980.e5.	2.9	381
233	Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer. Current Treatment Options in Oncology, 2018, 19, 1.	1.3	49
234	Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer. Cancer Research, 2018, 78, 6691-6702.	0.4	36
235	Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nature Communications, 2018, 9, 3970.	5.8	192
236	Defective DNA repair in hereditary ovarian cancers: Implications for therapy. American Journal of Health-System Pharmacy, 2018, 75, 1697-1707.	0.5	4

#	Article	IF	Citations
237	A new promising way of maintenance therapy in advanced ovarian cancer: a comparative clinical study. BMC Cancer, 2018, 18, 904.	1.1	36
238	Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials. Drug Design, Development and Therapy, 2018, Volume 12, 3013-3019.	2.0	26
239	PARP inhibition in platinum-based chemotherapy: Chemopotentiation and neuroprotection. Pharmacological Research, 2018, 137, 104-113.	3.1	38
240	Maintenance PARP inhibitor therapy: is maintaining quality of life enough?. Lancet Oncology, The, 2018, 19, e504.	5.1	3
241	Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer. Obstetrics and Gynecology Science, 2018, 61, 352.	0.6	4
242	Role of DNA Repair in Carcinogenesis and Cancer Therapeutics. , 2018, , 363-363.		0
243	It's time to warm up to hyperthermic intraperitoneal chemotherapy for patients with ovarian cancer. Gynecologic Oncology, 2018, 151, 555-561.	0.6	29
244	Emerging PARP inhibitors for treating breast cancer. Expert Opinion on Emerging Drugs, 2018, 23, 211-221.	1.0	10
245	Cancer of the ovary, fallopian tube, and peritoneum. International Journal of Gynecology and Obstetrics, 2018, 143, 59-78.	1.0	205
246	Targeted therapy for gynecologic cancers: Toward the era of precision medicine. International Journal of Gynecology and Obstetrics, 2018, 143, 131-136.	1.0	17
247	Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. British Journal of Cancer, 2018, 119, 1075-1085.	2.9	133
248	Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer. The Enzymes, 2018, 44, 83-101.	0.7	18
249	A <scp>RAD</scp> 51 assay feasible in routine tumor samples calls <scp>PARP</scp> inhibitor response beyond <scp>BRCA</scp> mutation. EMBO Molecular Medicine, 2018, 10, .	3.3	169
250	Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes. British Journal of Cancer, 2018, 119, 1401-1409.	2.9	175
251	Low-grade Serous Ovarian Carcinoma. Geburtshilfe Und Frauenheilkunde, 2018, 78, 972-976.	0.8	27
252	Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management. Clinics, 2018, 73, e450s.	0.6	100
254	CDH1, DLEC1 and SFRP5 methylation panel as a prognostic marker for advanced epithelial ovarian cancer. Epigenomics, 2018, 10, 1397-1413.	1.0	14
255	Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer. British Journal of Cancer, 2018, 119, 1060-1066.	2.9	47

#	Article	IF	Citations
256	Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer. International Journal of Molecular Sciences, 2018, 19, 3249.	1.8	7
257	Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. New England Journal of Medicine, 2018, 379, 2495-2505.	13.9	1,854
258	Targeted therapy for ovarian cancer: the rapidly evolving landscape of PARP inhibitor use. Minerva Obstetrics and Gynecology, 2018, 70, 150-170.	0.5	19
259	Major clinical research advances in gynecologic cancer in 2017. Journal of Gynecologic Oncology, 2018, 29, e31.	1.0	19
260	The Era of PARP inhibitors in ovarian cancer: â€œClass Actionâ€•or not? A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2018, 131, 83-89.	2.0	37
261	Resurrection of PARP Inhibitors in Breast Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 1150-1156.	2.3	18
262	A contemporary review of male breast cancer: current evidence and unanswered questions. Cancer and Metastasis Reviews, 2018, 37, 599-614.	2.7	63
263	Recurrent ovarian cancer 8 months after induction and bevacizumab consolidation: rationale for using trabectedinÂ+Âpegylated liposomal doxorubicin in second line. Expert Review of Anticancer Therapy, 2018, 18, 13-17.	1.1	3
264	Biliary Tract Cancer: State of the Art and potential role of DNA Damage Repair. Cancer Treatment Reviews, 2018, 70, 168-177.	3.4	55
265	Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition. Cancer Treatment Reviews, 2018, 71, 1-7.	3.4	91
266	Surgical and Medical Management of Epithelial Ovarian Cancer. , 2018, , 884-904.		0
267	Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. Lancet Oncology, The, 2018, 19, 1360-1371.	5.1	61
268	Advances in the use of PARP inhibitor therapy for breast cancer. Drugs in Context, 2018, 7, 1-30.	1.0	101
269	Exploring the Role of Fallopian Ciliated Cells in the Pathogenesis of High-Grade Serous Ovarian Cancer. International Journal of Molecular Sciences, 2018, 19, 2512.	1.8	30
270	Involved-field radiation therapy for recurrent ovarian cancer: Results of a multi-institutional prospective phase II trial. Gynecologic Oncology, 2018, 151, 39-45.	0.6	25
271	Novel Systemic Treatments in High Grade Ovarian Cancer. , 0, , .		0
272	Genomic Copy Number Alterations in Serous Ovarian Cancer. , 2018, , .		0
274	PARPi related toxicities: do we need more appropriate instruments to evaluate it?. Annals of Oncology, 2018, 29, 1613-1616.	0.6	2

#	Article	IF	Citations
275	Safety and dose modification for patients receiving niraparib. Annals of Oncology, 2018, 29, 1784-1792.	0.6	125
276	New Therapies for Ovarian Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 632-635.	2.3	8
277	Challenges with biomarkers in cancer drug discovery and development. Expert Opinion on Drug Discovery, 2018, 13, 685-690.	2.5	28
278	Biomarkers for Homologous Recombination Deficiency in Cancer. Journal of the National Cancer Institute, 2018, 110, 704-713.	3.0	223
279	Molecular Targeted Therapy for Epithelial Ovarian Cancer. , 2018, , 153-166.		0
280	A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients. Clinical Cancer Research, 2018, 24, 4482-4493.	3.2	91
281	The role of niraparib for the treatment of ovarian cancer. Future Oncology, 2018, 14, 2565-2577.	1.1	10
282	Financial toxicity â€“ An overlooked side effect. Gynecologic Oncology, 2018, 150, 3-6.	0.6	17
283	Gynecologic Cancer. , 2018, , 121-178.		0
284	Synthetic lethal therapies for cancer: whatâ€™s next after PARP inhibitors?. Nature Reviews Clinical Oncology, 2018, 15, 564-576.	12.5	303
285	Validation and Implementation of BRCA1/2 Variant Screening in Ovarian Tumor Tissue. Journal of Molecular Diagnostics, 2018, 20, 600-611.	1.2	18
286	Personalising Treatment for High-Grade Serous Ovarian Carcinoma. Clinical Oncology, 2018, 30, 515-524.	0.6	16
287	Metastatic gynecologic malignancies: advances in treatment and management. Clinical and Experimental Metastasis, 2018, 35, 521-533.	1.7	11
288	Conceptual frameworks of synthetic lethality in clear cell carcinoma of the ovary (Review). Biomedical Reports, 2018, 9, 112-118.	0.9	2
289	DNA damage repair in ovarian cancer: unlocking the heterogeneity. Journal of Ovarian Research, 2018, 11, 50.	1.3	49
290	PARP Inhibitors in Epithelial Ovarian Cancer. Recent Patents on Anti-Cancer Drug Discovery, 2018, 13, 145-158.	0.8	35
291	One-Carbon Metabolism: Biological Players in Epithelial Ovarian Cancer. International Journal of Molecular Sciences, 2018, 19, 2092.	1.8	27
292	Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap. Journal of Medical Genetics, 2018, 55, 571-577.	1.5	33

#	Article	IF	Citations
293	Niraparib: A Review in Ovarian Cancer. Targeted Oncology, 2018, 13, 533-539.	1.7	15
294	Targeted Therapies for Pancreatic Cancer. Cancers, 2018, 10, 36.	1.7	69
295	Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591877848.	1.4	23
296	PARP Inhibitor Drugs in the Treatment of Breast, Ovarian, Prostate and Pancreatic Cancers: An Update of Clinical Trials. Current Drug Targets, 2018, 19, 21-37.	1.0	100
297	Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer. Npj Breast Cancer, 2018, 4, 16.	2.3	163
298	BRCA2 Loss-of-Function and High Sensitivity to Cisplatin-Based Chemotherapy in a Patient With a Pleomorphic Soft Tissue Sarcoma: Effect of Genomic Medicine. American Journal of the Medical Sciences, 2018, 356, 404-407.	0.4	5
299	Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. Lancet Oncology, The, 2018, 19, 1117-1125.	5.1	95
300	PARP inhibitors and quality of life in ovarian cancer. Lancet Oncology, The, 2018, 19, 1012-1014.	5.1	18
301	Recurrent loss of heterozygosity correlates with clinical outcome in pancreatic neuroendocrine cancer. Npj Genomic Medicine, 2018, 3, 18.	1.7	37
302	Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591878665.	1.4	105
303	Loss of MED12 Induces Tumor Dormancy in Human Epithelial Ovarian Cancer via Downregulation of EGFR. Cancer Research, 2018, 78, 3532-3543.	0.4	23
304	Sperm associated antigen 9 (SPAG9) a promising therapeutic target of ovarian carcinoma. Tumor Biology, 2018, 40, 101042831877365.	0.8	9
305	Biomarker Assessment of HR Deficiency, Tumor BRCA1/2 Mutations, and CCNE1 Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy. Molecular Cancer Research, 2018, 16, 1103-1111.	1.5	83
306	Epigenetic loss of heparan sulfate 3â€<scp>O</scp>â€sulfation sensitizes ovarian carcinoma to oncogenic signals and predicts prognosis. International Journal of Cancer, 2018, 143, 1943-1953.	2.3	11
307	Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer. Cell, 2018, 173, 1755-1769.e22.	13.5	261
308	When should Surgery be used for Recurrent Ovarian Carcinoma?. Clinical Oncology, 2018, 30, 493-497.	0.6	30
310	Latest clinical evidence and further development of PARP inhibitors in ovarian cancer. Annals of Oncology, 2018, 29, 1366-1376.	0.6	101
311	Inadequate Rates of BRCA Testing with its Negative Consequences for Women with Epithelial Ovarian Cancer and their Families: an Overview of the Literature. Clinical Oncology, 2018, 30, 472-483.	0.6	14

#	Article	IF	Citations
312	Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy. Drug Design, Development and Therapy, 2018, Volume 12, 1501-1509.	2.0	27
313	Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer. Drug Design, Development and Therapy, 2018, Volume 12, 605-617.	2.0	26
314	Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation. Expert Review of Anticancer Therapy, 2018, 18, 947-958.	1.1	5
315	The role of cancer stem cells and the therapeutic potential of TRX-E-002-1 in ovarian cancer. Expert Opinion on Orphan Drugs, 2018, 6, 465-475.	0.5	2
316	Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX. Clinical Cancer Research, 2018, 24, 6204-6211.	3.2	61
317	Pathology Consultation for the Gynecologic Oncologist: What the Surgeon Wants to Know. Archives of Pathology and Laboratory Medicine, 2018, 142, 1503-1508.	1.2	1
318	Functional Ex Vivo Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects. Clinical Cancer Research, 2018, 24, 6277-6287.	3.2	53
319	Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells. Medicines (Basel, Switzerland), 2018, 5, 16.	0.7	123
320	BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer. British Journal of Cancer, 2018, 119, 683-692.	2.9	29
321	Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease. Future Oncology, 2018, 14, 3101-3110.	1.1	10
322	Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRÎ±)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. Gynecologic Oncology, 2018, 151, 46-52.	0.6	48
323	A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Annals of Oncology, 2018, 29, 1895-1902.	0.6	424
324	BRCAness and prostate cancer: diagnostic and therapeutic considerations. Prostate Cancer and Prostatic Diseases, 2018, 21, 488-498.	2.0	12
325	Cardiovascular safety of oncologic agents: A double-edged sword even in the era of targeted therapies â€“ part 1. Expert Opinion on Drug Safety, 2018, 17, 875-892.	1.0	14
326	Cardiovascular safety of oncologic agents: a double-edged sword even in the era of targeted therapies â€“ Part 2. Expert Opinion on Drug Safety, 2018, 17, 893-915.	1.0	8
327	BRCA1/2 testing: therapeutic implications for breast cancer management. British Journal of Cancer, 2018, 119, 141-152.	2.9	142
328	PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey. Clinical Cancer Research, 2018, 24, 4062-4065.	3.2	31
329	Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal carcinomatosis: systematic review of clinical and experimental evidence with special emphasis on ovarian cancer. Archives of Gynecology and Obstetrics, 2018, 298, 243-257.	0.8	52

#	Article	IF	Citations
330	Emerging therapeutic modalities of PARP inhibitors in breast cancer. Cancer Treatment Reviews, 2018, 68, 62-68.	3.4	28
331	Maintenance treatment of recurrent ovarian cancer: Is it ready for prime time?. Cancer Treatment Reviews, 2018, 69, 53-65.	3.4	30
332	Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial. British Journal of Cancer, 2018, 119, 12-18.	2.9	9
333	Origins based clinical and molecular complexities of epithelial ovarian cancer. International Journal of Biological Macromolecules, 2018, 118, 1326-1345.	3.6	21
334	Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors. Annals of Oncology, 2018, 29, 1948-1954.	0.6	60
335	Niraparib for the treatment of ovarian cancer. Expert Review of Anticancer Therapy, 2018, 18, 727-733.	1.1	15
336	Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities. Trends in Cardiovascular Medicine, 2019, 29, 29-39.	2.3	43
337	PARP Inhibition to Enhance Response to Chemotherapy. , 2019, , 231-257.		1
338	Ovarian Carcinoma Histotype: Strengths and Limitations of Integrating Morphology With Immunohistochemical Predictions. International Journal of Gynecological Pathology, 2019, 38, 353-362.	0.9	45
339	Determination of interactions between human serum albumin and niraparib through multi-spectroscopic and computational methods. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2019, 206, 126-134.	2.0	36
340	Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Genetics in Medicine, 2019, 21, 213-223.	1.1	151
341	Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors. Oncologist, 2019, 24, 319-326.	1.9	29
342	Severe haematological toxicities in relapsed ovarian cancer treated with olaparib or niraparib: an Italian cost-minimization analysis. Global & Regional Health Technology Assessment, 2019, 2019, 228424031984394.	0.2	0
343	Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer. Cells, 2019, 8, 860.	1.8	34
344	Advances in the Management of Platinum-Sensitive Relapsed Ovarian Cancer. Journal of Clinical Oncology, 2019, 37, 2424-2436.	0.8	29
345	Update on Genetic Testing in Gynecologic Cancer. Journal of Clinical Oncology, 2019, 37, 2501-2509.	0.8	26
346	Immunotherapy in Ovarian Cancer: Are We There Yet?. Journal of Clinical Oncology, 2019, 37, 2460-2471.	0.8	73
347	A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24. Cancer Chemotherapy and Pharmacology, 2019, 84, 791-798.	1.1	17

#	Article	IF	Citations
348	Site-specific analysis of the Asp- and Glu-ADP-ribosylated proteome by quantitative mass spectrometry. Methods in Enzymology, 2019, 626, 301-321.	0.4	9
349	Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy. Translational Oncology, 2019, 12, 1386-1394.	1.7	7
350	Efficacy and pharmacodynamics of niraparib in BRCA-mutant and wild-type intracranial triple-negative breast cancer murine models. Neuro-Oncology Advances, 2019, 1, vdz005.	0.4	9
351	Evidence to date: talazoparib in the treatment of breast cancer . OncoTargets and Therapy, 2019, Volume 12, 5177-5187.	1.0	30
352	Overcoming Resistance to PARP Inhibition. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 161-189.	0.1	0
353	Adiponectin receptor agonist AdipoRon induces apoptotic cell death and suppresses proliferation in human ovarian cancer cells. Molecular and Cellular Biochemistry, 2019, 461, 37-46.	1.4	31
356	Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies. International Journal of Gynecological Cancer, 2019, 29, 956-968.	1.2	4
357	PARP-1 and its associated nucleases in DNA damage response. DNA Repair, 2019, 81, 102651.	1.3	122
358	Fallopian Tube Carcinoma. Journal of Oncology Practice, 2019, 15, 375-382.	2.5	28
359	The 34th Annual Meeting of the Korean Society of Gynecologic Oncology 2019: meeting report. Journal of Gynecologic Oncology, 2019, 30, e91.	1.0	5
360	Resistance to chemotherapy and anti-angiogenic therapy in ovarian cancer. Memo - Magazine of European Medical Oncology, 2019, 12, 144-148.	0.3	7
361	The Evolving Arena of Ovarian Cancer Maintenance Therapy. Oncology, 2019, 97, 202-205.	0.9	2
362	Activation of PARP-1 by snoRNAs Controls Ribosome Biogenesis and Cell Growth via the RNA Helicase DDX21. Molecular Cell, 2019, 75, 1270-1285.e14.	4.5	160
363	Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programme. European Journal of Cancer, 2019, 118, 156-165.	1.3	11
364	PARP inhibitors for BRCA wild type ovarian cancer; gene alterations, homologous recombination deficiency and combination therapy. Japanese Journal of Clinical Oncology, 2019, 49, 703-707.	0.6	27
365	Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors. International Journal of Molecular Sciences, 2019, 20, 3100.	1.8	32
366	Targeting DNA repair in breast cancer. Breast, 2019, 47, 33-42.	0.9	11
367	Pharmaceutical Management of Ovarian Cancer: Current Status. Drugs, 2019, 79, 1231-1239.	4.9	49

#	Article	IF	Citations
368	Poly(ADP-ribose) polymerase-1 antagonizes DNA resection at double-strand breaks. Nature Communications, 2019, 10, 2954.	5.8	122
369	Epithelial Tumors of the Ovary. , 2019, , 841-966.		10
370	Relationship between Microsatellite Instability, Immune Cells Infiltration, and Expression of Immune Checkpoint Molecules in Ovarian Carcinoma: Immunotherapeutic Strategies for the Future. International Journal of Molecular Sciences, 2019, 20, 5129.	1.8	19
371	Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status. Cancer Treatment Reviews, 2019, 80, 101909.	3.4	63
372	Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers. Gynecologic Oncology, 2019, 155, 262-269.	0.6	19
374	Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study. Gynecologic Oncology, 2019, 155, 400-405.	0.6	20
375	PARP Inhibition in Cancer: An Update on Clinical Development. Targeted Oncology, 2019, 14, 657-679.	1.7	133
376	Role of APD-Ribosylation in Bone Health and Disease. Cells, 2019, 8, 1201.	1.8	6
377	Comparison of PARPis with Angiogenesis Inhibitors and Chemotherapy for Maintenance in Ovarian Cancer: A Network Meta-Analysis. Advances in Therapy, 2019, 36, 3368-3380.	1.3	14
378	Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer. JAMA Oncology, 2019, 5, 1731.	3.4	150
380	Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives â€“ a review. Journal of Ovarian Research, 2019, 12, 103.	1.3	68
381	Real-world adverse events with niraparib 200 mg/day maintenance therapy in ovarian cancer: a retrospective study. Future Oncology, 2019, 15, 4197-4206.	1.1	15
382	Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. New England Journal of Medicine, 2019, 381, 1929-1939.	13.9	217
383	Pan-Cancer Analysis of Potential Synthetic Lethal Drug Targets Specific to Alterations in DNA Damage Response. Frontiers in Oncology, 2019, 9, 1136.	1.3	14
384	Mapping genetic interactions in cancer: a road to rational combination therapies. Genome Medicine, 2019, 11, 62.	3.6	16
385	Hopes and failures in front-line ovarian cancer therapy. Critical Reviews in Oncology/Hematology, 2019, 143, 14-19.	2.0	51
386	Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints. Expert Opinion on Investigational Drugs, 2019, 28, 771-785.	1.9	9
387	Real-World Impact of Survival by Period of Diagnosis in Epithelial Ovarian Cancer Between 1990 and 2014. Frontiers in Oncology, 2019, 9, 639.	1.3	31

#	Article	IF	Citations
388	PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib. Gynecologic Oncology, 2019, 155, 144-150.	0.6	28
389	Clinical efficacy of the optimal biological dose in early-phase trials of anti-cancer targeted therapies. European Journal of Cancer, 2019, 120, 40-46.	1.3	19
390	Targeting DNA Replication Stress and DNA Double-Strand Break Repair for Optimizing SCLC Treatment. Cancers, 2019, 11, 1289.	1.7	11
391	Olaparib maintenance for first-line treatment of ovarian cancer:Âwill SOLO1 reset the standard of care?. Future Oncology, 2019, 15, 1845-1853.	1.1	12
392	Olaparib in the treatment of ovarian cancer. Future Oncology, 2019, 15, 3435-3449.	1.1	13
393	Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. Lancet Oncology, The, 2019, 20, 1409-1419.	5.1	179
394	Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer. Frontiers in Oncology, 2019, 9, 1015.	1.3	42
395	Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes. Cancers, 2019, 11, 1373.	1.7	13
396	Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State. Targeted Oncology, 2019, 14, 505-525.	1.7	40
397	Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial. Journal of Clinical Oncology, 2019, 37, 3183-3191.	0.8	29
398	Prospects for combining immune checkpoint blockade with PARP inhibition. Journal of Hematology and Oncology, 2019, 12, 98.	6.9	92
399	Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. New England Journal of Medicine, 2019, 381, 2403-2415.	13.9	627
400	Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. New England Journal of Medicine, 2019, 381, 2391-2402.	13.9	1,337
401	Positron-Emission Tomographic Imaging of a Fluorine 18â€“Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patientâ€“Derived Xenografts. Journal of Thoracic Oncology, 2019, 14, 1743-1752.	0.5	14
402	Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. Cancer Chemotherapy and Pharmacology, 2019, 83, 717-726.	1.1	4
403	Prevalence of germline pathogenic BRCA1/2 variants in sequential epithelial ovarian cancer cases. Journal of Medical Genetics, 2019, 56, 301-307.	1.5	21
404	53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer. Gynecologic Oncology, 2019, 153, 127-134.	0.6	56
405	Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status. Journal of Ovarian Research, 2019, 12, 9.	1.3	83

#	Article	IF	Citations
406	Germline and Somatic Tumor Testing in Gynecologic Cancer Care. Obstetrics and Gynecology Clinics of North America, 2019, 46, 37-53.	0.7	8
407	Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas. International Journal of Cancer, 2019, 145, 1209-1220.	2.3	23
408	Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer. JAMA Oncology, 2019, 5, 393.	3.4	303
409	Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets. Molecular Cell, 2019, 73, 885-899.e6.	4.5	137
410	PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms. Journal of Cellular and Molecular Medicine, 2019, 23, 2303-2313.	1.6	103
411	Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil. BMC Cancer, 2019, 19, 4.	1.1	17
412	Secondary hematologic malignancies with poly adenosine diphosphate ribose polymerase inhibitors: Is the buzz real? -Insights from a meta-analysis of phase 3 randomized controlled trials. Journal of Geriatric Oncology, 2019, 10, 518-520.	0.5	2
413	Ovarian Cancer. Obstetrics and Gynecology Clinics of North America, 2019, 46, 67-88.	0.7	12
414	Chemotherapy, Biologic, and Immunotherapy Breakthroughs in Cancer Care. Obstetrics and Gynecology Clinics of North America, 2019, 46, 137-154.	0.7	3
415	PET Imaging of PARP Expression Using 18F-Olaparib. Journal of Nuclear Medicine, 2019, 60, 502-503.	2.8	2
416	Poly-ADP-ribosyl-polymerase inhibitor resistance mechanisms and their therapeutic implications. Current Opinion in Obstetrics and Gynecology, 2019, 31, 12-17.	0.9	7
417	Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives. Critical Reviews in Oncology/Hematology, 2019, 140, 67-72.	2.0	51
418	Chlorambucil targets <scp>BRCA</scp> 1/2â€deficient tumours and counteracts <scp>PARP</scp> inhibitor resistance. EMBO Molecular Medicine, 2019, 11, e9982.	3.3	26
419	Comparative efficacy of targeted maintenance therapy for newly diagnosed epithelial ovarian cancer: a network meta-analysis . Cancer Management and Research, 2019, Volume 11, 4119-4128.	0.9	2
420	Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591984975.	1.4	70
421	Cancer Genomics for Oncologists: Cancer Risk and Management of BRCA1 and BRCA2 Carriers. Current Genetic Medicine Reports, 2019, 7, 116-123.	1.9	0
422	The Role of Precision Medicine in the Diagnosis and Treatment of Patients with Rare Cancers. Cancer Treatment and Research, 2019, 178, 81-108.	0.2	2
423	A decade of clinical development of PARP inhibitors in perspective. Annals of Oncology, 2019, 30, 1437-1447.	0.6	437

#	Article	IF	Citations
424	Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making?. ESMO Open, 2019, 4, e000480.	2.0	47
425	Activation of Wnt signaling promotes olaparib resistant ovarian cancer. Molecular Carcinogenesis, 2019, 58, 1770-1782.	1.3	68
426	Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer. Lung Cancer, 2019, 134, 167-173.	0.9	9
427	Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. Oncotarget, 2019, 10, 3533-3546.	0.8	19
428	Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients. Gynecologic Oncology, 2019, 154, 420-425.	0.6	21
429	Liquid Biopsies for Ovarian Carcinoma: How Blood Tests May Improve the Clinical Management of a Deadly Disease. Cancers, 2019, 11, 774.	1.7	23
430	Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial. Journal of Clinical Oncology, 2019, 37, 2968-2973.	0.8	121
431	Comment on: â€œCost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United Statesâ€. Pharmacoeconomics, 2019, 37, 1065-1067.	1.7	6
432	A phase 1b dose escalation study of ipafricept (OMP 54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer. Gynecologic Oncology, 2019, 154, 294-301.	0.6	64
434	Ovarian cancer relapse: From the latest scientific evidence to the best practice. Critical Reviews in Oncology/Hematology, 2019, 140, 28-38.	2.0	31
435	Cellular determinants and therapeutic implications of inflammation in pancreatic cancer. , 2019, 201, 202-213.		50
436	Intraperitoneal (IP) port cytology after completion of primary therapy for advanced stage ovarian cancer: A novel approach to a â€œsecond lookâ€. Gynecologic Oncology, 2019, 154, 290-293.	0.6	2
437	Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence. Nature Communications, 2019, 10, 2556.	5.8	132
438	Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer. JAMA Oncology, 2019, 5, 1132.	3.4	285
439	Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. JAMA Oncology, 2019, 5, 1141.	3.4	355
440	PARP Inhibitors in Ovarian Cancer: The Route to â€œIthacaâ€. Diagnostics, 2019, 9, 55.	1.3	52
441	The current state of molecular testing in the treatment of patients with solid tumors, 2019. Ca-A Cancer Journal for Clinicians, 2019, 69, 305-343.	157.7	203
442	Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies. , 2019, 201, 94-102.		106

#	Article	IF	Citations
443	Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status. Gynecologic Oncology, 2019, 154, 144-149.	0.6	24
444	Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes. BMC Cancer, 2019, 19, 422.	1.1	22
445	Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer. Journal of Ovarian Research, 2019, 12, 40.	1.3	45
446	Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era. Genetics and Molecular Biology, 2019, 42, 215-231.	0.6	14
447	Current Systemic Treatment Landscape of Advanced Gynecologic Malignancies. Targeted Oncology, 2019, 14, 269-283.	1.7	8
448	The DNA Damaging Revolution: PARP Inhibitors and Beyond. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 185-195.	1.8	144
449	Wanna Get Away? Maintenance Treatments and Chemotherapy Holidays in Gynecologic Cancers. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, e152-e166.	1.8	12
450	Paclitaxel and Alisertib in Recurrent Ovarian Cancerâ€"In Reply. JAMA Oncology, 2019, 5, 910.	3.4	1
451	Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer . Cancer Management and Research, 2019, Volume 11, 4371-4390.	0.9	77
452	Enabling drug discovery for the PARP protein family through the detection of mono-ADP-ribosylation. Biochemical Pharmacology, 2019, 167, 97-106.	2.0	38
453	Veliparib: a new therapeutic option in ovarian cancer?. Future Oncology, 2019, 15, 1975-1987.	1.1	9
454	Epithelial ovarian cancer: Evolution of management in the era of precision medicine. Ca-A Cancer Journal for Clinicians, 2019, 69, 280-304.	157.7	821
455	Variant classification in precision oncology. International Journal of Cancer, 2019, 145, 2996-3010.	2.3	76
456	Gene expression differences between matched pairs of ovarian cancer patient tumors and patient-derived xenografts. Scientific Reports, 2019, 9, 6314.	1.6	33
457	ESMOâ€"ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Annals of Oncology, 2019, 30, 672-705.	0.6	665
458	ESMOâ€"ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. International Journal of Gynecological Cancer, 2019, 29, 728-760.	1.2	167
459	Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy. Journal of Clinical Oncology, 2019, 37, 2257-2269.	0.8	135
460	Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option. Annals of Oncology, 2019, 30, 721-732.	0.6	53

#	Article	IF	Citations
461	Ovarian Cancer Maintenance: Practiceâ€Changing Data Calls for Changing Practice. Oncologist, 2019, 24, 576-579.	1.9	0
462	Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer. International Journal of Biological Sciences, 2019, 15, 962-972.	2.6	10
463	Identifying disparities in germline and somatic testing for ovarian cancer. Gynecologic Oncology, 2019, 153, 297-303.	0.6	25
464	DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors. Cancer Cell, 2019, 35, 519-533.e8.	7.7	79
465	PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review. BioDrugs, 2019, 33, 255-273.	2.2	31
466	Womenâ€™s cancers: how the discovery of BRCA genes is driving current concepts of cancer biology and therapeutics. Ecancermedicalscience, 2019, 13, 904.	0.6	12
467	Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer, 2019, 125, 1963-1972.	2.0	39
468	Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions. Cells, 2019, 8, 200.	1.8	6
469	Poly (ADP-Ribose) Polymerase Inhibition for Chemotherapy-Induced Peripheral Neuropathy: A Meta-Analysis of Placebo-Controlled Trials. Journal of Palliative Medicine, 2019, 22, 977-980.	0.6	7
470	Developing a Prognostic Gene Panel of Epithelial Ovarian Cancer Patients by a Machine Learning Model. Cancers, 2019, 11, 270.	1.7	19
471	High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints. International Journal of Molecular Sciences, 2019, 20, 952.	1.8	381
472	Efficacy of pegylated liposomal doxorubicin maintenance therapy in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective study. Archives of Gynecology and Obstetrics, 2019, 299, 1641-1649.	0.8	5
473	Analysis of BRCAness with multiplex ligation-dependent probe amplification using formalin-fixed and paraffin-embedded pancreatic ductal adenocarcinoma tissue obtained via endoscopic ultrasound-guided fine-needle aspiration biopsy. Pancreatology, 2019, 19, 419-423.	0.5	3
474	Epithelial ovarian cancer. Lancet, The, 2019, 393, 1240-1253.	6.3	1,039
475	Emerging therapeutic targets for patients with advanced prostate cancer. Cancer Treatment Reviews, 2019, 76, 1-9.	3.4	26
476	MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer. EBioMedicine, 2019, 43, 225-237.	2.7	48
477	Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib. Future Oncology, 2019, 15, 1707-1715.	1.1	27
478	Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations. Cancers, 2019, 11, 416.	1.7	49

#	Article	IF	Citations
479	Therapeutic Targeting of Collective Invasion in Ovarian Cancer. International Journal of Molecular Sciences, 2019, 20, 1466.	1.8	47
480	Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer. Current Oncology Reports, 2019, 21, 42.	1.8	15
481	Olaparib and Î±-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncology, The, 2019, 20, 570-580.	5.1	191
482	Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer. Gynecologic Oncology, 2019, 152, 445-451.	0.6	3
483	Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome. Annals of Hematology, 2019, 98, 1383-1392.	0.8	9
484	2017â€“2018 Scientific Advances in Thoracic Oncology: Small Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 768-783.	0.5	44
485	New and Novel Therapies for Gynecologic Cancers. Seminars in Oncology Nursing, 2019, 35, 217-219.	0.7	10
486	Exploring the Frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types. Cancers, 2019, 11, 354.	1.7	12
487	Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score. Journal of Clinical Oncology, 2019, 37, 336-349.	0.8	101
488	Budget impact of niraparib as maintenance treatment in recurrent ovarian cancer following platinum-based chemotherapy. Journal of Comparative Effectiveness Research, 2019, 8, 577-587.	0.6	3
489	Expression of miRâ€‘26b in ovarian carcinoma tissues and its correlation with clinicopathology. Oncology Letters, 2019, 17, 4417-4422.	0.8	7
490	Subcellular compartmentalization of NAD+ and its role in cancer: A sereNADe of metabolic melodies. , 2019, 200, 27-41.		53
491	Rucaparib in the landscape of PARP inhibition in ovarian cancer. Expert Review of Anticancer Therapy, 2019, 19, 437-446.	1.1	2
492	Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883). Journal of Medical Genetics, 2019, 56, 574-580.	1.5	34
493	Detecting the mutational signature of homologous recombination deficiency in clinical samples. Nature Genetics, 2019, 51, 912-919.	9.4	209
494	Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 9008-9013.	3.3	108
495	Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncology, The, 2019, 20, 636-648.	5.1	366
496	Fighting against the challenge of treating patients with late-line ovarian cancer: are we there yet?. Lancet Oncology, The, 2019, 20, 603-605.	5.1	3

#	Article	IF	Citations
497	Determination of the DNA binding properties of a novel PARP inhibitor MK-4827 with calf-thymus DNA by molecular simulations and detailed spectroscopic investigations. New Journal of Chemistry, 2019, 43, 6702-6711.	1.4	10
498	The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer. International Journal of Gynecological Cancer, 2019, 29, 166-173.	1.2	17
499	PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers. Journal of Clinical Medicine, 2019, 8, 435.	1.0	106
500	ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers. Gynecologic Oncology, 2019, 153, 416-424.	0.6	26
501	Pharmacologic characterization of fluzoparib, a novel poly(<scp>ADP</scp>â€ribose) polymerase inhibitor undergoing clinical trials. Cancer Science, 2019, 110, 1064-1075.	1.7	61
502	Integrated structural variation and point mutation signatures in cancer genomes using correlated topic models. PLoS Computational Biology, 2019, 15, e1006799.	1.5	44
503	An Advanced Strategy for Comprehensive Profiling of ADP-ribosylation Sites Using Mass Spectrometry-based Proteomics*. Molecular and Cellular Proteomics, 2019, 18, 1010a-1026.	2.5	113
504	Combinatorial therapy of immune checkpoint and cancer pathways provides a novel perspective on ovarian cancer treatment (Review). Oncology Letters, 2019, 17, 2583-2591.	0.8	16
505	PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers. Clinical Cancer Research, 2019, 25, 3759-3771.	3.2	265
506	An oncoinformatics study to predict the inhibitory potential of recent FDA-approved anti-cancer drugs against human Polo-like kinase 1 enzyme: a step towards dual-target cancer medication. 3 Biotech, 2019, 9, 70.	1.1	3
507	The role of dePARylation in DNA damage repair and cancer suppression. DNA Repair, 2019, 76, 20-29.	1.3	7
508	Major clinical research advances in gynecologic cancer in 2018. Journal of Gynecologic Oncology, 2019, 30, e18.	1.0	29
510	Therapeutic implications of germline genetic findings in cancer. Nature Reviews Clinical Oncology, 2019, 16, 386-396.	12.5	39
511	Phase III trials in ovarian cancer: The evolving landscape of front line therapy. Gynecologic Oncology, 2019, 153, 436-444.	0.6	17
512	Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models. Scientific Reports, 2019, 9, 1853.	1.6	167
513	Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?. Oncologist, 2019, 24, 1469-1478.	1.9	25
514	Chemotherapy Toxicity in BRCA Mutation Carriers Undergoing Firstâ€Line Platinumâ€Based Chemotherapy. Oncologist, 2019, 24, e1471-e1475.	1.9	9
515	Treatment of recurrent epithelial ovarian cancer. Cancer, 2019, 125, 4609-4615.	2.0	49

#	Article	IF	Citations
516	Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date . OncoTargets and Therapy, 2019, Volume 12, 11497-11506.	1.0	21
517	Secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: are we missing something?. Annals of Translational Medicine, 2019, 7, S372-S372.	0.7	5
518	Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy. Oncologist, 2019, 24, 1340-1347.	1.9	73
519	Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety. International Journal of Gynecological Cancer, 2019, 29, 1396-1404.	1.2	19
520	Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity. Clinical Cancer Research, 2019, 25, 7517-7526.	3.2	34
521	Efficacy of PARP Inhibitors in the Treatment of Ovarian Cancer: A Literature-Based Review. Asian Journal of Oncology, 2019, 05, 01-18.	0.2	0
522	Synergistic clinical efficacy of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. Annals of Translational Medicine, 2019, 7, S308-S308.	0.7	0
524	Niraparib as maintenance therapy in a patient with ovarian cancer and brain metastases. BMJ Case Reports, 2019, 12, e230738.	0.2	18
525	Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents. Genome Biology, 2019, 20, 240.	3.8	82
526	Advances and perspectives of PARP inhibitors. Experimental Hematology and Oncology, 2019, 8, 29.	2.0	81
527	Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline BRCA mutations: OPINION Phase IIIb study design. Future Oncology, 2019, 15, 3651-3663.	1.1	9
528	Natural Products and Synthetic Analogs as a Source of Antitumor Drugs. Biomolecules, 2019, 9, 679.	1.8	117
529	Analysis of tumour ecological balance reveals resource-dependent adaptive strategies of ovarian cancer. EBioMedicine, 2019, 48, 224-235.	2.7	8
530	Preclinical Studies Comparing Efficacy and Toxicity of DNA Repair Inhibitors, Olaparib, and AsiDNA, in the Treatment of Carboplatin-Resistant Tumors. Frontiers in Oncology, 2019, 9, 1097.	1.3	13
531	Chemotherapy-free strategy for platinum-sensitive recurrent ovarian cancer. Lancet Oncology, The, 2019, 20, e654.	5.1	1
532	Is there a role for maintenance therapy after platinum chemotherapy in bladder cancer in the era of immune therapy?. Future Oncology, 2019, 15, 3877-3879.	1.1	0
533	Emerging serine-threonine kinase inhibitors for treating ovarian cancer. Expert Opinion on Emerging Drugs, 2019, 24, 239-253.	1.0	6
534	A view on drug resistance in cancer. Nature, 2019, 575, 299-309.	13.7	1,391

#	Article	IF	Citations
535	Germline and somatic mutations of homologous recombination-associated genes in Japanese ovarian cancer patients. Scientific Reports, 2019, 9, 17808.	1.6	38
536	Personalized Medicine for Primary Treatment of Serous Ovarian Cancer. New England Journal of Medicine, 2019, 381, 2471-2474.	13.9	27
537	Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. New England Journal of Medicine, 2019, 381, 2416-2428.	13.9	1,176
538	Poly(ADP-Ribose) Polymerase Inhibitors in Pancreatic Cancer: A New Treatment Paradigms and Future Implications. Cancers, 2019, 11, 1980.	1.7	29
539	Poly (ADP-ribose) polymerase inhibitors combined with other small-molecular compounds for the treatment of ovarian cancer. Anti-Cancer Drugs, 2019, 30, 554-561.	0.7	2
540	Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 399-406.	0.6	34
541	A Comprehensive Review of Ovarian Serous Carcinoma. Advances in Anatomic Pathology, 2019, 26, 329-339.	2.4	40
542	Maintenance Therapy in Metastatic Solid Tumors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 615-623.	0.6	4
543	Biomarkers in ovarian cancer: To be or not to be. Cancer, 2019, 125, 4563-4572.	2.0	38
544	Current role of poly(ADP-ribose) polymerase inhibitors. Current Opinion in Oncology, 2019, 31, 394-403.	1.1	2
545	U.S. Food and Drug Administrationâ€“Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer. Obstetrics and Gynecology, 2019, 133, 795-802.	1.2	28
546	Challenges in the identification of inherited risk of ovarian cancer: where should we go from here?. Gynecologic Oncology, 2019, 152, 3-6.	0.6	1
547	Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US. Journal of Medical Economics, 2019, 22, 187-195.	1.0	7
548	Undo the brake of tumour immune tolerance with antibodies, peptide mimetics and small molecule compounds targeting PDâ€1/PDâ€L1 checkpoint at different locations for acceleration of cytotoxic immunity to cancer cells. Clinical and Experimental Pharmacology and Physiology, 2019, 46, 105-115.	0.9	16
549	Exploring and comparing adverse events between PARP inhibitors. Lancet Oncology, The, 2019, 20, e15-e28.	5.1	287
550	Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1871, 199-224.	3.3	53
551	Update in the use and evaluation of poly (ADP-ribose) polymerase inhibitors in epithelial ovarian cancer: current and pending clinical research. Current Opinion in Obstetrics and Gynecology, 2019, 31, 4-11.	0.9	8
552	PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness. Cancer Research, 2019, 79, 311-319.	0.4	404

#	Article	IF	Citations
553	Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States. Pharmacoeconomics, 2019, 37, 391-405.	1.7	36
554	Novel treatment options in platinum-sensitive recurrent ovarian cancer: A review. Gynecologic Oncology, 2019, 152, 416-425.	0.6	31
555	Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas. Clinical Cancer Research, 2019, 25, 1087-1097.	3.2	113
556	PARP Trapping Beyond Homologous Recombination and Platinum Sensitivity in Cancers. Annual Review of Cancer Biology, 2019, 3, 131-150.	2.3	63
557	New Treatment Options for Ovarian Cancer. , 2019, , 533-540.		0
558	PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow. Molecular Cancer Research, 2019, 17, 409-419.	1.5	158
559	BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discovery, 2019, 9, 210-219.	7.7	278
560	Exaggeration of PFS by blinded, independent, central review (BICR). Annals of Oncology, 2019, 30, 332-338.	0.6	17
561	High-grade serous ovarian carcinoma with mucinous differentiation: report of a rare and unique case suggesting transition from the â€œSETâ€•feature of high-grade serous carcinoma to the â€œSTEMâ€•feature. Diagnostic Pathology, 2019, 14, 4.	0.9	8
562	Synergistic Cytotoxic Effect of Busulfan and the PARP Inhibitor Veliparib in Myeloproliferative Neoplasms. Biology of Blood and Marrow Transplantation, 2019, 25, 855-860.	2.0	13
563	Targeting DNA repair in precision medicine. Advances in Protein Chemistry and Structural Biology, 2019, 115, 135-155.	1.0	8
564	Dosage adjustments in pivotal clinical trials with oral targeted therapies in solid tumors conducted in Europe. European Journal of Clinical Pharmacology, 2019, 75, 697-706.	0.8	3
566	A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer. EBioMedicine, 2019, 40, 375-381.	2.7	85
567	Efficacy and safety of niraparib as maintenance treatment in older patients (â‰¥â€¯70â€¯years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial. Gynecologic Oncology, 2019, 152, 560-567.	0.6	35
568	Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors. Biochemical Pharmacology, 2019, 167, 125-132.	2.0	9
569	State-of-the-art strategies for targeting the DNA damage response in cancer. Nature Reviews Clinical Oncology, 2019, 16, 81-104.	12.5	736
570	Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data. Critical Reviews in Oncology/Hematology, 2019, 133, 58-73.	2.0	30
571	PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper. Journal of Geriatric Oncology, 2019, 10, 337-345.	0.5	25

#	Article	IF	Citations
572	A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors. Clinical Cancer Research, 2019, 25, 496-505.	3.2	33
573	Predictive Biomarkers and Targeted Therapies in Gynecological Cancers. , 2019, , 445-456.		0
574	PARP inhibitors in ovarian cancer. Cancer Treatment Reviews, 2019, 73, 1-9.	3.4	158
575	Identifying the need to refine the potential patient risk factors for niraparib-induced thrombocytopenia. Gynecologic Oncology, 2019, 152, 265-269.	0.6	3
576	Niraparib â€“ A promising drug with hematological toxicity. Journal of Oncology Pharmacy Practice, 2019, 25, 1749-1753.	0.5	3
577	Novel Therapeutic Approaches and Targets for Ovarian Cancer. , 2019, , 547-574.		2
578	Poly-ADP ribosylation in DNA damage response and cancer therapy. Mutation Research - Reviews in Mutation Research, 2019, 780, 82-91.	2.4	61
579	Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition. Journal of the National Cancer Institute, 2020, 112, 161-169.	3.0	47
580	Genetic counseling of patients with ovarian carcinoma: acceptance, timing, and psychological wellbeing. Journal of Community Genetics, 2020, 11, 183-191.	0.5	4
581	Next-generation sequencing-based BRCA testing on cytological specimens from ovarian cancer ascites reveals high concordance with tumour tissue analysis. Journal of Clinical Pathology, 2020, 73, 168-171.	1.0	14
582	Real-World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10. Oncologist, 2020, 25, e109-e119.	1.9	13
583	PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers. Cancer Letters, 2020, 469, 124-133.	3.2	22
584	Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment. Annals of Palliative Medicine, 2020, 9, 1296-1306.	0.5	5
585	Genetic testing in ovarian cancer â€“ clinical impact and current practices. Hormone Molecular Biology and Clinical Investigation, 2020, 41, .	0.3	4
586	ADP-Ribosylation Levels and Patterns Correlate with Gene Expression and Clinical Outcomes in Ovarian Cancers. Molecular Cancer Therapeutics, 2020, 19, 282-291.	1.9	20
587	Overview of imaging findings associated with systemic therapies in advanced epithelial ovarian cancer. Abdominal Radiology, 2020, 45, 828-841.	1.0	2
588	Genetic Factors. , 2020, , 180-208.e11.		4
589	Final results from GCIG/ENGOT/AGOâ€OVAR 12, a randomised placeboâ€controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer. International Journal of Cancer, 2020, 146, 439-448.	2.3	40

#	Article	IF	Citations
590	Carcinoma of the Ovaries and Fallopian Tubes. , 2020, , 1525-1543.e7.		0
591	Phase I Pharmacokinetic Study of Niraparib in Chinese Patients with Epithelial Ovarian Cancer. Oncologist, 2020, 25, 19.	1.9	6
592	Synthetic lethality as an engine for cancer drug target discovery. Nature Reviews Drug Discovery, 2020, 19, 23-38.	21.5	295
593	Genomic profiling of the residual disease of advanced highâ€grade serous ovarian cancer after neoadjuvant chemotherapy. International Journal of Cancer, 2020, 146, 1851-1861.	2.3	19
594	GATA1-regulated JAG1 promotes ovarian cancer progression by activating Notch signal pathway. Protoplasma, 2020, 257, 901-910.	1.0	23
595	PARP-inhibitor potpourri: A comparative review of class safety, efficacy, and cost. Journal of Oncology Pharmacy Practice, 2020, 26, 718-729.	0.5	13
596	Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making. Gynecologic Oncology, 2020, 156, 517-522.	0.6	16
597	A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer. Gynecologic Oncology, 2020, 156, 689-694.	0.6	16
598	BRCA Mutations and Homologous Recombination Repair Deficiency in Treatment With Niraparib Combined With Pembrolizumabâ€"Reply. JAMA Oncology, 2020, 6, 441.	3.4	4
599	Maintenance Therapy in the Treatment of Recurrent Epithelial Ovarian Cancer. Clinical Obstetrics and Gynecology, 2020, 63, 86-91.	0.6	2
600	Targeted therapies in gynaecological cancers. Histopathology, 2020, 76, 157-170.	1.6	30
601	A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer. Gynecologic Oncology, 2020, 156, 13-22.	0.6	9
602	Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review. Translational Oncology, 2020, 13, 410-422.	1.7	52
603	Latest clinical evidence of maintenance therapy in ovarian cancer. Current Opinion in Obstetrics and Gynecology, 2020, 32, 15-21.	0.9	19
604	A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer. Gynecologic Oncology, 2020, 156, 23-31.	0.6	40
605	Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours. British Journal of Cancer, 2020, 122, 483-490.	2.9	8
606	Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?. , 2020, 207, 107450.		101
607	A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin. Clinical Cancer Research, 2020, 26, 1372-1384.	3.2	66

#	Article	IF	Citations
608	Immunotherapy for Gynecologic Cancer: Current Applications and Future Directions. Clinical Obstetrics and Gynecology, 2020, 63, 48-63.	0.6	27
609	Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations. Drugs, 2020, 80, 131-146.	4.9	10
610	Targeted therapy clinical trials in ovarian cancer: improved outcomes by gene mutation screening. Anti-Cancer Drugs, 2020, 31, 101-109.	0.7	4
611	Comprehensive profiling of BRCA1 and BRCA2 variants in breast and ovarian cancer in Chinese patients. Human Mutation, 2020, 41, 696-708.	1.1	21
612	Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors. Biochemical and Biophysical Research Communications, 2020, 522, 121-126.	1.0	24
613	Delving into PARP inhibition from bench to bedside and back. , 2020, 206, 107446.		11
614	A TAZâ€“ANGPTL4â€“NOX2 Axis Regulates Ferroptotic Cell Death and Chemoresistance in Epithelial Ovarian Cancer. Molecular Cancer Research, 2020, 18, 79-90.	1.5	188
615	Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials. Journal of Cancer Research and Clinical Oncology, 2020, 146, 721-737.	1.2	21
616	Maintenance Therapy in the Primary Treatment of Epithelial Ovarian Cancer. Clinical Obstetrics and Gynecology, 2020, 63, 80-85.	0.6	0
617	Durable Near-Complete Response to Olaparib Plus Temozolomide and Radiation in a Patient With ATM-Mutated Glioblastoma and MSH6-Deficient Lynch Syndrome. JCO Precision Oncology, 2020, 4, 841-847.	1.5	4
618	Clinical assays for assessment of homologous recombination DNA repair deficiency. Gynecologic Oncology, 2020, 159, 887-898.	0.6	70
619	TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker. Annals of Oncology, 2020, 31, 1518-1525.	0.6	46
620	Newly diagnosed ovarian cancer: Which first-line treatment?. Cancer Treatment Reviews, 2020, 91, 102111.	3.4	23
621	Management of nausea and vomiting from poly(ADP-ribose) polymerase inhibitor therapy for advanced ovarian cancer. Gynecologic Oncology, 2020, 159, 581-587.	0.6	9
622	Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). International Journal of Gynecological Cancer, 2020, 30, 1657-1664.	1.2	220
623	Survival benefits of PARP inhibitors in advanced breast cancer: aÂmirage?. Annals of Oncology, 2020, 31, 1432-1434.	0.6	4
624	Nanoparticles in precision medicine for ovarian cancer: From chemotherapy to immunotherapy. International Journal of Pharmaceutics, 2020, 591, 119986.	2.6	30
625	Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy. Life Sciences, 2020, 261, 118434.	2.0	23

#	Article	IF	Citations
626	STAT3 imparts BRCAnessÂby impairing homologous recombination repair in Epstein-Barr virus-transformed B lymphocytes. PLoS Pathogens, 2020, 16, e1008849.	2.1	12
627	The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib. Gynecologic Oncology, 2020, 159, 850-859.	0.6	4
628	Comparison of Poly (ADP-ribose) Polymerase Inhibitors (PARPis) as Maintenance Therapy for Platinum-Sensitive Ovarian Cancer: Systematic Review and Network Meta-Analysis. Cancers, 2020, 12, 3026.	1.7	11
629	Hypertensive Cardiotoxicity in Cancer Treatmentâ€"Systematic Analysis of Adjunct, Conventional Chemotherapy, and Novel Therapiesâ€"Epidemiology, Incidence, and Pathophysiology. Journal of Clinical Medicine, 2020, 9, 3346.	1.0	19
630	Anlotinib as Exploratory Therapy for Platinum-Resistant Ovarian Cancer: A Retrospective Study on Efficacy and Safety . OncoTargets and Therapy, 2020, Volume 13, 9857-9863.	1.0	10
631	Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial. Gynecologic Oncology, 2020, 159, 442-448.	0.6	28
632	High-throughput approaches for precision medicine in high-grade serous ovarian cancer. Journal of Hematology and Oncology, 2020, 13, 134.	6.9	36
633	ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Annals of Oncology, 2020, 31, 1606-1622.	0.6	238
634	Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome. Nature Communications, 2020, 11, 4995.	5.8	70
635	Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy. European Journal of Cancer, 2020, 139, 59-67.	1.3	12
636	Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer. Expert Opinion on Emerging Drugs, 2020, 25, 445-453.	1.0	15
637	The DNA damaging revolution. Critical Reviews in Oncology/Hematology, 2020, 156, 103117.	2.0	9
638	Cost-effectiveness analysis comparing â€œPARP inhibitors-for-allâ€•to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer. Gynecologic Oncology, 2020, 159, 483-490.	0.6	19
639	Homologous recombination deficiency real-time clinical assays, ready or not?. Gynecologic Oncology, 2020, 159, 877-886.	0.6	39
640	Suppression of DDX39B sensitizes ovarian cancer cells to DNA-damaging chemotherapeutic agents via destabilizing BRCA1 mRNA. Oncogene, 2020, 39, 7051-7062.	2.6	18
641	Real-world evidence of poly ADP-ribose polymerase inhibitors in the treatment of ovarian cancer: A systematic literature review. Journal of Oncology Pharmacy Practice, 2020, 26, 1977-1986.	0.5	5
642	Year 1: Experiences of a tertiary cancer centre following implementation of reflex BRCA1 and BRCA2 tumor testing for all high-grade serous ovarian cancers in a universal healthcare system. Gynecologic Oncology, 2020, 158, 747-753.	0.6	12
643	Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England. European Journal of Human Genetics, 2020, 28, 1541-1547.	1.4	22

#	Article	IF	Citations
644	Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study. Journal of Oncology, 2020, 2020, 1-6.	0.6	2
645	The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer. Annals of Oncology, 2020, 31, 1135-1147.	0.6	58
646	Potential of platinum-resensitization by Wnt signaling modulators as treatment approach for epithelial ovarian cancer. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2559-2574.	1.2	4
649	Frequency and prognostic value of mutations associated with the homologous recombination DNA repair pathway in a large pan cancer cohort. Scientific Reports, 2020, 10, 20223.	1.6	15
650	DNA damaging agents in ovarian cancer. European Journal of Cancer, Supplement, 2020, 15, 67-72.	2.2	2
651	Tumor BRCA Testing in High Grade Serous Carcinoma: Mutation Rates and Optimal Tissue Requirements. Cancers, 2020, 12, 3468.	1.7	12
652	Lessons learned from understanding chemotherapy resistance in epithelial tubo-ovarian carcinoma from BRCA1and BRCA2mutation carriers. Seminars in Cancer Biology, 2020, 77, 110-126.	4.3	16
653	Measuring Quality of Life in Ovarian Cancer Clinical Trialsâ€"Can We Improve Objectivity and Cross Trial Comparisons?. Cancers, 2020, 12, 3296.	1.7	13
654	Utility of a custom designed next generation DNA sequencing gene panel to molecularly classify endometrial cancers according to The Cancer Genome Atlas subgroups. BMC Medical Genomics, 2020, 13, 179.	0.7	3
655	Improved prognosis for recurrent epithelial ovarian cancer by early diagnosis and 125I seeds implantation during suboptimal secondary cytoreductive surgery: a case report and literature review. Journal of Ovarian Research, 2020, 13, 141.	1.3	3
656	Treatment of epithelial ovarian cancer. BMJ, The, 2020, 371, m3773.	3.0	359
657	Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial. Journal of Clinical Oncology, 2020, 38, 3528-3537.	0.8	64
658	Brain Metastases from Ovarian Cancer: Current Evidence in Diagnosis, Treatment, and Prognosis. Cancers, 2020, 12, 2156.	1.7	27
659	Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement. Gynecologic Oncology, 2020, 159, 8-12.	0.6	18
660	Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer. Cancers, 2020, 12, 2184.	1.7	17
661	Patient-Derived Ovarian Cancer Organoids Mimic Clinical Response and Exhibit Heterogeneous Inter- and Intrapatient Drug Responses. Cell Reports, 2020, 31, 107762.	2.9	155
662	PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives . Cancer Management and Research, 2020, Volume 12, 6123-6135.	0.9	25
663	Homologous repair deficiency score for identifying breast cancers with defective DNA damage response. Scientific Reports, 2020, 10, 12506.	1.6	23

#	Article	IF	Citations
664	Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence. Signal Transduction and Targeted Therapy, 2020, 5, 137.	7.1	79
665	Real-World Study of Adding Bevacizumab to Chemotherapy for Ovarian, Tubal, and Peritoneal Cancer as Front-Line or Relapse Therapy (ROBOT): 8-Year Experience. Frontiers in Oncology, 2020, 10, 1095.	1.3	8
666	Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer. BMC Cancer, 2020, 20, 703.	1.1	22
667	Tumor Testing for Somatic and Germline BRCA1/BRCA2 Variants in Ovarian Cancer Patients in the Context of Strong Founder Effects. Frontiers in Oncology, 2020, 10, 1318.	1.3	11
668	Use of fertility treatments in BRCA1/2 mutation carriers and risk for ovarian and breast cancer: a systematic review. Archives of Gynecology and Obstetrics, 2020, 302, 715-720.	0.8	9
669	PARP Inhibitors in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Meta-Analysis of Randomized Clinical Trials. Frontiers in Oncology, 2020, 10, 1204.	1.3	13
670	Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study. Gynecologic Oncology, 2020, 159, 79-87.	0.6	6
671	Current and emerging biologic therapies for triple negative breast cancer. Expert Opinion on Biological Therapy, 2022, 22, 591-602.	1.4	11
672	BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer. Breast Cancer Research, 2020, 22, 79.	2.2	8
673	PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 3468-3493.	0.8	175
674	Modeling the Diversity of Epithelial Ovarian Cancer through Ten Novel Well Characterized Cell Lines Covering Multiple Subtypes of the Disease. Cancers, 2020, 12, 2222.	1.7	10
675	Systematic Review and Meta-Analysis of Correlation of Progression-Free Survival-2 and Overall Survival in Solid Tumors. Frontiers in Oncology, 2020, 10, 1349.	1.3	22
676	Clinical Utility of Preoperative Assessment in Ovarian Cancer Cytoreduction. Diagnostics, 2020, 10, 568.	1.3	6
677	Targeting DNA damage response kinases in cancer therapy. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2020, 821, 111725.	0.4	6
678	Synthetic Lethality through the Lens of Medicinal Chemistry. Journal of Medicinal Chemistry, 2020, 63, 14151-14183.	2.9	31
679	Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatment. Cancer Treatment Reviews, 2020, 90, 102107.	3.4	21
680	High density of stroma-localized CD11c-positive macrophages is associated with longer overall survival in high-grade serous ovarian cancer. Gynecologic Oncology, 2020, 159, 860-868.	0.6	4
681	Recycling the Purpose of Old Drugs to Treat Ovarian Cancer. International Journal of Molecular Sciences, 2020, 21, 7768.	1.8	18

#	Article	IF	Citations
682	Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice. Gynecologic Oncology, 2020, 159, 112-117.	0.6	10
683	PARP Inhibitor in Advanced Endometrial Carcinoma Beyond BRCA and Related Genetic Mutations. JCO Precision Oncology, 2020, 4, 1025-1026.	1.5	1
685	ESMO management and treatment adapted recommendations in the COVID-19 era: gynaecological malignancies. ESMO Open, 2020, 5, e000827.	2.0	18
686	Poly(ADP-ribose) polymerase inhibition: past, present and future. Nature Reviews Drug Discovery, 2020, 19, 711-736.	21.5	275
687	Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation. Journal of Hematology and Oncology, 2020, 13, 118.	6.9	95
688	Niraparib in the treatment of previously treated advanced ovarian, fallopian tubeÂor primary peritoneal cancer. Future Oncology, 2020, 16, 2701-2711.	1.1	1
689	Secondary and tertiary ovarian cancer recurrence: what is the best management?. Gland Surgery, 2020, 9, 1118-1129.	0.5	18
690	Development of new medical treatment for epithelial ovarian cancer recurrence. Gland Surgery, 2020, 9, 1149-1163.	0.5	12
691	Recent developments in PARP14 research. Future Medicinal Chemistry, 2020, 12, 1657-1667.	1.1	6
692	The new world of poly-(ADP)-ribose polymerase inhibitors (PARPi) used in the treatment of gynecological cancers. International Journal of Gynecological Cancer, 2020, 30, 1608-1618.	1.2	4
693	PARP inhibitors in ovarian cancer: evidence for maintenance and treatment strategies. Chinese Clinical Oncology, 2020, 9, 51-51.	0.4	4
694	Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?. Current Opinion in Oncology, 2020, 32, 442-450.	1.1	10
695	Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?. Archives of Gynecology and Obstetrics, 2020, 302, 1087-1102.	0.8	31
696	Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis. International Journal of Gynecological Cancer, 2020, 30, 1569-1575.	1.2	10
697	Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis. International Journal of Gynecological Cancer, 2020, 30, 1576-1582.	1.2	9
698	PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance. Frontiers in Cell and Developmental Biology, 2020, 8, 564601.	1.8	315
699	Prevalence of BRCA1 and BRCA2 Mutations in Patients with Primary Ovarian Cancer â€“ Does the German Checklist for Detecting the Risk of Hereditary Breast and Ovarian Cancer Adequately Depict the Need for Consultation?. Geburtshilfe Und Frauenheilkunde, 2020, 80, 932-940.	0.8	7
700	Breast cancer (BRCA) gene testing in ovarian cancer. Chinese Clinical Oncology, 2020, 9, 63-63.	0.4	3

#	Article	IF	Citations
702	Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity. EBioMedicine, 2020, 59, 102923.	2.7	22
703	When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials. European Urology Oncology, 2020, 3, 594-611.	2.6	63
704	Using whole-genome sequencing data to derive the homologous recombination deficiency scores. Npj Breast Cancer, 2020, 6, 33.	2.3	19
705	First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion. ESMO Open, 2020, 5, e001110.	2.0	42
706	Molecular Features and Clinical Management of Hereditary Gynecological Cancers. International Journal of Molecular Sciences, 2020, 21, 9504.	1.8	13
707	Results of the interprofessional and interdisciplinary Berlin round table on patient-reported outcomes, quality of life, and treatment expectations of patients with gynecological cancer under maintenance treatment. International Journal of Gynecological Cancer, 2020, 30, 1603-1607.	1.2	4
708	A functional polymorphism in the poly(ADP-ribose) polymerase-1 gene is associated with platinum-based chemotherapeutic response and prognosis in epithelial ovarian cancer patients. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 255, 183-189.	0.5	0
709	Treatment of Recurrent Epithelial Ovarian Cancer. Geburtshilfe Und Frauenheilkunde, 2020, 80, 1195-1204.	0.8	13
710	Clinical Outcome of Leiomyosarcomas With Somatic Alteration in Homologous Recombination Pathway Genes. JCO Precision Oncology, 2020, 4, 1350-1360.	1.5	18
711	Checkpoint Inhibitors in Gynecological Malignancies: Are we There Yet?. BioDrugs, 2020, 34, 749-762.	2.2	5
713	Streamlining genetic testing for women with ovarian cancer in a Northern California health care system. Gynecologic Oncology, 2020, 159, 221-228.	0.6	10
714	Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors. International Journal of Gynecological Cancer, 2020, 30, 1026-1033.	1.2	3
715	PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage Repair. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e116-e131.	1.8	30
716	Therapeutic applications of PARP inhibitors in ovarian cancer. Biomedicine and Pharmacotherapy, 2020, 127, 110204.	2.5	29
717	BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects . Cancer Management and Research, 2020, Volume 12, 2731-2742.	0.9	69
718	Combined CCNE1 highâ€level amplification and overexpression is associated with unfavourable outcome in tuboâ€ovarian highâ€grade serous carcinoma. Journal of Pathology: Clinical Research, 2020, 6, 252-262.	1.3	33
719	Vitamin C Inhibits Metastasis of Peritoneal Tumors By Preventing Spheroid Formation in ID8 Murine Epithelial Peritoneal Cancer Model. Frontiers in Pharmacology, 2020, 11, 645.	1.6	7
720	The development and evaluation of a nationwide training program for oncology health professionals in the provision of genetic testing for ovarian cancer patients. Gynecologic Oncology, 2020, 158, 431-439.	0.6	15

#	Article	IF	Citations
721	Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults. Breast Cancer Research and Treatment, 2020, 182, 491-502.	1.1	2
722	Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer. Cancers, 2020, 12, 1206.	1.7	6
723	Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis. Gynecologic Oncology, 2020, 158, 16-24.	0.6	40
724	The anti-DKK1 antibody DKN-01 as an immunomodulatory combination partner for the treatment of cancer. Expert Opinion on Investigational Drugs, 2020, 29, 639-644.	1.9	41
725	Immune Therapy Opportunities in Ovarian Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e228-e240.	1.8	25
726	Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials. Cancer Treatment Reviews, 2020, 87, 102040.	3.4	35
727	Genomics-guided pre-clinical development of cancer therapies. Nature Cancer, 2020, 1, 482-492.	5.7	23
728	PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?. Cancers, 2020, 12, 1378.	1.7	29
729	Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis. International Journal of Molecular Sciences, 2020, 21, 3805.	1.8	17
730	Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma. , 2020, 8, e000375.		14
731	Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian Carcinomas. Cancers, 2020, 12, 1315.	1.7	18
732	Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors. Cancers, 2020, 12, 1502.	1.7	145
733	Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells. Cancers, 2020, 12, 1503.	1.7	17
734	Old dogs, new trick: classic cancer therapies activate cGAS. Cell Research, 2020, 30, 639-648.	5.7	104
735	Breakthrough therapy-designated oncology drugs: are they rightfully criticized?. Drug Discovery Today, 2020, 25, 1580-1584.	3.2	3
736	PARP inhibitor resistance: the underlying mechanisms and clinical implications. Molecular Cancer, 2020, 19, 107.	7.9	235
737	Biomimetic device and foreign body reaction cooperate for efficient tumour cell capture in murine advanced ovarian cancer. DMM Disease Models and Mechanisms, 2020, 13, .	1.2	2
738	First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor. British Journal of Cancer, 2020, 123, 525-533.	2.9	46

#	Article	IF	Citations
739	Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review. BMC Cancer, 2020, 20, 507.	1.1	48
740	ATM-deficient lung, prostate and pancreatic cancer cells are acutely sensitive to the combination of olaparib and the ATR inhibitor AZD6738. Genome Instability & Disease, 2020, 1, 197-205.	0.5	9
741	Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance. Targeted Oncology, 2020, 15, 391-406.	1.7	11
742	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). Clinical Cancer Research, 2020, 26, 5411-5423.	3.2	43
743	Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592092198.	1.4	8
744	SOLO 3 Trial: How Do the Results Fit in With Current Evidence?. Journal of Clinical Oncology, 2020, 38, 2697-2698.	0.8	1
745	The forefront of ovarian cancer therapy: update on PARP inhibitors. Annals of Oncology, 2020, 31, 1148-1159.	0.6	191
746	State of the art and up-and-coming angiogenesis inhibitors for ovarian cancer. Expert Opinion on Pharmacotherapy, 2020, 21, 1579-1590.	0.9	10
747	The emerging role of precision medicine in the treatment of ovarian cancer. Expert Review of Precision Medicine and Drug Development, 2020, 5, 283-297.	0.4	3
748	Targeting Cancer Stem Cells to Overcome Therapy Resistance in Ovarian Cancer. Cells, 2020, 9, 1402.	1.8	46
749	Wnt Signaling in Gynecologic Malignancies. International Journal of Molecular Sciences, 2020, 21, 4272.	1.8	45
750	How and when to refer patients for oncogenetic counseling in the era of PARP inhibitors. Therapeutic Advances in Medical Oncology, 2020, 12, 175883591989753.	1.4	8
751	BRCA1 Promoter Methylation Status in 1031 Primary Breast Cancers Predicts Favorable Outcomes Following Chemotherapy. JNCI Cancer Spectrum, 2020, 4, pkz100.	1.4	7
752	Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Annals of Pharmacotherapy, 2020, 54, 1010-1015.	0.9	6
753	Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series. Journal of Ovarian Research, 2020, 13, 29.	1.3	4
754	PARP inhibitors in the treatment of ovarian cancer. Memo - Magazine of European Medical Oncology, 2020, 13, 198-201.	0.3	1
755	Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nature Communications, 2020, 11, 1459.	5.8	176
756	â€˜The same old storyâ€™: thoughts on authorized doses of anticancer drugs. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592090541.	1.4	5

#	Article	IF	Citations
757	Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging. International Journal of Biological Sciences, 2020, 16, 1363-1375.	2.6	22
758	Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: a review. International Journal of Gynecological Cancer, 2020, 30, 684-694.	1.2	6
759	Variants of uncertain clinical significance in hereditary breast and ovarian cancer genes: best practices in functional analysis for clinical annotation. Journal of Medical Genetics, 2020, 57, 509-518.	1.5	33
760	Recommendations for Advancing the Diagnosis and Management of Hereditary Breast and Ovarian Cancer in Brazil. JCO Global Oncology, 2020, 6, 439-452.	0.8	25
761	Integrated analysis of gene expression and DNA methylation profiles in ovarian cancer. Journal of Ovarian Research, 2020, 13, 30.	1.3	29
762	Ovarian Cancer, Cancer Stem Cells and Current Treatment Strategies: A Potential Role of Magmas in the Current Treatment Methods. Cells, 2020, 9, 719.	1.8	43
763	Tratamiento quirÃºrgico de las recidivas de los tumores epiteliales del ovario. EMC - GinecologÃa-Obstetricia, 2020, 56, 1-8.	0.0	0
764	Changes in DNA Damage Response Markers with Treatment in Advanced Ovarian Cancer. Cancers, 2020, 12, 707.	1.7	14
765	Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer. BMC Cancer, 2020, 20, 204.	1.1	25
766	Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives. Diagnostics, 2020, 10, 146.	1.3	56
767	PARP Inhibitors in Prostate and Urothelial Cancers. Frontiers in Oncology, 2020, 10, 114.	1.3	13
768	Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer. BMC Cancer, 2020, 20, 185.	1.1	15
769	Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service. Clinical Therapeutics, 2020, 42, 1192-1209.e12.	1.1	9
770	Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer. Frontiers in Oncology, 2020, 10, 958.	1.3	9
771	Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer. Cancers, 2020, 12, 1761.	1.7	8
772	Basophils from Cancer Patients Respond to Immune Stimuli and Predict Clinical Outcome. Cells, 2020, 9, 1631.	1.8	26
773	Homologous recombination deficiency in epithelial ovarian cancer. Memo - Magazine of European Medical Oncology, 2020, 13, 367-370.	0.3	2
774	Homologous recombination deficiency in breast cancer. Memo - Magazine of European Medical Oncology, 2020, 13, 375-379.	0.3	2

#	Article	IF	Citations
775	Pharmacological methods to transcriptionally modulate double-strand break DNA repair. International Review of Cell and Molecular Biology, 2020, 354, 187-213.	1.6	8
776	Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer. Frontiers in Oncology, 2020, 10, 954.	1.3	8
777	The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis. World Journal of Surgical Oncology, 2020, 18, 151.	0.8	14
778	Efficacy and safety of lowâ€dose apatinib in ovarian cancer patients with platinumâ€resistance or platinumâ€refractoriness: A singleâ€center retrospective study. Cancer Medicine, 2020, 9, 5899-5907.	1.3	9
779	PARPs and ADP-ribosylation in RNA biology: from RNA expression and processing to protein translation and proteostasis. Genes and Development, 2020, 34, 302-320.	2.7	91
780	PARP and PARG inhibitors in cancer treatment. Genes and Development, 2020, 34, 360-394.	2.7	360
781	Metastatic Thymoma Harboring a Deleterious BRCA2 Mutation Derives Durable Clinical Benefit from Olaparib. Oncologist, 2020, 25, 301-305.	1.9	9
782	PARP inhibitors: a tsunami of indications in different malignancies. Pharmacogenomics, 2020, 21, 221-230.	0.6	16
783	Germline and Somatic Testing in Ovarian Cancer: Shifting Sands of Recommendations. Gynecologic Oncology, 2020, 156, 515-516.	0.6	1
784	Oncologist-led BRCA â€˜mainstreamingâ€™ in the ovarian cancer clinic: A study of 255 patients and its impact on their management. Scientific Reports, 2020, 10, 3390.	1.6	34
785	A profile on the FoundationFocus CDxBRCA tests. Expert Review of Molecular Diagnostics, 2020, 20, 285-292.	1.5	15
786	The kinase polypharmacology landscape of clinical PARP inhibitors. Scientific Reports, 2020, 10, 2585.	1.6	68
787	Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma. Scientific Reports, 2020, 10, 2757.	1.6	134
788	Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial. Journal of Clinical Oncology, 2020, 38, 1164-1174.	0.8	194
789	Using nextâ€generation sequencing to redefine BRCAness in tripleâ€negative breast cancer. Cancer Science, 2020, 111, 1375-1384.	1.7	35
790	The antitumorigenic roles of BRCA1â€“BARD1 in DNA repair and replication. Nature Reviews Molecular Cell Biology, 2020, 21, 284-299.	16.1	199
791	ADP ribose polymerase inhibitors for treating non-small cell lung cancer: new additions to the pharmacotherapeutic armamentarium. Expert Opinion on Pharmacotherapy, 2020, 21, 679-686.	0.9	3
792	Genetic testing for epithelial ovarian cancer. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2020, 65, 125-138.	1.4	17

#	Article	IF	Citations
794	CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes. Gynecologic Oncology, 2020, 157, 405-410.	0.6	30
795	Predictive Relevance of Circulating miR-622 in Patients with Newly Diagnosed and Recurrent High-Grade Serous Ovarian Carcinoma. Clinical Chemistry, 2020, 66, 352-362.	1.5	15
796	Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors. Clinical Cancer Research, 2020, 26, 2546-2555.	3.2	33
797	Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer. Biomedicine and Pharmacotherapy, 2020, 123, 109661.	2.5	58
798	JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer. European Journal of Cancer, 2020, 126, 125-135.	1.3	48
799	The underreporting of phase III chemo-therapeutic clinical trial data of older patients with cancer: A systematic review. Journal of Geriatric Oncology, 2020, 11, 369-379.	0.5	20
800	Comprehensive analysis of mRNAâ€level and miRNAâ€level subpathway activities for identifying robust ovarian cancer prognostic signatures. Journal of Cellular and Molecular Medicine, 2020, 24, 2582-2592.	1.6	1
801	A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer. Gynecologic Oncology, 2020, 157, 214-221.	0.6	2
802	Enabling Precision Oncology Through Precision Diagnostics. Annual Review of Pathology: Mechanisms of Disease, 2020, 15, 97-121.	9.6	50
803	Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 1222-1245.	0.8	202
804	Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment. Gynecologic Oncology, 2020, 156, 561-567.	0.6	21
805	MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC. Journal of Hematology and Oncology, 2020, 13, 9.	6.9	22
806	Neoadjuvant chemotherapy-related platinum resistance in ovarian cancer. Drug Discovery Today, 2020, 25, 1232-1238.	3.2	28
807	Recurrent Treatment in Ovarian Cancer Patients: What Are the Best Regimens and the Order They Should Be Given?. Current Treatment Options in Oncology, 2020, 21, 49.	1.3	7
808	Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2020, 21, 710-722.	5.1	70
809	Expanding use of rucaparib as maintenance therapy in recurrent ovarian cancer: updates from the ARIEL3 trial. Lancet Oncology, The, 2020, 21, 616-617.	5.1	2
810	DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduction and Targeted Therapy, 2020, 5, 60.	7.1	474
811	Targeting tumor microenvironment in ovarian cancer: Premise and promise. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1873, 188361.	3.3	105

#	Article	IF	Citations
812	Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ENGOT-ov22 and GCIG survey (Expression IV). International Journal of Gynecological Cancer, 2020, 30, 509-514.	1.2	9
813	Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events. International Journal of Gynecological Cancer, 2020, 30, 903-915.	1.2	52
814	Mesenchymal Stem Cells As Guideposts for Nanoparticle-Mediated Targeted Drug Delivery in Ovarian Cancer. Cancers, 2020, 12, 965.	1.7	19
815	Therapeutic Strategies and Biomarkers to Modulate PARP Activity for Targeted Cancer Therapy. Cancers, 2020, 12, 972.	1.7	14
816	PARP Inhibitors in Ovarian Cancer. New England Journal of Medicine, 2020, 382, 1572-1575.	13.9	9
817	Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect. Gynecologic Oncology, 2020, 157, 578-584.	0.6	19
818	Recommendations to improve the clinical adoption of NGSâ€based cancer diagnostics in Singapore. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 222-231.	0.7	8
819	The Chicago Consensus on Peritoneal Surface Malignancies: Management of Ovarian Neoplasms. Annals of Surgical Oncology, 2020, 27, 1780-1787.	0.7	13
820	The role of the CDCA gene family in ovarian cancer. Annals of Translational Medicine, 2020, 8, 190-190.	0.7	29
821	Real-world direct healthcare costs of treating recurrent high-grade serous ovarian cancer with cytotoxic chemotherapy. Journal of Comparative Effectiveness Research, 2020, 9, 537-551.	0.6	4
822	Germline <i>BRCA</i> Mutation Rates in Latina Women Presenting for Gynecologic Oncology Care. Gynecologic and Obstetric Investigation, 2020, 85, 214-221.	0.7	1
823	Exploring the Synergy between PARP and CHK1 Inhibition in Matched BRCA2 Mutant and Corrected Cells. Cancers, 2020, 12, 878.	1.7	18
824	The Chicago Consensus on peritoneal surface malignancies: Management of ovarian neoplasms. Cancer, 2020, 126, 2553-2560.	2.0	11
825	PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias. Blood Reviews, 2021, 45, 100696.	2.8	17
826	Gastrointestinal events with PARP inhibitors in cancer patients: A metaâ€analysis of phase II/III randomized controlled trials. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 241-255.	0.7	10
827	Clinical impact of BRCA2 mRNA expression in high-grade serous ovarian cancer: validation using the TCGA cohort. Acta OncolÃ³gica, 2021, 60, 187-190.	0.8	0
828	Parthanatos and its associated components: Promising therapeutic targets for cancer. Pharmacological Research, 2021, 163, 105299.	3.1	50
829	PARP inhibitors as maintenance therapy in newly diagnosed advanced ovarian cancer: a metaâ€analysis. BJOG: an International Journal of Obstetrics and Gynaecology, 2021, 128, 485-493.	1.1	23

#	Article	IF	Citations
830	A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance. Annals of Oncology, 2021, 32, 103-112.	0.6	98
831	Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100. Journal of Clinical Oncology, 2021, 39, 966-977.	0.8	122
832	Impact of BRCA1/2 Mutations on the Efficacy of Secondary Cytoreductive Surgery. Annals of Surgical Oncology, 2021, 28, 3637-3645.	0.7	8
833	Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials. Critical Reviews in Oncology/Hematology, 2021, 157, 103145.	2.0	34
834	Current Ovarian Cancer Maintenance Strategies and Promising New Developments. Journal of Cancer, 2021, 12, 38-53.	1.2	36
835	Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort. Gynecologic Oncology, 2021, 160, 175-181.	0.6	21
836	Indazole scaffold: a generalist for marketed and clinical drugs. Medicinal Chemistry Research, 2021, 30, 501-518.	1.1	23
837	Lived experiences of women reporting fatigue during PARP inhibitor maintenance treatment for advanced ovarian cancer: A qualitative study. Gynecologic Oncology, 2021, 160, 227-233.	0.6	6
838	Management of ovarian cancer: guidelines of the Italian Medical Oncology Association (AIOM). Tumori, 2021, 107, 100-109.	0.6	8
839	Biomimetic carrier-free nanoparticle delivers digoxin and doxorubicin to exhibit synergetic antitumor activity in vitro and in vivo. Chemical Engineering Journal, 2021, 406, 126801.	6.6	17
840	Clinical presentation, diagnosis and management of therapyâ€related hematological disorders in women with epithelial ovarian cancer treated with chemotherapy and polyâ€ADPâ€ribose polymerase inhibitors: A singleâ€center experience. International Journal of Cancer, 2021, 148, 170-177.	2.3	9
842	Targeting tumor resistance mechanisms. Faculty Reviews, 2021, 10, 6.	1.7	0
843	Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial. Journal of Gynecologic Oncology, 2021, 32, e82.	1.0	6
844	Treatment Free Intervals after Subsequent Chemotherapy Lines in Recurrent Ovarian Cancer. Journal of Cancer Therapy, 2021, 12, 346-357.	0.1	2
845	A source of hope for platinum-resistant ovarian cancer?. Lancet, The, 2021, 397, 254-256.	6.3	11
846	Oregovomab: an investigational agent for the treatment of advanced ovarian cancer. Expert Opinion on Investigational Drugs, 2021, 30, 103-110.	1.9	9
847	SEOM clinical guideline in ovarian cancer (2020). Clinical and Translational Oncology, 2021, 23, 961-968.	1.2	22
848	DNA Damage Repair Inhibitor for Breast Cancer Treatment. Advances in Experimental Medicine and Biology, 2021, 1187, 159-179.	0.8	0

#	Article	IF	Citations
849	Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in TP53- and BRCA1-Deficient Cells. Cancer Research, 2021, 81, 2774-2787.	0.4	17
850	Homologous Recombination Repair Mechanisms in Serous Endometrial Cancer. Cancers, 2021, 13, 254.	1.7	12
851	Haematologic toxicities with PARP inhibitors in cancer patients: an upâ€toâ€date metaâ€analysis of 29 randomized controlled trials. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 571-584.	0.7	26
852	Epithelial Ovarian Cancer and Cancer Stem Cells. Advances in Experimental Medicine and Biology, 2021, 1330, 21-32.	0.8	4
853	Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance. Experimental and Molecular Medicine, 2021, 53, 42-51.	3.2	93
854	How to start niraparib in real-world Asian ovarian cancer patients?. Journal of Gynecologic Oncology, 2021, 32, e36.	1.0	0
855	How to sequence treatment in relapsed ovarian cancer. Future Oncology, 2021, 17, 1-8.	1.1	1
856	Comprehensive Genomic Profiling-Guided Niraparib Treatment of Triple-Negative Breast Cancer in a Patient With Extensive Brain Metastasis: Case Report and Literature Review. Journal of Immunotherapy and Precision Oncology, 2021, 4, 16-20.	0.6	1
857	Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer. Journal of Gynecologic Oncology, 2021, 32, e16.	1.0	8
858	BRCA Mutations and PARP Inhibitors in Breast and/or Ovarian Cancer Patients. International Journal of Pharmaceutical Research and Allied Sciences, 2021, 10, 33-49.	0.1	1
859	Dendritic Cell Vaccines in Ovarian Cancer. Frontiers in Immunology, 2020, 11, 613773.	2.2	25
860	Ovarian Cancer: Towards Personalizing Ovarian Cancer Treatments Using Patient-Derived Organoids. , 2021, , .		0
861	Comparisons of survival outcomes between bevacizumab and olaparib inBRCA-mutated, platinum-sensitive relapsed ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3052). Journal of Gynecologic Oncology, 2021, 32, e90.	1.0	2
862	CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients. Clinical Epigenetics, 2021, 13, 15.	1.8	10
863	<scp>PARP</scp> inhibitors in ovarian cancer: An overview of the practiceâ€changing trials. Genes Chromosomes and Cancer, 2021, 60, 385-397.	1.5	51
864	Chemoresistance in female-specific cancers and the associated anti-resistance therapies. , 2021, , 49-69.		0
865	The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study. Japanese Journal of Clinical Oncology, 2021, 51, 693-699.	0.6	4
866	PARP inhibitorsâ€”understanding the risk of myelodysplastic syndrome and acute myeloid leukaemia. Lancet Haematology,the, 2021, 8, e97-e99.	2.2	1

#	Article	IF	Citations
867	Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?. Seminars in Cancer Biology, 2021, 77, 67-82.	4.3	12
868	Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. Lancet Haematology,the, 2021, 8, e122-e134.	2.2	139
869	Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer. Cancers, 2021, 13, 946.	1.7	31
870	Molecular Signatures of Gynecological Cancers: Clinicians Perspective. Indian Journal of Surgical Oncology, 2021, 12, 103-110.	0.3	1
872	Tumor hepatitis B virus RNA identifies a clinically and molecularly distinct subset of hepatocellular carcinoma. PLoS Computational Biology, 2021, 17, e1008699.	1.5	5
873	Risk of fatigue with PARP inhibitors in cancer patients: a systematic review and meta-analysis of 29 phase II/III randomized controlled trials. Journal of Chemotherapy, 2021, 33, 452-461.	0.7	5
874	Hereditary Breast Ovarian Cancer Syndrome: One Case, Multiple Lessons. Journal of Gynecology and Womens Health, 2021, 21, .	0.1	0
875	Homologous Recombination Deficiency Testing for BRCA-Like Tumors: The Road to Clinical Validation. Cancers, 2021, 13, 1004.	1.7	28
876	Prognostic and clinical significance of Solute Carrier Family 7 Member 1 in ovarian cancer. Translational Cancer Research, 2021, 10, 602-612.	0.4	6
877	A Phase I doseâ€escalation study of two cycles carboplatinâ€olaparib followed by olaparib monotherapy in patients with advanced cancer. International Journal of Cancer, 2021, 148, 3041-3050.	2.3	5
878	Comparative Efficacy and Safety of PARP Inhibitors as Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis. Frontiers in Oncology, 2020, 10, 573801.	1.3	9
879	Pathogenicity assessment of variants for breast cancer susceptibility genes based on BRCAness of tumor sample. Cancer Science, 2021, 112, 1310-1319.	1.7	3
880	Stiffness increases with myofibroblast content and collagen density in mesenchymal high grade serous ovarian cancer. Scientific Reports, 2021, 11, 4219.	1.6	37
881	Systemic treatment of newly diagnosed advanced epithelial ovarian cancer: From chemotherapy to precision medicine. Critical Reviews in Oncology/Hematology, 2021, 158, 103209.	2.0	11
882	Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades. Molecular Cancer, 2021, 20, 27.	7.9	54
883	Maintenance avelumab in metastatic bladder cancer as a step towards sequencing immunotherapy. Immunotherapy, 2021, 13, 271-275.	1.0	0
884	Tumour Versus Germline BRCA Testing in Ovarian Cancer: A Single-Site Institution Experience in the United Kingdom. Diagnostics, 2021, 11, 547.	1.3	2
885	Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors. Cancers, 2021, 13, 1298.	1.7	24

#	Article	IF	Citations
886	Phase II consolidation trial with anti-Lewis-Y monoclonal antibody (hu3S193) in platinum-sensitive ovarian cancer after a second remission. International Journal of Gynecological Cancer, 2021, 31, 562-568.	1.2	4
887	Molecular and clinical predictors of improvement in progressionâ€free survival with maintenance PARP inhibitor therapy in women with platinumâ€sensitive, recurrent ovarian cancer: A metaâ€analysis. Cancer, 2021, 127, 2432-2441.	2.0	14
888	Nanomaterials Enhance the Immunomodulatory Effect of Molecular Targeted Therapy. International Journal of Nanomedicine, 2021, Volume 16, 1631-1661.	3.3	19
889	Alternative Non-Homologous End-Joining: Error-Prone DNA Repair as Cancerâ€™s Achillesâ€™ Heel. Cancers, 2021, 13, 1392.	1.7	29
890	Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer. EMBO Molecular Medicine, 2021, 13, e13366.	3.3	30
891	Structural Variants at theBRCA1/2Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma. Clinical Cancer Research, 2021, 27, 3201-3214.	3.2	27
892	Targeting the Hypoxic and Acidic Tumor Microenvironment with pH-Sensitive Peptides. Cells, 2021, 10, 541.	1.8	33
893	Germline Mutations in Other Homologous Recombination Repair-Related Genes Than BRCA1/2: Predictive or Prognostic Factors?. Journal of Personalized Medicine, 2021, 11, 245.	1.1	14
894	Molecular disruption of DNA polymerase Î² for platinum sensitisation and synthetic lethality in epithelial ovarian cancers. Oncogene, 2021, 40, 2496-2508.	2.6	12
895	PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival. Aging, 2021, 13, 8975-8988.	1.4	13
896	Ovarian Carcinoma with Peritoneal Metastasis: Rethinking of Management. Archives of Clinical and Experimental Medicine, 2021, 6, 32-36.	0.1	0
898	Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know. Expert Opinion on Investigational Drugs, 2021, 30, 543-554.	1.9	13
899	Hereditary breast cancer and ovarian cancer: clinical course and treatment. Opuholi Zenskoj Reproduktivnoj Sistemy, 2021, 16, 54-65.	0.1	0
900	Identifying patients eligible for PARP inhibitor treatment: from NGS-based tests to 3D functional assays. British Journal of Cancer, 2021, 125, 7-14.	2.9	14
901	Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer. Drug Resistance Updates, 2021, 55, 100744.	6.5	43
902	Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway. International Journal of Molecular Sciences, 2021, 22, 3916.	1.8	13
903	Assessing Preclinical Research Models for Immunotherapy for Gynecologic Malignancies. Cancers, 2021, 13, 1694.	1.7	1
904	Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients. Circulation Research, 2021, 128, 1040-1061.	2.0	59

#	Article	IF	Citations
905	Proteomic Studies on the Management of High-Grade Serous Ovarian Cancer Patients: A Mini-Review. Cancers, 2021, 13, 2067.	1.7	7
906	First-Line PARP Inhibitorsâ€"Emerging Side Effects Require Caution: A Case of PARPi-Induced Pneumonitis. Journal of Immunotherapy and Precision Oncology, 2021, 4, 171-174.	0.6	4
907	The role of the microbiome in ovarian cancer: mechanistic insights into oncobiosis and to bacterial metabolite signaling. Molecular Medicine, 2021, 27, 33.	1.9	60
909	PARP inhibitors: shifting the paradigm in theÂtreatment of pancreatic cancer. Medical Oncology, 2021, 38, 61.	1.2	2
910	Report from the European Society of Gynaecological Oncology (ESGO) 2020 State-of-the-Art Virtual Meeting. International Journal of Gynecological Cancer, 2021, 31, 658-669.	1.2	5
911	Cellular Mechanism of Gene Mutations and Potential Therapeutic Targets in Ovarian Cancer. Cancer Management and Research, 2021, Volume 13, 3081-3100.	0.9	26
912	Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy. International Journal of Molecular Sciences, 2021, 22, 4203.	1.8	49
913	Real-world experience of olaparib as maintenance therapy in BRCA-mutated recurrent ovarian cancer. Archives of Gynecology and Obstetrics, 2021, 304, 1055-1063.	0.8	5
914	Conditional Relative Survival of Ovarian Cancer: A Korean National Cancer Registry Study. Frontiers in Oncology, 2021, 11, 639839.	1.3	9
915	Effect of PARP Inhibitors as Maintenance Treatment on Restricted Mean Survival Time in Platinum-Sensitive Recurrent Ovarian Cancer: A Systematic Review and Meta-analysis. Annals of Pharmacotherapy, 2022, 56, 27-34.	0.9	2
916	Successful treatment of an adult patient with diffuse midline glioma employing olaparib combined with bevacizumab. Investigational New Drugs, 2021, 39, 1432-1435.	1.2	2
917	Indazole as a Privileged Scaffold: The Derivatives and their Therapeutic Applications. Anti-Cancer Agents in Medicinal Chemistry, 2021, 21, 839-860.	0.9	20
918	Analysis of adverse events attribution and reporting in cancer clinical trials: A systematic review. Critical Reviews in Oncology/Hematology, 2021, 160, 103296.	2.0	5
919	Transient Response of Olaparib on Pulmonary Artery Sarcoma Harboring Multiple Homologous Recombinant Repair Gene Alterations. Journal of Personalized Medicine, 2021, 11, 357.	1.1	3
920	FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers. Cancers, 2021, 13, 1866.	1.7	12
921	Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trialâ˜†. Annals of Oncology, 2021, 32, 512-521.	0.6	93
922	Age of ovarian cancer diagnosis among BRIP1, RAD51C, and RAD51D mutation carriers identified through multi-gene panel testing. Journal of Ovarian Research, 2021, 14, 61.	1.3	12
923	Synthetic Lethality in Cancer Therapeutics: The Next Generation. Cancer Discovery, 2021, 11, 1626-1635.	7.7	91

#	Article	IF	Citations
924	Real-world hematological adverse events in Chinese patients with advanced ovarian cancer treated with an individualized starting dose of niraparib. Annals of Translational Medicine, 2021, 9, 869-869.	0.7	6
925	Ipilimumab and Pembrolizumab Mixed Response in a 41-Year-Old Patient with SMARCA4-Deficient Thoracic Sarcoma: An Interdisciplinary Case Study. Case Reports in Oncology, 2021, 14, 706-715.	0.3	15
926	Genetic alterations and their therapeutic implications in epithelial ovarian cancer. BMC Cancer, 2021, 21, 499.	1.1	27
927	Narrative review of novel chemotherapeutic agents in management of ovarian cancer. Gynecology and Pelvic Medicine, 0, 4, 19-19.	0.1	0
928	Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 632-642.	5.1	40
929	BRCA Genetic Test and Risk-Reducing Salpingo-Oophorectomy for Hereditary Breast and Ovarian Cancer: State-of-the-Art. Cancers, 2021, 13, 2562.	1.7	13
930	Management of advanced ovarian cancer in Spain: an expert Delphi consensus. Journal of Ovarian Research, 2021, 14, 72.	1.3	2
931	MET Expression and Cancer Stem Cell Networks Impact Outcome in High-Grade Serous Ovarian Cancer. Genes, 2021, 12, 742.	1.0	6
932	Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study. Gynecologic Oncology, 2021, 161, 512-515.	0.6	4
933	The role of blinded independent radiologic review in ovarian cancer clinical trials: Discerning the value. Gynecologic Oncology, 2021, 161, 491-495.	0.6	2
934	Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019. Journal of Clinical Oncology, 2021, 39, 1631-1640.	0.8	62
935	Pilot study of an online training program to increase genetic literacy and communication skills in oncology healthcare professionals discussing BRCA1/2 genetic testing with breast and ovarian cancer patients. Familial Cancer, 2022, 21, 157-166.	0.9	9
936	Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study. International Journal of Gynecological Cancer, 2021, 31, ijgc-2020-002343.	1.2	4
937	The impact of rifampicin on the pharmacokinetics of fuzuloparib in healthy Chinese male volunteers. British Journal of Clinical Pharmacology, 2021, , .	1.1	4
938	4-step, 2-h carboplatin desensitization in Japanese patients with ovarian cancer: a prospective study. International Journal of Clinical Oncology, 2021, 26, 1553-1560.	1.0	6
939	Present and Future for PARP Inhibitors in Ovarian Cancer. Advances in Oncology, 2021, 1, 139-154.	0.1	0
940	Poly (adenosine diphosphate [ADP]â€“ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis. Archives of Gynecology and Obstetrics, 2021, 304, 285-296.	0.8	10
941	Assessing the pricing and benefits of oncology products: an update. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 335-342.	0.7	4

#	Article	IF	Citations
942	FLABRA, frontline approach for BRCA testing in an ovarian cancer population: aÂLatin America epidemiologic study. Future Oncology, 2021, 17, 1601-1609.	1.1	2
943	Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer. Clinical Cancer Research, 2021, 27, 3734-3743.	3.2	17
944	Estrogen enhances the cytotoxicity of PARP inhibitors on breast cancer cells through stimulating nitric oxide production. Journal of Steroid Biochemistry and Molecular Biology, 2021, 209, 105853.	1.2	8
945	BRCA mutated pancreatic cancer: A change is coming. World Journal of Gastroenterology, 2021, 27, 1943-1958.	1.4	42
946	The Role of PARP Inhibitors in the Treatment of Prostate Cancer: Recent Advances in Clinical Trials. Biomolecules, 2021, 11, 722.	1.8	9
947	Precision medicine for hereditary tumors in gynecologicâ€‰malignancies. Journal of Obstetrics and Gynaecology Research, 2021, 47, 2597-2606.	0.6	11
948	Targeted Therapies in Older Adults With Solid Tumors. Journal of Clinical Oncology, 2021, 39, 2128-2137.	0.8	7
949	The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China. Journal of Ovarian Research, 2021, 14, 68.	1.3	6
950	Joint IARC/NCI International Cancer Seminar Series Report: expert consensus on future directions for ovarian carcinoma research. Carcinogenesis, 2021, 42, 785-793.	1.3	6
951	Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis. European Journal of Cancer, 2021, 149, 134-152.	1.3	41
952	PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data. Oral Oncology, 2021, 117, 105292.	0.8	21
953	Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice. Cancer Treatment Reviews, 2021, 97, 102187.	3.4	31
954	Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer. Expert Opinion on Pharmacotherapy, 2021, 22, 1-23.	0.9	3
955	Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3. International Journal of Gynecological Cancer, 2021, 31, 949-958.	1.2	7
956	Recurrent ovarian cancer in the era of poly-ADP ribose polymerase inhibitors: time to re-assess established clinical practices. ESMO Open, 2021, 6, 100135.	2.0	9
957	Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials. Gynecologic Oncology, 2021, 161, 653-659.	0.6	26
958	PARP inhibitor associated treatment related myeloid neoplasms: What was a â€œRareâ€•complication may be less so. Gynecologic Oncology, 2021, 161, 639-641.	0.6	3
959	PARP inhibitors promote stromal fibroblast activation by enhancing CCL5 autocrine signaling in ovarian cancer. Npj Precision Oncology, 2021, 5, 49.	2.3	10

#	Article	IF	Citations
960	An Algorithm Combining Patient Performance Status, Second Hit Analysis, PROVEAN and Dann Prediction Tools Could Foretell Sensitization to PARP Inhibitors in Digestive, Skin, Ovarian and Breast Cancers. Cancers, 2021, 13, 3113.	1.7	0
961	The systemic treatment of recurrent ovarian cancer revisited. Annals of Oncology, 2021, 32, 710-725.	0.6	61
962	The RAD51-FFPE Test; Calibration of a Functional Homologous Recombination Deficiency Test on Diagnostic Endometrial and Ovarian Tumor Blocks. Cancers, 2021, 13, 2994.	1.7	23
963	PARP inhibitors in gastric cancer: beacon of hope. Journal of Experimental and Clinical Cancer Research, 2021, 40, 211.	3.5	27
964	PARP-1 Regulates Estrogen-Dependent Gene Expression in Estrogen Receptor Î±â€“Positive Breast Cancer Cells. Molecular Cancer Research, 2021, 19, 1688-1698.	1.5	11
965	A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (Review). International Journal of Oncology, 2021, 59, .	1.4	66
966	Evaluation of the management of PARP inhibitor toxicities in ovarian and endometrial cancer within a multi-institution health-system. Journal of Oncology Pharmacy Practice, 2022, 28, 1102-1110.	0.5	1
967	Recent Advances in Therapeutic Application of DNA Damage Response Inhibitors against Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2022, 22, 469-484.	0.9	3
968	Research Progress of PARP Inhibitor Monotherapy and Combination Therapy for Endometrial Cancer. Current Drug Targets, 2022, 23, 145-155.	1.0	5
969	Remarkable Response to Olaparib in a Patient with Combined Hepatocellular-Cholangiocarcinoma Harboring a Biallelic BRCA2 Mutation. OncoTargets and Therapy, 2021, Volume 14, 3895-3901.	1.0	9
970	Frontline Maintenance Treatment for Ovarian Cancer. Current Oncology Reports, 2021, 23, 97.	1.8	3
971	Biomarkers for Homologous Recombination Deficiency in Cancer. Journal of Personalized Medicine, 2021, 11, 612.	1.1	38
972	A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors. Nature Cancer, 2021, 2, 598-610.	5.7	168
974	PARP inhibitors and immunotherapy in ovarian and endometrial cancers. British Journal of Radiology, 2021, 94, 20210002.	1.0	4
975	Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover). Clinical Cancer Research, 2021, 27, 4983-4993.	3.2	9
976	Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primaryÂanalysis of FORWARD I. Annals of Oncology, 2021, 32, 757-765.	0.6	105
977	Olaparib for the treatment of metastatic prostate cancer. Future Oncology, 2021, 17, 2413-2429.	1.1	2
978	Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer. Gynecologic Oncology, 2021, 163, 50-56.	0.6	1

#	Article	IF	Citations
979	Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma. Clinical Cancer Research, 2021, 27, 6622-6637.	3.2	7
980	Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer. American Journal of Obstetrics and Gynecology, 2021, 225, 68.e1-68.e11.	0.7	10
981	DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy. Signal Transduction and Targeted Therapy, 2021, 6, 254.	7.1	239
982	Olaparib as maintenance therapy and salvage therapy in recurrent ovarian cancer: The early experience in Taiwan. Taiwanese Journal of Obstetrics and Gynecology, 2021, 60, 634-638.	0.5	2
983	Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nature Reviews Clinical Oncology, 2021, 18, 773-791.	12.5	198
984	Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance. NAR Cancer, 2021, 3, zcab028.	1.6	20
985	Phase 2 non-randomised trial of secondary cytoreduction and hyperthermic intraperitoneal chemotherapy in recurrent platinum-sensitive ovarian cancer. Ecancermedicalscience, 2021, 15, 1260.	0.6	1
986	Changes in Stem Cell Regulation and Epithelial Organisation during Carcinogenesis and Disease Progression in Gynaecological Malignancies. Cancers, 2021, 13, 3349.	1.7	2
987	Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5â€“13/TESARO PR-30â€“50â€“10-C BRAVO Study. Clinical Cancer Research, 2021, 27, 5482-5491.	3.2	25
988	Emerging role of PARPâ€1 and PARthanatos in ischemic stroke. Journal of Neurochemistry, 2022, 160, 74-87.	2.1	39
989	Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database. Gynecologic Oncology, 2021, 163, 64-71.	0.6	3
990	Persistent response of an ovarian cancer patient after a short-term single-agent immunotherapy. Anti-Cancer Drugs, 2021, Publish Ahead of Print, .	0.7	0
991	Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment. Cancer Chemotherapy and Pharmacology, 2021, 88, 825-836.	1.1	8
992	Retrospective analysis of the role of cyclin E1 overexpression as a predictive marker for the efficacy of bevacizumab in platinum-sensitive recurrent ovarian cancer. Ecancermedicalscience, 2021, 15, 1262.	0.6	2
993	Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study. Journal of Clinical Oncology, 2021, 39, 2594-2604.	0.8	66
994	Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial. Gynecologic Oncology, 2021, 163, 41-49.	0.6	17
995	Efficacy and Safety of PARP Inhibitor Combination Therapy in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2021, 11, 638295.	1.3	6
996	Phase I Trial of Stereotactic MRI-Guided Online Adaptive Radiation Therapy (SMART) for the Treatment of Oligometastatic Ovarian Cancer. International Journal of Radiation Oncology Biology Physics, 2022, 112, 379-389.	0.4	28

#	Article	IF	Citations
997	Clinical benefit of systemic therapies for recurrent ovarian cancerâ€"ESMO-MCBS scores. ESMO Open, 2021, 6, 100229.	2.0	5
998	Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials. Expert Opinion on Investigational Drugs, 2021, 30, 975-983.	1.9	7
999	Association of Genetic Testing Results With Mortality Among Women With Breast Cancer or Ovarian Cancer. Journal of the National Cancer Institute, 2022, 114, 245-253.	3.0	5
1000	Skip pattern approach toward the early access of innovative anticancer drugs. ESMO Open, 2021, 6, 100227.	2.0	1
1001	Comparative Assessment of Diagnostic Homologous Recombination Deficiencyâ€"Associated Mutational Signatures in Ovarian Cancer. Clinical Cancer Research, 2021, 27, 5681-5687.	3.2	18
1002	Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial. Gynecologic Oncology, 2021, 162, 375-381.	0.6	7
1003	Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer. Vaccines, 2021, 9, 894.	2.1	9
1005	PARP inhibitors in advanced prostate cancer: when to use them?. Endocrine-Related Cancer, 2021, 28, T79-T93.	1.6	5
1006	Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study. Journal of Thoracic Oncology, 2021, 16, 1403-1414.	0.5	26
1007	Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 489-496.	0.7	7
1008	Safety profile of poly (ADP-ribose) polymerase (PARP) inhibitors in cancer: a network meta-analysis of randomized controlled trials. Annals of Translational Medicine, 2021, 9, 1229-1229.	0.7	10
1009	A CLEARER VIEW ON OVARIAN CLEAR CELL CARCINOMA. Acta Clinica Belgica, 2021, , 1-13.	0.5	4
1010	Impact of COVID-19 on medical treatment patterns in gynecologic oncology: a MITO group survey. International Journal of Gynecological Cancer, 2021, 31, 1363-1368.	1.2	3
1011	Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. Journal of Clinical Oncology, 2021, 39, 2698-2709.	0.8	83
1012	The evolving role of PARP inhibitors in advanced ovarian cancer. Forum of Clinical Oncology, 2021, 12, 82-104.	0.1	0
1013	Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review. Gynecologic Oncology, 2021, 162, 482-495.	0.6	31
1014	Targeting DNA damage repair pathways in pancreas cancer. Cancer and Metastasis Reviews, 2021, 40, 891-908.	2.7	18
1015	Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer. Gynecologic Oncology, 2021, 163, 254-261.	0.6	14

#	Article	IF	Citations
1016	An In-Depth Review of Niraparib in Ovarian Cancer: Mechanism of Action, Clinical Efficacy and Future Directions. Oncology and Therapy, 2021, 9, 347-364.	1.0	10
1017	Medication guide for the perioperative management of oral antineoplastic agents in cancer patients. Expert Opinion on Drug Safety, 2022, 21, 107-119.	1.0	2
1018	Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach. Journal of Investigative Dermatology, 2021, 141, 2028-2036.e2.	0.3	17
1019	Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of BRCA2 Status. Cells, 2021, 10, 2434.	1.8	2
1020	Prevalence of predictive biomarkers in a large cohort of molecularly defined adult-type ovarian granulosa cell tumors. Gynecologic Oncology, 2021, 162, 728-734.	0.6	4
1021	Molecular Pathology of Ovarian Epithelial Neoplasms. Surgical Pathology Clinics, 2021, 14, 415-428.	0.7	2
1022	Genomic Determinants of Homologous Recombination Deficiency across Human Cancers. Cancers, 2021, 13, 4572.	1.7	3
1023	Let-7i Reduces Aggressive Phenotype and Induces BRCAness in Ovarian Cancer Cells. Cancers, 2021, 13, 4617.	1.7	4
1024	Adverse Events as a Potential Clinical Marker of Antitumor Efficacy in Ovarian Cancer Patients Treated With Poly ADP-Ribose Polymerase Inhibitor. Frontiers in Oncology, 2021, 11, 724620.	1.3	3
1025	Outcomes after targeted treatment based on somatic tumor genetic testing for women with gynecologic cancers. Gynecologic Oncology, 2021, 163, 220-228.	0.6	4
1026	Next Generation Sequencing of Tumor and Matched Plasma Samples: Identification of Somatic Variants in ctDNA From Ovarian Cancer Patients. Frontiers in Oncology, 2021, 11, 754094.	1.3	5
1027	Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm?. Anticancer Research, 2021, 41, 4687-4695.	0.5	2
1028	Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinumâ€based regimen and disease at baseline on efficacy and safety. Cancer Medicine, 2021, 10, 7162-7173.	1.3	4
1029	Breast cancer treatment-related cardiovascular disturbances: advocacy for a watchful attitude in this never-ending story. Expert Opinion on Drug Safety, 2021, , 1-13.	1.0	0
1030	Ovarian Cancerâ€“Specific BRCA-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial. Clinical Cancer Research, 2021, 27, 6559-6569.	3.2	9
1031	Adjuvant and post-surgical treatment in high-grade epithelial ovarian cancer. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2022, 78, 64-73.	1.4	9
1032	Synthetic Lethality in Ovarian Cancer. Molecular Cancer Therapeutics, 2021, 20, 2117-2128.	1.9	20
1033	Real-world Experience of Niraparib in Newly-diagnosed Epithelial Ovarian Cancer. Anticancer Research, 2021, 41, 4603-4607.	0.5	0

#	Article	IF	Citations
1034	Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy. European Journal of Cancer, 2021, 154, 190-200.	1.3	9
1035	Metformin Affects Olaparib Sensitivity through Induction of Apoptosis in Epithelial Ovarian Cancer Cell Lines. International Journal of Molecular Sciences, 2021, 22, 10557.	1.8	13
1036	Synthetic lethality theory approaches to effective substance discovery and functional mechanisms elucidation of anti-cancer phytomedicine. Phytomedicine, 2021, 91, 153718.	2.3	5
1037	Surgery due to mechanical bowel obstruction in relapsed ovarian cancer: clinical and surgical results of a bicentric analysis of 87 patients. Archives of Gynecology and Obstetrics, 2022, 305, 963-968.	0.8	6
1038	Comparative safety and tolerability of approved PARP inhibitors in cancer: A systematic review and network meta-analysis. Pharmacological Research, 2021, 172, 105808.	3.1	20
1039	Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises. Trends in Cancer, 2021, 7, 958-970.	3.8	18
1040	Histological patterns and intra-tumor heterogeneity as prognostication tools in high grade serous ovarian cancers. Gynecologic Oncology, 2021, 163, 498-505.	0.6	7
1041	Budget impact analysis of niraparib for first-line maintenance therapy in advanced ovarian cancer from a US payer perspective. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 1377-1387.	0.5	0
1042	Efficacy and safety of PARP inhibitors in patients with BRCA-mutated advanced breast cancer: A meta-analysis and systematic review. Breast, 2021, 60, 26-34.	0.9	9
1043	Principles of radiation therapy and chemotherapy in gynecologic cancer. , 2022, , 618-636.e1.		2
1044	Malignant diseases of the ovary, fallopian tube, and peritoneum. , 2022, , 707-753.e7.		2
1045	Primary platinum resistance and its prognostic impact in patients with recurrent ovarian cancer: an analysis of three prospective trials from the NOGGO study group. Journal of Gynecologic Oncology, 2021, 32, e37.	1.0	5
1046	Immunohistochemical Biomarkers as a Surrogate of Molecular Analysis in Ovarian Carcinomas: A Review of the Literature. Diagnostics, 2021, 11, 199.	1.3	24
1047	Phase 2 single-arm study on the safety of maintenance niraparib in Japanese patients with platinum-sensitive relapsed ovarian cancer. Journal of Gynecologic Oncology, 2021, 32, e21.	1.0	7
1048	The role of PARP inhibitors in BRCA mutated pancreatic cancer. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110148.	1.4	21
1049	PARP inhibitors in the treatment of ovarian cancer: a review. Current Opinion in Obstetrics and Gynecology, 2021, 33, 1-6.	0.9	17
1050	A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01). Journal of Gynecologic Oncology, 2021, 32, e31.	1.0	17
1051	DNA Damage Response. , 2021, , 1-12.		0

#	Article	IF	Citations
1052	Genomic Cancer Risk Assessment. , 2020, , 187-207.		1
1053	PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer. Critical Reviews in Oncology/Hematology, 2020, 152, 102973.	2.0	31
1054	PARP inhibition in the ovarian cancer patient: Current approvals and future directions. , 2020, 213, 107588.		7
1055	Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials. Bioscience Reports, 2020, 40, .	1.1	13
1056	Nephrotoxicity Associated With Niraparib. American Journal of Kidney Diseases, 2020, 76, 898-900.	2.1	8
1057	Homologous recombination repair deficiency as a therapeutic target in sarcoma. Seminars in Oncology, 2020, 47, 380-389.	0.8	26
1058	Update on the Role of Poly (ADP-Ribose) Polymerase Inhibitors in the DNA Repair-Deficient Pancreatic Cancers: A Narrative Review. Journal of Pancreatic Cancer, 2020, 6, 107-115.	1.6	5
1059	Concordance Between Tumor and Germline BRCA Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial. Journal of the National Cancer Institute, 2021, 113, 917-923.	3.0	26
1060	Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment. Obstetrics and Gynecology, 2021, 137, 108-121.	1.2	150
1061	The Many Uses of p53 Immunohistochemistry in Gynecological Pathology: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual9 Meeting. International Journal of Gynecological Pathology, 2021, 40, 32-40.	0.9	37
1067	Repositioning PARP inhibitors for SARSâ€CoVâ€2 infection(COVIDâ€19); a new multiâ€pronged therapy for acute respiratory distress syndrome?. British Journal of Pharmacology, 2020, 177, 3635-3645.	2.7	52
1068	Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors. International Journal of Gynecological Cancer, 2020, 30, 89-93.	1.2	30
1069	EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression. Clinical Cancer Research, 2020, 26, 4206-4215.	3.2	84
1070	The evolving landscape of predictive biomarkers of response to PARP inhibitors. Journal of Clinical Investigation, 2018, 128, 1727-1730.	3.9	47
1071	A PET imaging agent for evaluating PARP-1 expression in ovarian cancer. Journal of Clinical Investigation, 2018, 128, 2116-2126.	3.9	100
1072	XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592097420.	1.4	10
1073	Genomic Alteration in Metastatic Breast Cancer and Its Treatment. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 30-43.	1.8	107
1074	Avatrombopag Optimizes Response to Niraparib by Managing Thrombocytopenia Associated with Poly-ADP Ribose Polymerase (PARP) Inhibition in Ovarian Cancer and Breast Cancer: A Case Series. American Journal of Case Reports, 2020, 21, e927008.	0.3	5

#	Article	IF	Citations
1075	The frequency of cancer predisposition gene mutations in hereditary breast and ovarian cancer patients in Taiwan: From BRCA1/2 to multi-gene panels. PLoS ONE, 2017, 12, e0185615.	1.1	22
1076	DFT investigations on arylsulphonyl pyrazole derivatives as potential ligands of selected kinases. Open Chemistry, 2020, 18, 857-873.	1.0	6
1077	Constitutional Mosaic Epimutations â€“ a hidden cause of cancer?. Cell Stress, 2019, 3, 118-135.	1.4	22
1078	AURKA inhibition mimics BRCAness. Aging, 2017, 9, 1945-1946.	1.4	6
1079	â€œBack to a false normalityâ€• new intriguing mechanisms of resistance to PARP inhibitors. Oncotarget, 2017, 8, 23891-23904.	0.8	24
1080	Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer. Oncotarget, 2017, 8, 44073-44081.	0.8	63
1081	Germline mutations in pancreatic cancer and potential new therapeutic options. Oncotarget, 2017, 8, 73240-73257.	0.8	40
1082	Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting. Oncotarget, 2017, 8, 43653-43661.	0.8	85
1083	BRCA mutations in the manifestation and treatment of ovarian cancer. Oncotarget, 2017, 8, 97657-97670.	0.8	32
1084	Loss of BRCA1 promotor hypermethylation in recurrent high-grade ovarian cancer. Oncotarget, 2017, 8, 83063-83074.	0.8	20
1085	High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy. Oncotarget, 2017, 8, 104430-104443.	0.8	5
1086	ADAM17 inhibition enhances platinum efficiency in ovarian cancer. Oncotarget, 2018, 9, 16043-16058.	0.8	17
1087	Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk. Oncotarget, 2019, 10, 2855-2868.	0.8	13
1088	Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer. Oncotarget, 2019, 10, 6981-6996.	0.8	9
1089	PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues. , 2019, 2, 665-679.		20
1090	Mechanisms of resistance to PARP inhibitors - an evolving challenge in oncology. , 2019, 2, 608-617.		3
1091	Current practices on genetic testing in ovarian cancer. Annals of Translational Medicine, 2020, 8, 1703-1703.	0.7	7
1092	Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?. Annals of Translational Medicine, 2020, 8, 1706-1706.	0.7	17

#	Article	IF	Citations
1093	Biliary tract cancer prognostic and predictive genomics. Chinese Clinical Oncology, 2019, 8, 42-42.	0.4	15
1094	Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2020, 32, 370-382.	0.7	18
1095	Niraparib as Maintenance Therapy in Germline ATM-mutated and Somatic BRCA2-mutated Ovarian Cancer with Brain Metastases: A Case Report and Literature Review . OncoTargets and Therapy, 2020, Volume 13, 12979-12986.	1.0	7
1096	DNA Double Strand Break Repair - Related Synthetic Lethality. Current Medicinal Chemistry, 2019, 26, 1446-1482.	1.2	9
1097	Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance. Current Drug Targets, 2020, 21, 167-178.	1.0	10
1098	Hereditary ovarian cancers: state of the art. Minerva Medica, 2019, 110, 301-319.	0.3	15
1099	New medical approaches in advanced ovarian cancer. Minerva Medica, 2019, 110, 367-384.	0.3	6
1100	PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation. Cancers, 2020, 12, 394.	1.7	91
1101	The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas. Cancers, 2020, 12, 2805.	1.7	30
1102	Integration of PARP-inhibitors in ovarian cancer therapy. Exploration of Targeted Anti-tumor Therapy, 2020, 1, 171-182.	0.5	3
1103	Major clinical research advances in gynecologic cancer in 2019. Journal of Gynecologic Oncology, 2020, 31, e48.	1.0	10
1104	A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study. Journal of Gynecologic Oncology, 2020, 31, e61.	1.0	6
1105	Pharmacological ascorbate induces â€˜BRCAnessâ€™ and enhances the effects of Poly(ADPâ€˜Ribose) polymerase inhibitors against BRCA1/2 wildâ€˜type ovarian cancer. Oncology Letters, 2020, 19, 2629-2638.	0.8	8
1106	Expression and clinical significance of methylâ€˜CpG binding domain protein 2 in highâ€˜grade serous ovarian cancer. Oncology Letters, 2020, 20, 2749-2756.	0.8	7
1107	PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective (Review). Oncology Letters, 2020, 20, 1-1.	0.8	16
1108	miRâ€˜1299/NOTCH3/TUG1 feedback loop contributes to the malignant proliferation of ovarian cancer. Oncology Reports, 2020, 44, 438-448.	1.2	16
1109	Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer. Obstetrics and Gynecology Science, 2020, 63, 643-654.	0.6	4
1110	New Therapies for Ovarian Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 619-621.	2.3	19

#	Article	IF	Citations
1111	Molecular Testing Identifies Determinants of Exceptional Response and Guides Precision Therapy in a Patient with Lethal, Treatment-emergent Neuroendocrine Prostate Cancer. Cureus, 2019, 11, e5197.	0.2	4
1112	Genetic Alterations in Ovarian Cancer as Prognostic and Predictive Biomarkers of Therapy Response and Surgical Outcomes. , 2021, , 135-166.		0
1113	Cutting-Edge Technologies for Ovarian Cancer: An Overview of the Impact of Genetic Testing, Next-Generation Sequencing, and Single-Cell Analysis. , 2021, , 203-229.		0
1114	The Hallmarks of Ovarian Cancer: Actionable Genetics, Targetable Pathways, and Predictive Biomarkers. , 2021, , 59-133.		0
1115	An Introduction to the Current Management of Ovarian Cancer in the Era of Precision Oncology. , 2021, , 19-57.		0
1116	Insights into ovarian cancer care: report from the ANZGOG Ovarian Cancer Webinar Series 2020. Journal of Gynecologic Oncology, 2021, 32, e95.	1.0	5
1117	JASPER: Phase 2 trial of firstâ€line niraparib plus pembrolizumab in patients with advanced nonâ€“small cell lung cancer. Cancer, 2022, 128, 65-74.	2.0	36
1118	Molecular response to PARP1 inhibition in ovarian cancer cells as determined by mass spectrometry based proteomics. Journal of Ovarian Research, 2021, 14, 140.	1.3	8
1119	The role of patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testing. Journal of Experimental and Clinical Cancer Research, 2021, 40, 338.	3.5	12
1120	PARP Inhibitors and Haematological Malignanciesâ€”Friend or Foe?. Cancers, 2021, 13, 5328.	1.7	6
1121	Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. International Journal of Gynecology and Obstetrics, 2021, 155, 61-85.	1.0	145
1122	Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physicianâ€™s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33). International Journal of Gynecological Cancer, 2021, 31, 1369-1373.	1.2	12
1123	Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. Gynecologic Oncology, 2021, 163, 246-253.	0.6	62
1124	Evolution of Clinical Trials in Ovarian Cancer Management over the Past 20 Years: Never Settle Down, Always Go Beyond. Journal of Oncology, 2021, 2021, 1-5.	0.6	3
1125	Homologous Recombination Deficiency Assays in Epithelial Ovarian Cancer: Current Status and Future Direction. Frontiers in Oncology, 2021, 11, 675972.	1.3	21
1126	Diverse landscape of dermatologic toxicities from smallâ€molecule inhibitor cancer therapy. Journal of Cutaneous Pathology, 2022, 49, 61-81.	0.7	5
1127	Generation of Two Paclitaxel-Resistant High-Grade Serous Carcinoma Cell Lines With Increased Expression of P-Glycoprotein. Frontiers in Oncology, 2021, 11, 752127.	1.3	9
1128	Harnessing multimodal data integration to advance precision oncology. Nature Reviews Cancer, 2022, 22, 114-126.	12.8	168

#	Article	IF	Citations
1130	A DNA Damage Response Gene Panel for Different Histologic Types of Epithelial Ovarian Carcinomas and Their Outcomes. Biomedicines, 2021, 9, 1384.	1.4	4
1131	Setting a diagnostic benchmark for tumor BRCA testing: detection of BRCA1 and BRCA2 large genomic rearrangements in FFPE tissue â€“ A pilot study. Experimental and Molecular Pathology, 2021, 123, 104705.	0.9	1
1132	Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer. Cancer Science, 2021, 112, 5055-5067.	1.7	6
1133	Development of New Cancer Treatment by Identifying and Focusing the Genetic Mutations or Altered Expression in Gynecologic Cancers. Genes, 2021, 12, 1593.	1.0	2
1134	Targeting DNA Repair Response Promotes Immunotherapy in Ovarian Cancer: Rationale and Clinical Application. Frontiers in Immunology, 2021, 12, 661115.	2.2	7
1135	Immunological configuration of ovarian carcinoma: features and impact on disease outcome. , 2021, 9, e002873.		30
1136	Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational Study. Cancers, 2021, 13, 5152.	1.7	7
1137	Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer. Journal of Translational Medicine, 2021, 19, 415.	1.8	25
1138	Ovarian cancerâ€”ASCO annual meeting update 2021. Memo - Magazine of European Medical Oncology, 2021, 14, 342.	0.3	1
1139	PARP inhibitors: clinical relevance and the role of multidisciplinary cancer teams on drug safety. Expert Opinion on Drug Safety, 2022, 21, 541-551.	1.0	2
1140	PARP inhibitors in ovarian cancer treatment: more than a hope. Cancer Breaking News, 2016, 4, 3-5.	0.0	0
1143	New perspectives for colorectal cancer. Oncotarget, 2017, 8, 41782-41783.	0.8	0
1144	Maintenance treatment with gemcitabine have a promising activity on metastatic bladder cancer survival. Turkish Journal of Urology, 2017, 43, 273-278.	1.3	3
1146	Neue Arzneimittel 2017. , 2018, , 53-148.		0
1147	Gynecological Symptoms. , 2018, , 505-526.		0
1148	Epithelial Tumors of the Ovary. , 2018, , 1-128.		0
1150	Role of Poly Adenosine Diphosphate Ribose Polymerase Inhibitors in Advanced Stage Ovarian Cancer. Cureus, 2018, 10, e2685.	0.2	2
1152	Management of QT Prolongation Induced by Anticancer Drugs. Current Clinical Pathology, 2019, , 123-132.	0.0	0

#	Article	IF	Citations
1153	Maligne epitheliale Tumoren des Ovars. , 2019, , 101-129.		0
1154	Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinations. Drugs in Context, 2018, 7, 1-9.	1.0	3
1156	Time to go functional! Determining tumorsâ€™ DNA repair capacity ex vivo. Oncotarget, 2018, 9, 36826-36827.	0.8	0
1157	Advances in the Treatment of Endometrial and Ovarian Cancer. Oncology & Hematology Review, 2019, 15, 23.	0.2	0
1158	Onkologika. , 2019, , 817-875.		0
1159	Maintenance Treatment for Recurrent Ovarian Carcinoma â€“ Evidence Supporting the Efficacy and Safety of PARP Inhibitors. European Oncology and Haematology, 2019, 15, 29.	0.0	1
1160	Identification of patients with pancreatic adenocarcinoma due to inheritable mutation: Challenges of daily clinical practice. World Journal of Gastrointestinal Oncology, 2019, 11, 102-116.	0.8	2
1161	Rucaparib and Niraparib in Advanced Ovarian Cancer. Journal of the Advanced Practitioner in Oncology, 2019, 10, 402-408.	0.2	4
1163	Current topics in hereditary breast and ovarian cancer. Okayama Igakkai Zasshi, 2019, 131, 89-96.	0.0	1
1165	Molecular Testing in Ovarian Cancer: Recommendations and Treatment Considerations. , 2020, , 171-186.		0
1166	Practical aspects of treating relapsed BRCA-associated ovarian cancer. Meditsinskiy Sovet, 2019, , 144-149.	0.1	0
1167	Olaparib, a new hope for ovarian cancer. Indian Journal of Cancer, 2020, 57, 346-347.	0.2	0
1168	Onkologika. , 2020, , 671-732.		2
1172	PARP1 inhibitors in breast cancer therapy. Mechanism of action and clinical use. Opuholi Zenskoj Reproduktivnoj Sistemy, 2020, 16, 55-64.	0.1	0
1176	Paradigm shifts in gynecologic oncology. International Journal of Gynecological Cancer, 2021, 31, ijgc-2021-003108.	1.2	2
1177	Association of Soluble B7-H4 and Circulating Tumor Cells in Blood of Advanced Epithelial Ovarian Cancer Patients. Frontiers in Oncology, 2021, 11, 721067.	1.3	4
1178	U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review. Clinical Cancer Research, 2022, 28, 1058-1071.	3.2	11
1179	BRCA1 Versus BRCA2 and PARP Inhibitors Efficacy in Solid Tumors:A Meta-Analysis of Randomized Controlled Trials. Frontiers in Oncology, 2021, 11, 718871.	1.3	6

#	Article	IF	Citations
1180	Adverse events of targeted therapies approved for women's cancers. International Journal of Women's Dermatology, 2021, 7, 552-559.	1.1	0
1181	Stakeholder attitudes towards establishing a national genomics registry of inherited cancer predisposition: a qualitative study. Journal of Community Genetics, 2022, 13, 59-73.	0.5	2
1182	Utilization of Poly(ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer: A Retrospective Cohort Study of US Healthcare Claims Data. Advances in Therapy, 2022, 39, 328-345.	1.3	9
1183	Ovarian cancer risk assessment in the era of next-generation sequencing. Annals of Translational Medicine, 2020, 8, 1704-1704.	0.7	3
1184	Targeting Six Hallmarks of Cancer in Ovarian Cancer Therapy. Current Cancer Drug Targets, 2020, 20, 853-867.	0.8	1
1185	Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile. Targeted Oncology, 2021, 16, 59-68.	1.7	9
1188	A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial. International Journal of Gynecological Cancer, 2021, 31, 617-622.	1.2	21
1189	Breast metastasis from pelvic high-grade serous adenocarcinoma: a report of two cases. Surgical Case Reports, 2020, 6, 317.	0.2	1
1190	Current and future landscape of poly (ADP-ribose) polymerase inhibition resistance. Current Opinion in Obstetrics and Gynecology, 2021, 33, 19-25.	0.9	8
1191	Maligne Tumoren des Ovars. , 2020, , 439-454.		0
1193	Olaparib and bevacizumab in front-line maintenance of ovarian cancer: an over reliance in unpowered subgroup analysis of the PAOLA-1 trial?. Journal of Gynecologic Oncology, 2020, 31, e95.	1.0	0
1194	Management options for gynecological cancers in low- to middle-income countries amidst COVID-19 pandemic. Journal of Cancer Research and Practice, 2020, 7, 121.	0.2	1
1195	Inhibitors of the Fanconi anaemia pathway as potential antitumour agents for ovarian cancer. , 2020, 1, 26-52.		0
1198	Longâ€'term response to Olaparib in carcinomatous meningitis of a BRCA2 mutated ovarian cancer: A case report. Molecular and Clinical Oncology, 2020, 13, 73-75.	0.4	8
1199	Current and Future Directions for PARP Inhibition. Journal of the Advanced Practitioner in Oncology, 2020, 11, 297-300.	0.2	0
1200	Targeting DNA Damage Response Pathway in Ovarian Clear Cell Carcinoma. Frontiers in Oncology, 2021, 11, 666815.	1.3	9
1201	Quantitative Analysis of the Efficacy of PARP Inhibitors as Maintenance Therapy in Recurrent Ovarian Cancer. Frontiers in Pharmacology, 2021, 12, 771836.	1.6	0
1202	BRCA1/2 Mutation Types Do Not Affect Prognosis in Ovarian Cancer Patients. Current Oncology, 2021, 28, 4446-4456.	0.9	2

#	Article	IF	Citations
1203	Role of Maintenance Gemcitabine in Advanced Carcinoma Gallbladder. South Asian Journal of Cancer, 2020, 09, 204-208.	0.2	1
1204	Pathways to Genome-targeted Therapies in Serous Ovarian Cancer. Journal of Nature and Science, 2017, 3, .	1.1	0
1205	Poly (ADP-ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: A Drug Class Review. P and T, 2018, 43, 549-556.	1.0	9
1206	Using PARP Inhibitors in Advanced Ovarian Cancer. Oncology, 2018, 32, 339-43.	0.4	19
1207	Treatment algorithm in patients with ovarian cancer. Facts, Views & Vision in ObGyn, 2020, 12, 227-239.	0.5	2
1208	TSL-1502, a glucuronide prodrug of a poly (ADP-ribose) polymerase (PARP) inhibitor, exhibits potent anti-tumor activity in preclinical models. American Journal of Cancer Research, 2021, 11, 1632-1645.	1.4	1
1209	Efficacy of Poly(ADP-Ribose) Polymerase Inhibitors for Hereditary Ovarian Cancer. , 2021, , 313-324.		0
1211	Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis. Frontiers in Oncology, 2021, 11, 785102.	1.3	4
1212	Treatment Perspectives for Ovarian Cancer in Europe and the United States: Initial Therapy and Platinum-Sensitive Recurrence after PARP Inhibitors or Bevacizumab Therapy. Current Oncology Reports, 2021, 23, 148.	1.8	7
1214	Maintenance Treatment of Newly Diagnosed Advanced Ovarian Cancer: Time for a Paradigm Shift?. Cancers, 2021, 13, 5756.	1.7	11
1215	Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations. Frontiers in Pharmacology, 2021, 12, 743073.	1.6	10
1216	Characteristics of Germline Non-BRCA Mutation Status of High-Risk Breast Cancer Patients in China and Correlation with High-Risk Factors and Multigene Testing Suggestions. Frontiers in Genetics, 2021, 12, 674094.	1.1	15
1217	Melanoma Targeted Therapies beyond BRAF-Mutant Melanoma: Potential Druggable Mutations and Novel Treatment Approaches. Cancers, 2021, 13, 5847.	1.7	16
1218	BRCA1/ATF1-Mediated Transactivation is Involved in Resistance to PARP Inhibitors and Cisplatin. Cancer Research Communications, 2021, 1, 90-105.	0.7	6
1219	Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma. Cancer Research, 2022, 82, 307-319.	0.4	8
1221	Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours. British Journal of Cancer, 2022, 126, 576-585.	2.9	7
1222	Structure-based virtual screening towards the discovery of novelÂFOXM1Âinhibitors. Future Medicinal Chemistry, 2022, 14, 207-219.	1.1	3
1224	European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer. Annals of Oncology, 2022, 33, 276-287.	0.6	68

#	Article	IF	Citations
1226	DNA Damage Response. , 2021, , 536-547.		0
1228	Onkologika. , 2021, , 579-638.		0
1229	Real-World Data From a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients With Precision Medicine. JCO Precision Oncology, 2022, 6, e2000508.	1.5	7
1230	Homologous Recombination Deficiency Associated With Response to Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer Patients: The First Real-World Evidence From China. Frontiers in Oncology, 2021, 11, 746571.	1.3	10
1231	Homologous recombination deficiency testing in first-line ovarian cancer. Annals of Oncology, 2022, 33, 231-233.	0.6	1
1232	Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study. ESMO Open, 2022, 7, 100311.	2.0	7
1233	Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer. Neoplasia, 2022, 24, 63-75.	2.3	14
1235	Use of PARP Inhibitors for Ovarian Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 636-638.	2.3	1
1236	Poly(ADP-Ribose) Polymerase Inhibitor Inhibition in Ovarian Cancer. Cancer Journal (Sudbury, Mass), 2021, 27, 432-440.	1.0	5
1237	PARP Inhibitors in Pancreatic Cancer. Cancer Journal (Sudbury, Mass), 2021, 27, 465-475.	1.0	18
1238	New Roles of Poly(ADP-Ribose) Polymerase Inhibitors in the Treatment of Breast Cancer. Cancer Journal (Sudbury, Mass), 2021, 27, 441-456.	1.0	3
1239	Beyond BRCA1/2: Homologous Recombination Repair Genetic Profile in a Large Cohort of Apulian Ovarian Cancers. Cancers, 2022, 14, 365.	1.7	5
1240	PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers. Cancers, 2022, 14, 599.	1.7	8
1241	Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets. BMC Cancer, 2022, 22, 13.	1.1	15
1242	Clinical significance of metabolism-related genes and FAK activity in ovarian high-grade serous carcinoma. BMC Cancer, 2022, 22, 59.	1.1	3
1243	Safety Profile of Niraparib as Maintenance Therapy for Ovarian Cancer: A Systematic Review and Meta-Analysis. Current Oncology, 2022, 29, 321-336.	0.9	5
1244	Homologous Recombination Deficiency: Concepts, Definitions, and Assays. Oncologist, 2022, 27, 167-174.	1.9	69
1245	A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial. Journal of Gynecologic Oncology, 2022, 33, .	1.0	6

#	Article	IF	Citations
1246	Validation of Anticorrelated TGFÎ² Signaling and Alternative End-Joining DNA Repair Signatures that Predict Response to Genotoxic Cancer Therapy. Clinical Cancer Research, 2022, 28, 1372-1382.	3.2	6
1247	Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study. Gynecologic Oncology, 2022, 165, 40-48.	0.6	10
1248	Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis. Gynecologic Oncology, 2022, 164, 498-504.	0.6	24
1249	Medication adherence reporting in pivotal clinical trials: overview of oral oncological drugs. European Journal of Hospital Pharmacy, 2023, 30, 328-332.	0.5	4
1250	<scp>PARP</scp> mediated <scp>DNA</scp> damage response, genomic stability and immune responses. International Journal of Cancer, 2022, 150, 1745-1759.	2.3	18
1252	The key players of parthanatos: opportunities for targeting multiple levels in the therapy of parthanatos-based pathogenesis. Cellular and Molecular Life Sciences, 2022, 79, 60.	2.4	35
1253	Oleanolic Acid (OA) Targeting UNC5B Inhibits Proliferation and EMT of Ovarian Cancer Cell and Increases Chemotherapy Sensitivity of Niraparib. Journal of Oncology, 2022, 2022, 1-12.	0.6	2
1254	Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. Gynecologic Oncology, 2022, 164, 245-253.	0.6	15
1255	A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI â€“ GINECO study. Gynecologic Oncology, 2022, 165, 30-39.	0.6	11
1256	Testing for homologous recombination deficiency â€“ does it provide new insights for the use of veliparib?. Gynecologic Oncology, 2022, 164, 243-244.	0.6	0
1257	Mutation Landscape of Homologous Recombination Repair Genes in Epithelial Ovarian Cancer in China and Its Relationship With Clinicopathlological Characteristics. Frontiers in Oncology, 2022, 12, 709645.	1.3	4
1258	Patients' and oncologists' preferences for second-line maintenance PARP inhibitor therapy in epithelial ovarian cancer. Future Oncology, 2022, 18, 491-503.	1.1	3
1259	Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology. Cancer Treatment Reviews, 2022, 104, 102337.	3.4	6
1260	Re-treatment with PARPi in patients with recurrent epithelial ovarian cancer: A single institutional experience. Gynecologic Oncology Reports, 2022, 40, 100939.	0.3	7
1261	Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study. Gynecologic Oncology, 2022, 165, 97-104.	0.6	8
1262	Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA). Clinical Cancer Research, 2022, 28, 2278-2285.	3.2	12
1263	The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases. Molecular Cancer Therapeutics, 2022, 21, 555-567.	1.9	11
1264	Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Patients With Advanced Nonâ€“Squamous Nonâ€“Small Cell Lung Cancer. Clinical Lung Cancer, 2022, 23, 214-225.	1.1	14

#	Article	IF	Citations
1266	Molecular methods for increasing the effectiveness of ovarian cancer treatment: a systematic review. Future Oncology, 2022, 18, 1627-1650.	1.1	3
1268	Perspectives on PARP Inhibitor Combinations for Ovarian Cancer. Frontiers in Oncology, 2021, 11, 754524.	1.3	7
1269	Targeting the DNA damage response: PARP inhibitors and new perspectives in the landscape of cancer treatment. Critical Reviews in Oncology/Hematology, 2021, 168, 103539.	2.0	11
1270	The Use of Targeted Agents in the Treatment of Gynecologic Cancers. Current Treatment Options in Oncology, 2022, 23, 15-28.	1.3	3
1271	Torsades de pointes in patients with cancer. , 2022, , 285-301.		0
1272	Mechanisms of chemotherapy resistance in ovarian cancer. Cancer Drug Resistance (Alhambra, Calif), 0, , .	0.9	17
1273	PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies. Journal of Gynecologic Oncology, 2022, 33, .	1.0	18
1274	The BRCA Gene in Epithelial Ovarian Cancer. Cancers, 2022, 14, 1235.	1.7	9
1275	PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components. OncoTargets and Therapy, 2022, Volume 15, 165-180.	1.0	15
1276	Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study. Cancers, 2022, 14, 915.	1.7	4
1277	RAD51 as a functional biomarker for homologous recombination deficiency in cancer: a promising addition to the HRD toolbox?. Expert Review of Molecular Diagnostics, 2022, 22, 185-199.	1.5	16
1278	Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives. Frontiers in Oncology, 2022, 12, 831612.	1.3	5
1279	Applicability of Anticancer Drugs for the Triple-Negative Breast Cancer Based on Homologous Recombination Repair Deficiency. Frontiers in Cell and Developmental Biology, 2022, 10, 845950.	1.8	4
1280	The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer. Annals of Oncology, 2022, 33, 593-601.	0.6	10
1281	Status of the Current Treatment Options and Potential Future Targets in Uterine Leiomyosarcoma: A Review. Cancers, 2022, 14, 1180.	1.7	8
1282	PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities. Cancers, 2022, 14, 1003.	1.7	18
1283	Evolution of Immunotherapy for Ovarian Cancer from a Birdâ€™s-Eye Perspective: A Text-Mining Analysis of Publication Trends and Topics. Frontiers in Oncology, 2022, 12, 795129.	1.3	5
1284	Everything Comes with a Price: The Toxicity Profile of DNA-Damage Response Targeting Agents. Cancers, 2022, 14, 953.	1.7	16

#	Article	IF	Citations
1285	Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. The Cochrane Library, 2022, 2022, CD007929.	1.5	22
1286	Angiogenesis: A Pivotal Therapeutic Target in the Drug Development of Gynecologic Cancers. Cancers, 2022, 14, 1122.	1.7	5
1287	PTEN Loss and BRCA1 Promoter Hypermethylation Negatively Predict for Immunogenicity in BRCA-Deficient Ovarian Cancer. JCO Precision Oncology, 2022, 6, e2100159.	1.5	4
1288	Durable Disease-free Survival in a Patient with Metastatic Triple-negative Breast Cancer Treated with Olaparib Monotherapy. Current Cancer Drug Targets, 2022, 22, 530-536.	0.8	4
1289	Clinical Benefit With PARP Inhibitor for Pathogenic Germline FANCA-Mutated Relapsed Epithelial Ovarian Cancer: A Case Report. Frontiers in Oncology, 2022, 12, 778545.	1.3	4
1290	Modulation of Type I Interferon Responses to Influence Tumor-Immune Cross Talk in PDAC. Frontiers in Cell and Developmental Biology, 2022, 10, 816517.	1.8	4
1291	Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives. Cancers, 2022, 14, 1098.	1.7	8
1292	Response to Chemotherapy and Clinical Outcome of Patients With Recurrent Epithelial Ovarian Cancer After PARP Inhibitor Maintenance Treatment: A Multicenter Retrospective Italian Study. Anticancer Research, 2022, 42, 2017-2022.	0.5	8
1293	Integrating Precision Medicine into the Contemporary Management of Gynecologic Cancers. Current Oncology Reports, 2022, 24, 889-904.	1.8	3
1294	Application of Regulatory Cell Death in Cancer: Based on Targeted Therapy and Immunotherapy. Frontiers in Immunology, 2022, 13, 837293.	2.2	23
1295	The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy. International Journal of Molecular Sciences, 2022, 23, 3871.	1.8	14
1296	Tumor BRCA Testing in Epithelial Ovarian Cancers: Past and Futureâ€"Five-Yearsâ€™ Single-Institution Experience of 762 Consecutive Patients. Cancers, 2022, 14, 1638.	1.7	3
1297	PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth. BMC Cancer, 2022, 22, 312.	1.1	3
1298	BRCA status and platinum sensitivity in advanced ovarian cancer according to Chemotherapy Response Score. International Journal of Gynecological Cancer, 2022, 32, 639-645.	1.2	5
1299	Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer. Cancers, 2022, 14, 1388.	1.7	22
1300	HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer. Cell Death and Disease, 2022, 13, 263.	2.7	19
1301	Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups. International Journal of Gynecological Cancer, 2022, 32, 799-803.	1.2	2
1302	Maintenance niraparib therapy for patients with relapsed platinum sensitive ovarian cancer: experience at a south coast network. Journal of Prescribing Practice, 2022, 4, 122-127.	0.1	0

#	Article	IF	Citations
1303	Novel Ex Vivo Models of Epithelial Ovarian Cancer: The Future of Biomarker and Therapeutic Research. Frontiers in Oncology, 2022, 12, 837233.	1.3	2
1304	Distinct Genomic Profiles Are Associated with Treatment Response and Survival in Ovarian Cancer. Cancers, 2022, 14, 1511.	1.7	5
1305	Pancytopenia in a patient treated with fusidic acid and niraparib: a case report. European Journal of Hospital Pharmacy, 2022, , ejhpharm-2021-002819.	0.5	1
1306	Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis. BMC Cancer, 2022, 22, 346.	1.1	4
1307	Antitumoral Effect of Plocabulin in High Grade Serous Ovarian Carcinoma Cell Line Models. Frontiers in Oncology, 2022, 12, 862321.	1.3	1
1308	Next Generation Sequencing and Molecular Biomarkers in Ovarian Cancerâ€"An Opportunity for Targeted Therapy. Diagnostics, 2022, 12, 842.	1.3	15
1309	Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS. Frontiers in Pharmacology, 2022, 13, 851246.	1.6	15
1310	Treatment patterns after poly-ADP ribose polymerase (PARP) inhibitors in epithelial ovarian cancer patients. International Journal of Gynecological Cancer, 2022, , ijgc-2021-003009.	1.2	0
1311	Clinical evidence and insights supporting the use of avelumab firstâ€line maintenance treatment in patients with advanced urothelial carcinoma in the Asiaâ€Pacific region. Asia-Pacific Journal of Clinical Oncology, 2022, 18, .	0.7	5
1312	Loss of Claudin-4 Reduces DNA Damage Repair and Increases Sensitivity to PARP Inhibitors. Molecular Cancer Therapeutics, 2022, 21, 647-657.	1.9	3
1313	Uterine carcinosarcoma associated with a germline nibrin (NBN) mutation. Gynecologic Oncology Reports, 2022, 40, 100979.	0.3	0
1314	Synthesis of novel dual target inhibitors of PARP and EGFR and their antitumor activities in triple negative breast cancers. Bioorganic and Medicinal Chemistry, 2022, 61, 116739.	1.4	9
1315	A phase I study of talazoparib (<scp>BMN</scp> 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (<scp>NCI9782</scp>). Cancer Medicine, 2022, 11, 3969-3981.	1.3	11
1316	Integrated, Integral, and Exploratory Biomarkers in the Development of Poly(ADP-Ribose) Polymerase Inhibitors. Cancer Journal (Sudbury, Mass), 2021, 27, 482-490.	1.0	0
1317	Development of Next-Generation Poly(ADP-Ribose) Polymerase 1â€"Selective Inhibitors. Cancer Journal (Sudbury, Mass), 2021, 27, 521-528.	1.0	10
1318	Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy. Cancer Journal (Sudbury, Mass), 2021, 27, 506-510.	1.0	1
1319	With Our Powers Combined. Cancer Journal (Sudbury, Mass), 2021, 27, 511-520.	1.0	1
1320	PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword. Cancers, 2021, 13, 6385.	1.7	19

#	Article	IF	Citations
1321	The Increasing Prognostic and Predictive Roles of the Tumor Primary Chemosensitivity Assessed by CA-125 Elimination Rate Constant K (KELIM) in Ovarian Cancer: A Narrative Review. Cancers, 2022, 14, 98.	1.7	16
1322	Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer. Biomedicines, 2022, 10, 77.	1.4	12
1323	Medium levels of transcription and replication related chromosomal instability are associated with poor clinical outcome. Scientific Reports, 2021, 11, 23429.	1.6	1
1324	Prise en charge mÃ©dicale de la rÃ©cidive du cancer Ã©pithÃ©lial de l'ovaire. Bulletin Du Cancer, 2021, 108, S22-S32.	0.6	0
1325	The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers. Journal of Hematology and Oncology, 2021, 14, 206.	6.9	24
1326	Treatment-induced sarcoidosis in a patient with metastatic clear cell ovarian cancer. BMJ Case Reports, 2021, 14, e247278.	0.2	1
1327	Targeting DNA repair pathway in cancer: Mechanisms and clinical application. MedComm, 2021, 2, 654-691.	3.1	34
1328	Revisiting the Implications of Positive Germline Testing Results Using Multi-gene Panels in Breast Cancer Patients. Cancer Genomics and Proteomics, 2022, 19, 60-78.	1.0	5
1329	Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer. Cells, 2021, 10, 3408.	1.8	4
1330	The future potential of genome-wide mutational profiles in HRD detection in breast cancer. Expert Review of Molecular Diagnostics, 2022, 22, 1-3.	1.5	0
1331	Organoids and epithelial ovarian cancer â€‘ a future tool for personalized treatment decisions?. Molecular and Clinical Oncology, 2021, 16, 29.	0.4	2
1332	Case Report: Niraparib as Maintenance Therapy in A Patient With Ovarian Carcinosarcoma. Frontiers in Oncology, 2021, 11, 603591.	1.3	3
1333	Treatment of Epithelial Ovarian Cancers, Fallopian Tube Cancers and Peritoneal Surface Cancers. , 2021, , 357-365.		0
1334	Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment on the POLO trial: a case report. Journal of Gastrointestinal Oncology, 2021, 12, 3133-3140.	0.6	2
1335	OUP accepted manuscript. Japanese Journal of Clinical Oncology, 2022, , .	0.6	0
1336	Recent Advances in Ovarian Cancer Treatment. Journal of the Nihon University Medical Association, 2022, 81, 23-28.	0.0	0
1337	Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification. Cancer Research, 2022, 82, 1646-1657.	0.4	40
1338	Appropriate Selection of PARP Inhibitors in Ovarian Cancer. Current Treatment Options in Oncology, 2022, 23, 887-903.	1.3	17

#	Article	IF	Citations
1339	A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer. Cancer Chemotherapy and Pharmacology, 2022, 89, 721-735.	1.1	5
1340	Individualization in the first-line treatment of advanced ovarian cancer based on the mechanism of action of molecularly targeted drugs. International Journal of Clinical Oncology, 2022, 27, 1001-1012.	1.0	8
1341	An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer. Cancer Chemotherapy and Pharmacology, 2022, 89, 683-695.	1.1	6
1342	Antiangiogenic Strategies in Epithelial Ovarian Cancer: Mechanism, Resistance, and Combination Therapy. Journal of Oncology, 2022, 2022, 1-15.	0.6	18
1343	Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial. Journal of Clinical Oncology, 2022, 40, 2436-2446.	0.8	24
1344	A Real World Perspective of PARP Inhibitor Use in Gynecological Cancer Patients. Journal of Pharmacy Practice, 2023, 36, 1134-1141.	0.5	2
1345	Targeting mutations in cancer. Journal of Clinical Investigation, 2022, 132, .	3.9	56
1354	Developing patient-derived organoids to predict PARP inhibitor response and explore resistance overcoming strategies in ovarian cancer. Pharmacological Research, 2022, 179, 106232.	3.1	8
1355	Research progress in the treatment of partial platinum-sensitive recurrent ovarian cancer. Journal of Central South University (Medical Sciences), 2021, 46, 644-652.	0.1	0
1356	The Overtreatment and Cost Effectiveness of Primary Secondary Maintenance Therapy with Poly-Adenosine Ribose Phosphate Inhibitors (PARPi) for Epithelial Ovarian Cancer (EOC).. Gynecology & Obstetrics (Sunnyvale, Calif), 2021, 11, .	0.1	0
1357	Exploiting induced vulnerability to overcome PARPi resistance and clonal heterogeneity in BRCA mutant triple-negative inflammatory breast cancer.. American Journal of Cancer Research, 2022, 12, 337-354.	1.4	0
1358	Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052). Journal of Gynecologic Oncology, 2022, 33, .	1.0	4
1360	Novel Therapeutic Approaches with DNA Damage Response Inhibitors for Melanoma Treatment. Cells, 2022, 11, 1466.	1.8	6
1361	Successful Treatment of a Patient With Brain Metastasis From Ovarian Cancer With BRCA Wild Type Using Niraparib: A Case Report and Review of the Literature. Frontiers in Oncology, 2022, 12, 873198.	1.3	5
1362	BCKDK Promotes Ovarian Cancer Proliferation and Migration by Activating the MEK/ERK Signaling Pathway. Journal of Oncology, 2022, 2022, 1-14.	0.6	5
1363	Combinatorial Treatment with PARP-1 Inhibitors and Cisplatin Attenuates Cervical Cancer Growth through Fos-Driven Changes in Gene Expression. Molecular Cancer Research, 2022, 20, 1183-1192.	1.5	7
1364	Niraparib Shows Superior Tissue Distribution and Efficacy in a Prostate Cancer Bone Metastasis Model Compared with Other PARP Inhibitors. Molecular Cancer Therapeutics, 2022, 21, 1115-1124.	1.9	3
1365	The Emerging Roles and Therapeutic Implications of Epigenetic Modifications in Ovarian Cancer. Frontiers in Endocrinology, 2022, 13, .	1.5	6

#	Article	IF	Citations
1366	Effect of bevacizumab combined with chemotherapy on SDF-1 and CXCR4 in epithelial ovarian cancer and its prognosis. World Journal of Surgical Oncology, 2022, 20, 154.	0.8	3
1367	Potential clinical utility of liquid biopsies in ovarian cancer. Molecular Cancer, 2022, 21, 114.	7.9	51
1368	Update on Biology and Genomics of Adrenocortical Carcinomas: Rationale for Emerging Therapies. Endocrine Reviews, 2022, 43, 1051-1073.	8.9	9
1369	The effect of PARP inhibitors in homologous recombination proficient ovarian cancer: meta-analysis. Journal of Chemotherapy, 2022, , 1-8.	0.7	3
1370	Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review. Cancers, 2022, 14, 2470.	1.7	4
1371	Rotational intraperitoneal pressurized aerosol chemotherapy with paclitaxel and cisplatin: pharmacokinetics, tissue concentrations, and toxicities in a pig model. Journal of Gynecologic Oncology, 2022, 33, .	1.0	2
1372	Clinical Landscape of PARP Inhibitors in Ovarian Cancer: Molecular Mechanisms and Clues to Overcome Resistance. Cancers, 2022, 14, 2504.	1.7	12
1373	Efficacy and Safety of Placebo During the Maintenance Therapy of Ovarian Cancer in Randomized Controlled Trials: A Systematic Review and Meta-analysis. Frontiers in Oncology, 2022, 12, .	1.3	0
1374	Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies. ESMO Open, 2022, 7, 100459.	2.0	26
1376	Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu. Gynecologic Oncology, 2022, 166, 351-357.	0.6	8
1377	Homologous Recombination Deficiency and Ovarian Cancer Treatment Decisions. Surgical Pathology Clinics, 2022, , .	0.7	0
1378	Saltâ€Inducible Kinase 2â€Triggered Release of Its Inhibitor from Hydrogel to Suppress Ovarian Cancer Metastasis. Advanced Science, 2022, 9, .	5.6	13
1379	Non-Coding RNAs Delivery by Small Extracellular Vesicles and Their Applications in Ovarian Cancer. Frontiers in Bioengineering and Biotechnology, 2022, 10, .	2.0	2
1380	Prospects of PARP Inhibitors in Treatment of BRCA-Mutated Pancreatic Cancer: a Literature Review. KreativnaÃ¢ HirurgiÃ¢ I OnkologiÃ¢, 2022, 12, 48-55.	0.1	0
1381	Adverse events in the placebo arm of maintenance therapy trials in advanced ovarian cancer: A systematic review and meta-analysis. European Journal of Cancer, 2022, 170, 169-178.	1.3	2
1383	Gynecologic malignancies. , 2023, , 310-318.		0
1384	Ovarian cancer recurrence: â€œis the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?â€• Cancer Drug Resistance (Alhambra, Calif), 2022, 5, 451-458.	0.9	6
1385	A Phase II Trial to Evaluate the Efficacy of Bortezomib and Liposomal Doxorubicin in Patients With BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer (KGOG 3044/EBLIN). In Vivo, 2022, 36, 1949-1958.	0.6	4

#	Article	IF	Citations
1386	PARP Inhibitors Rising as an Epoch-Making Strategy in First-Line Maintenance Therapy of Ovarian Cancer: A Systematic Review and Meta-Analysis. Cancer Investigation, 2022, 40, 889-900.	0.6	1
1387	Chemotherapy Regimens Received by Women with BRCA1/2 Pathogenic Variants for Early-Stage Breast Cancer Treatment. JNCI Cancer Spectrum, 0, , .	1.4	0
1388	Biomarker Assessment of Homologous Recombination Deficiency in Epithelial Ovarian Cancer: Association With Progression-Free Survival After Surgery. Frontiers in Molecular Biosciences, 0, 9, .	1.6	1
1389	Myelodysplastic Syndrome/Acute Myeloid Leukemia Following the Use of Poly-ADP Ribose Polymerase (PARP) Inhibitors: A Real-World Analysis of Postmarketing Surveillance Data. Frontiers in Pharmacology, 0, 13, .	1.6	8
1390	Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD). Npj Precision Oncology, 2022, 6, .	2.3	23
1391	PARP Inhibitors: A New Horizon for Patients with Prostate Cancer. Biomedicines, 2022, 10, 1416.	1.4	20
1392	Robust prognostic model based on immune infiltrationâ€related genes and clinical information in ovarian cancer. Journal of Cellular and Molecular Medicine, 0, , .	1.6	1
1393	Comparative Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Ovarian Cancer: A Systematic Review and Network Meta-Analysis. Frontiers in Oncology, 0, 12, .	1.3	8
1394	OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab. Gynecologic Oncology, 2022, 166, 219-229.	0.6	23
1395	Recent advances in structural types and medicinal chemistry of PARP-1 inhibitors. Medicinal Chemistry Research, 2022, 31, 1265-1276.	1.1	5
1396	A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers. Current Oncology, 2022, 29, 4354-4369.	0.9	1
1397	The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair. Cancers, 2022, 14, 2950.	1.7	9
1398	Optimizing treatment selection and sequencing decisions for first-line maintenance therapy of newly diagnosed advanced ovarian cancer â€“ International considerations amongst upper middle- and high-income countries (UMIC and HIC). Gynecologic Oncology Reports, 2022, 42, 101028.	0.3	5
1399	Predicting the likelihood of aBRCA1/2pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer. Journal of Clinical Pathology, 2023, 76, 684-689.	1.0	0
1400	Olaparib maintenance therapy after frontline chemotherapy in patients with BRCA-mutated ovarian cancer: real-world results in expanded access program. Meditsinskiy Sovet, 2022, , 77-83.	0.1	0
1401	Exploring the structural and functional requirements of Phyto-compounds and their synthetic scaffolds as anticancer agents: Medicinal chemistry perspective. Pharmacological Research Modern Chinese Medicine, 2022, 4, 100123.	0.5	3
1402	Hyperthermia synergistically enhances antitumor efficacy of PARP inhibitor through impacting homologous recombination repair and oxidative stress inÂvitro. Biochemical and Biophysical Research Communications, 2022, 619, 49-55.	1.0	1
1403	Molecular Mechanisms of Parthanatos and Its Role in Diverse Diseases. International Journal of Molecular Sciences, 2022, 23, 7292.	1.8	31

#	Article	IF	Citations
1404	Homologous recombination repair deficiency (HRD) testing in newly diagnosed advanced-stage epithelial ovarian cancer: A Belgian expert opinion. Facts, Views & Vision in ObGyn, 2022, 14, 111-120.	0.5	1
1405	Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial. Annals of Oncology, 2022, 33, 1021-1028.	0.6	50
1406	Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials. Journal of Market Access & Health Policy, 2022, 10, .	0.8	2
1407	Low BRCA1/2 germline mutation rate in a French-Canadian population with a diagnosis of epithelial tubo-ovarian carcinoma. Journal of Obstetrics and Gynaecology Canada, 2022, , .	0.3	0
1408	Epithelial Ovarian Cancer: Providing Evidence of Predisposition Genes. International Journal of Environmental Research and Public Health, 2022, 19, 8113.	1.2	48
1410	Impact of bevacizumab and secondary cytoreductive surgery on survival outcomes in platinum-sensitive relapsed ovarian clear cell carcinoma: A multicenter study in Korea. Gynecologic Oncology, 2022, 166, 444-452.	0.6	2
1412	Impairment of RAD17 Functions by miR-506-3p as a Novel Synthetic Lethal Approach Targeting DNA Repair Pathways in Ovarian Cancer. Frontiers in Oncology, 0, 12, .	1.3	2
1413	Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification. Clinical Cancer Research, 2022, 28, 3546-3556.	3.2	5
1414	Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis. Gynecologic Oncology, 2022, 166, 425-431.	0.6	12
1415	RAD21 Confers Poor Prognosis and Affects Ovarian Cancer Sensitivity to Poly(ADP-Ribose)Polymerase Inhibitors Through DNA Damage Repair. Frontiers in Oncology, 0, 12, .	1.3	3
1416	Reconsidering the mechanisms of action of <scp>PARP</scp> inhibitors based on clinical outcomes. Cancer Science, 2022, 113, 2943-2951.	1.7	11
1417	Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer. International Journal of Environmental Research and Public Health, 2022, 19, 8577.	1.2	49
1418	Cost-Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Cancer Treatment: A Systematic Review. Frontiers in Pharmacology, 0, 13, .	1.6	1
1419	Niraparib treatment for patients with BRCA-mutated ovarian cancer: review of clinical data and therapeutic context. Future Oncology, 2022, 18, 2505-2536.	1.1	4
1420	Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer. Nature Cancer, 2022, 3, 927-931.	5.7	12
1421	Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial. Lancet Oncology, The, 2022, 23, 1009-1020.	5.1	44
1422	High Expression of PARP1 in Tumor and Stroma Cells Predicts Different Prognosis and Platinum Resistance in Patients With Advanced Epithelial Ovarian Cancer. Frontiers in Oncology, 0, 12, .	1.3	1
1424	Effect of <i>BRCA1/2</i> Mutational Status on Survival Outcomes According to Secondary Cytoreductive Surgery and Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer: A Real-World Evidence Study. Cancer Research and Treatment, 0, , .	1.3	0

#	Article	IF	Citations
1425	The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review. International Journal of Molecular Sciences, 2022, 23, 8125.	1.8	9
1426	PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib. Scientific Reports, 2022, 12, .	1.6	3
1427	Management of oligometastatic ovarian cancer recurrence during PARP inhibitor maintenance. International Journal of Gynecological Cancer, 2022, 32, 1164-1170.	1.2	12
1428	Polyethylene Glycol 3350 (PEG 3350) as a Practical Vehicle for Rapid Reconstitution of PARPi-FL Formulations for Clinical Use. Molecular Imaging and Biology, 0, , .	1.3	0
1429	Health-related quality of life analysis in ovarian cancer clinical trials involving PARP inhibitors: a critical methodological perspective. Quality of Life Research, 0, , .	1.5	1
1430	Maintenance therapy for newly diagnosed epithelial ovarian cancerâ€“ a review. Journal of Ovarian Research, 2022, 15, .	1.3	11
1431	Longâ€‘term survival of a BRCA2 mutation carrier following second ovarian cancer relapse using PARPi therapy: A case report. Molecular and Clinical Oncology, 2022, 17, .	0.4	1
1432	Survey on implementation of molecular testing in ovarian cancer and PARP inhibitor: a national North-Eastern German Society of Gynecologic Oncology/Young Academy of Gynecologic Oncology/Arbeitsgemeinschaft GynÄkologische Onkologie intergroup analysis. International Journal of Gynecological Cancer, 0, , ijgc-2022-003637.	1.2	0
1433	Hematological toxicities in <scp>PARP</scp> inhibitors: A realâ€world study using <scp>FDA</scp> adverse event reporting system (<scp>FAERS</scp>) database. Cancer Medicine, 2023, 12, 3365-3375.	1.3	18
1434	A novel cell line panel reveals non-genetic mediators of platinum resistance and phenotypic diversity in high grade serous ovarian cancer. Gynecologic Oncology, 2022, , .	0.6	2
1435	PARP Inhibitors: Clinical Limitations and Recent Attempts to Overcome Them. International Journal of Molecular Sciences, 2022, 23, 8412.	1.8	19
1436	Are Women with Antecedent Low-Grade Cytology and <CIN2 Findings in Colposcopy Being Overmanaged?. Journal of Obstetrics and Gynaecology Canada, 2022, 44, 1054-1060.	0.3	1
1438	Comparative Analyses of Poly(ADP-Ribose) Polymerase Inhibitors. International Journal of Toxicology, 0, , 109158182211213.	0.6	0
1439	Case Report: Fluzoparib for multiple lines of chemotherapy refractory in metastatic cutaneous squamous cell carcinoma with BRCA2 pathogenic mutation. Frontiers in Pharmacology, 0, 13, .	1.6	1
1440	MicroRNA-dependent inhibition of WEE1 controls cancer stem-like characteristics and malignant behavior in ovarian cancer. Molecular Therapy - Nucleic Acids, 2022, 29, 803-822.	2.3	5
1441	Examining the Diagnostic Yield of Tumour Testing and Qualifying Germline Concordance for Hereditary Cancer Variants in Patients with High-Grade Serous Carcinoma. Genes, 2022, 13, 1398.	1.0	1
1442	What predicts the clinical benefits of PARP inhibitors in platinum-sensitive recurrent ovarian cancer: A real-world single-center retrospective cohort study from China. Frontiers in Oncology, 0, 12, .	1.3	4
1443	BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside. Cancers, 2022, 14, 3888.	1.7	56

#	Article	IF	Citations
1444	Pharmacotherapeutic treatment options for recurrent epithelial ovarian cancer. Expert Opinion on Pharmacotherapy, 2023, 24, 49-64.	0.9	1
1445	Phase I trial of ribociclib with platinum chemotherapy in ovarian cancer. JCI Insight, 2022, 7, .	2.3	6
1446	Japanese nationwide observational multicenter study of tumor BRCA1/2 variant testing in advanced ovarian cancer. Cancer Science, 2023, 114, 271-280.	1.7	6
1448	Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms. Current Hematologic Malignancy Reports, 2022, 17, 254-265.	1.2	6
1449	A pilot study investigating feasibility of mainstreaming germline BRCA1 and BRCA2 testing in high-risk patients with breast and/or ovarian cancer in three tertiary Cancer Centres in Ireland. Familial Cancer, 2023, 22, 135-149.	0.9	2
1450	Upregulation of PARG in prostate cancer cells suppresses their malignant behavior and downregulates tumor-promoting genes. Biomedicine and Pharmacotherapy, 2022, 153, 113504.	2.5	2
1451	Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial. EClinicalMedicine, 2022, 52, 101595.	3.2	14
1452	Next-generation sequencing identifies potential novel therapeutic targets in Chinese HGSOC patients. Pathology Research and Practice, 2022, 238, 154074.	1.0	4
1453	Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse Setting. Cancers, 2022, 14, 4414.	1.7	7
1454	Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis. ESMO Open, 2022, 7, 100558.	2.0	7
1455	Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer. Clinical Medicine Insights: Oncology, 2022, 16, 117955492211105.	0.6	4
1456	Recent advances of non-coding RNAs in ovarian cancer prognosis and therapeutics. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211180.	1.4	7
1457	Downregulation of S100A9 Reverses Cisplatin-Resistance and Inhibits Proliferation and Migration in Hypopharyngeal Carcinoma. Journal of Oncology, 2022, 2022, 1-12.	0.6	1
1458	Comprehensive Analysis of Adverse Events Induced by PARP Inhibitors Using JADER and Time to Onset. Life, 2022, 12, 1355.	1.1	2
1460	Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers. Clinical Cancer Research, 2022, 28, 4714-4723.	3.2	15
1461	Enrollment of Individuals From Racial and Ethnic Minority Groups in Gynecologic Cancer Precision Oncology Trials. Obstetrics and Gynecology, 2022, 140, 654-661.	1.2	7
1462	Impact of BRCA Gene Testing on Ovarian Cancer Management. European Journal of Medical and Health Sciences, 2022, 4, 1-6.	0.1	0
1463	A clinical case of repeat use of PARP inhibitors in a patient with <i>mBRCA</i>-associated ovarian cancer. Siberian Journal of Oncology, 2022, 21, 156-164.	0.1	0

#	Article	IF	Citations
1464	Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer. Cell Death and Disease, 2022, 13, .	2.7	17
1465	HRD-MILN: Accurately estimate tumor homologous recombination deficiency status from targeted panel sequencing data. Frontiers in Genetics, 0, 13, .	1.1	1
1466	Leveraging an Informatics Approach to Identify an Unmet Clinical Need for BRCA1/2 Testing Among Patients With Ovarian Cancer. JCO Clinical Cancer Informatics, 2022, , .	1.0	0
1467	PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer. , 0, , .		0
1468	Therapy for Recurrent High-Grade Epithelial Ovarian Cancerâ€"The Current Status and Future Trends. Indian Journal of Medical and Paediatric Oncology, 0, , .	0.1	0
1469	Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy. Clinical Cancer Research, 2023, 29, 40-49.	3.2	3
1470	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in an Australian institution: lessons from 20Âyearsâ€™ experience. BMC Surgery, 2022, 22, .	0.6	1
1471	Combination of ligand and structure based virtual screening approaches for the discovery of potential PARP1 inhibitors. PLoS ONE, 2022, 17, e0272065.	1.1	3
1472	Therapeutic targeting of DNA damage repair pathways guided by homologous recombination deficiency scoring in ovarian cancers. Fundamental and Clinical Pharmacology, 2023, 37, 194-214.	1.0	1
1473	ATF6-Mediated Signaling Contributes to PARP Inhibitor Resistance in Ovarian Cancer. Molecular Cancer Research, 2023, 21, 3-13.	1.5	7
1474	Germline BRCA mutation carriers are more likely to undergo cytoreductive surgery for relapsed, platinum sensitive, ovarian cancer. Gynecologic Oncology, 2022, , .	0.6	1
1476	Clinical significance of SPOCK2 expression signature for high-grade serous ovarian cancer patients. Frontiers in Genetics, 0, 13, .	1.1	0
1477	Integrated proteomics identifies PARP inhibitor-induced prosurvival signaling changes as potential vulnerabilities in ovarian cancer. Journal of Biological Chemistry, 2022, 298, 102550.	1.6	1
1478	PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond. Cancers, 2022, 14, 4332.	1.7	17
1479	Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival. Cancers, 2022, 14, 4621.	1.7	3
1481	Epithelial ovarian cancer: Review article. Cancer Treatment and Research Communications, 2022, 33, 100629.	0.7	26
1482	Recurrent Ovarian Cancer with BRCAness Phenotype: A Treatment Challenge. Advances in Therapy, 2022, 39, 5289-5299.	1.3	6
1483	Anti-cancer agents and drug-induced hypertension. Medical Alphabet, 2022, , 30-41.	0.0	0

#	Article	IF	Citations
1484	APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas. Annals of Oncology, 2022, 33, 1284-1295.	0.6	22
1485	High detection rate from genetic testing in BRCA-negative women with familial epithelial ovarian cancer. Genetics in Medicine, 2022, , .	1.1	2
1486	Characteristics of homologous recombination repair pathway genes mutation in ovarian cancers. , 2022, 1, 220-228.		0
1487	Reply to C. Marchetti et al. Journal of Clinical Oncology, 0, , .	0.8	0
1488	Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors. OncoTargets and Therapy, 0, Volume 15, 1105-1117.	1.0	7
1489	Temporal Patterns and Adoption of Germline and Somatic BRCA Testing in Ovarian Cancer. Obstetrics and Gynecology, 2022, 140, 758-767.	1.2	3
1491	Efficacy evaluation of multi-immunotherapy in ovarian cancer: From bench to bed. Frontiers in Immunology, 0, 13, .	2.2	8
1492	Overview of fuzuloparib in the treatment of ovarian cancer: background and future perspective. Journal of Gynecologic Oncology, 2022, 33, .	1.0	3
1493	Hereditary Ovarian Cancer. , 2022, , 43-55.		0
1494	Management of Recurrent Ovarian Cancer. , 2022, , 121-128.		0
1495	Personalized Treatment in Ovarian Cancer. Comprehensive Gynecology and Obstetrics, 2022, , 1-19.	0.0	0
1496	Contrasting clinical characteristics and treatment patterns in women with newly diagnosed advanced-stage epithelial ovarian cancer in Australia, South Korea and Taiwan. Journal of Gynecologic Oncology, 2022, 34, .	1.0	2
1497	Clinical Relevance of BRCA1/2 Pathogenic Variants and Impaired DNA Repair Pathways in Ovarian Carcinomas. Comprehensive Gynecology and Obstetrics, 2022, , 59-76.	0.0	0
1499	Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy. Pharmacological Research, 2022, 186, 106529.	3.1	13
1500	Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology. JCO Precision Oncology, 2022, , .	1.5	7
1501	Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors. Journal of Biomedical Science, 2022, 29, .	2.6	9
1502	Ad hocAnalysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in GermlineBRCAWild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects. Cancer Research Communications, 2022, 2, 1436-1444.	0.7	2
1503	State of the Biomarker Science in Ovarian Cancer: A National Cancer Institute Clinical Trials Planning Meeting Report. JCO Precision Oncology, 2022, , .	1.5	2

#	Article	IF	Citations
1504	A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes. Nature Cancer, 2022, 3, 1181-1191.	5.7	42
1505	Frontline Management of Advanced Epithelial Ovarian Cancer: A Comprehensive Statement by an Expert Group from Middle East and North Africa Region. Current Women's Health Reviews, 2022, 19, .	0.1	0
1506	Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology. Clinical Pharmacokinetics, 2022, 61, 1649-1675.	1.6	23
1507	Immune Checkpoint Inhibitors and Other Immune Therapies in Breast Cancer: A New Paradigm for Prolonged Adjuvant Immunotherapy. Biomedicines, 2022, 10, 2511.	1.4	10
1508	Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis. International Journal of Gynecological Cancer, 2022, 32, 1410-1418.	1.2	8
1509	Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer. Cell Death and Disease, 2022, 13, .	2.7	6
1510	DNA methylation of the immediate upstream region of BRCA1 major transcription start sites is an independent favorable prognostic factor in patients with high-grade serous ovarian cancer. Gynecologic Oncology, 2022, , .	0.6	1
1513	Data Set for the Reporting of Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma: Recommendations From the International Collaboration on Cancer Reporting (ICCR). International Journal of Gynecological Pathology, 2022, 41, S119-S142.	0.9	5
1514	Integrative Genomic Tests in Clinical Oncology. International Journal of Molecular Sciences, 2022, 23, 13129.	1.8	8
1515	Trabectedin and lurbinectedin: Mechanisms of action, clinical impact, and future perspectives in uterine and soft tissue sarcoma, ovarian carcinoma, and endometrial carcinoma. Frontiers in Oncology, 0, 12, .	1.3	11
1516	Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective. European Journal of Cancer, 2023, 179, 136-146.	1.3	13
1517	Societal costs of ovarian cancer in a population-based cohort â€“ a cost of illness analysis. Acta OncolÃ³gica, 2022, 61, 1369-1376.	0.8	1
1518	Synthesis and antineoplastic activity of ethylene glycol phenyl aminoethyl ether derivatives as FOXM1 inhibitors. European Journal of Medicinal Chemistry, 2022, 244, 114877.	2.6	1
1520	Epithelial ovarian cancer. , 2023, , 250-281.e8.		0
1521	Targeted therapy and molecular genetics. , 2023, , 464-488.e11.		0
1522	Resistance to Poly (ADP-Ribose) Polymerase Inhibitors (PARPi): Mechanisms and Potential to Reverse. Current Oncology Reports, 2022, 24, 1685-1693.	1.8	6
1523	A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors. International Journal of Clinical Oncology, 0, , .	1.0	0
1524	Cost-effectiveness of poly-(ADP-ribose) polymerase (PARP)-inhibitors for the maintenance treatment after responding to first- and second-line chemotherapy in advanced ovarian cancer. Journal of Oncology Pharmacy Practice, 0, , 107815522211377.	0.5	0

#	Article	IF	Citations
1525	A comprehensive comparison of medication strategies for platinum-sensitive recurrent ovarian cancer: A Bayesian network meta-analysis. Frontiers in Pharmacology, 0, 13, .	1.6	1
1526	Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain â€“ A GEICO study. BMC Cancer, 2022, 22, .	1.1	4
1528	Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors. JAMA Oncology, 2023, 9, 29.	3.4	21
1529	Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers. Breast Cancer Research, 2022, 24, .	2.2	4
1530	PARP Inhibitors as a Novel Treatment Strategy for Patients with BRCA-Mutated Metastatic Breast Cancer. European Medical Journal Oncology, 0, , 68-76.	0.0	1
1531	Molecular targets that sensitize cancer to radiation killing: From the bench to the bedside. Biomedicine and Pharmacotherapy, 2023, 158, 114126.	2.5	1
1532	Design and reporting of phase III oncology trials with prospective biomarker validation. Journal of the National Cancer Institute, 0, , .	3.0	1
1533	Les organoÃ¯des dèrivèls de tumeurs (ou tumoroÃ¯des), des outils de choix pour la mèdecine de prècision en oncologie. Medecine/Sciences, 2022, 38, 888-895.	0.0	1
1534	Referral, Genetic Counselling, and BRCA Testing in the Manitoba High-Grade Serous Ovarian Cancer Population, 2004â€“2019. Current Oncology, 2022, 29, 9365-9376.	0.9	0
1535	[18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study. Clinical Cancer Research, 2023, 29, 1515-1527.	3.2	6
1536	Clinical Significance of Tie-2-Expressing Monocytes/Macrophages and Angiopoietins in the Progression of Ovarian Cancerâ€”State-of-the-Art. Cells, 2022, 11, 3851.	1.8	0
1537	Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis. Annals of Oncology, 2023, 34, 152-162.	0.6	18
1538	Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality. Cancers, 2022, 14, 5795.	1.7	4
1539	Guidance on the management of adverse reactions induced by poly(ADP-ribose) polymerase inhibitors. Zhejiang Da Xue Xue Bao Yi Xue Ban = Journal of Zhejiang University Medical Sciences, 2022, 51, 765-774.	0.1	0
1540	A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib. Scientific Reports, 2022, 12, .	1.6	14
1541	Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trial. International Journal of Clinical Oncology, 2023, 28, 163-174.	1.0	1
1542	Concordance between single-nucleotide polymorphismâ€“based genomic instability assays and a next-generation sequencingâ€“based homologous recombination deficiency test. BMC Cancer, 2022, 22, .	1.1	4
1544	Association between control group therapy and magnitude of clinical benefit of cancer drugs. Scientific Reports, 2022, 12, .	1.6	0

#	Article	IF	Citations
1545	Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged â‰¥65 years from the PAOLA-1/ENGOT-ov25 trial. European Journal of Cancer, 2023, 181, 42-52.	1.3	5
1546	A novel combination of niraparib and anlotinib in platinum-resistant ovarian cancer: Efficacy and safety results from the phase II, multi-center ANNIE study. EClinicalMedicine, 2022, 54, 101767.	3.2	6
1547	Mass spectrometry imaging in gynecological cancers: the best is yet to come. Cancer Cell International, 2022, 22, .	1.8	0
1548	The potential of PARP inhibitors in targeted cancer therapy and immunotherapy. Frontiers in Molecular Biosciences, 0, 9, .	1.6	12
1549	Interstitial brachytherapy combined with PARP inhibitors in the treatment of chemoresistant recurrent epithelial ovarian cancer: A case report. Frontiers in Oncology, 0, 12, .	1.3	1
1550	Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers. Journal of Thoracic Oncology, 2023, 18, 463-475.	0.5	24
1551	The rapid evolution of PARP inhibitor therapy for advanced ovarian cancer: Lessons being learned and new questions emerging from phase 3 trial long-term outcome data. Gynecologic Oncology, 2022, 167, 401-403.	0.6	2
1553	Towards Personalized Management of Ovarian Cancer. Cancer Management and Research, 0, Volume 14, 3469-3483.	0.9	4
1555	Targeting DNA damage response pathways in cancer. Nature Reviews Cancer, 2023, 23, 78-94.	12.8	158
1556	Clinical Impact of Next-Generation Sequencing Multi-Gene Panel Highlighting the Landscape of Germline Alterations in Ovarian Cancer Patients. International Journal of Molecular Sciences, 2022, 23, 15789.	1.8	3
1557	Molecular Targeted Therapy in Oncology Focusing on DNA Repair Mechanisms. Archives of Medical Research, 2022, 53, 807-817.	1.5	1
1558	Evolving DNA repair synthetic lethality targets in cancer. Bioscience Reports, 2022, 42, .	1.1	3
1559	Trabectedin plus pegylated liposomal doxorubicin in patients with disease progression after PARP inhibitor maintenance: a real-life caseâ€“control study. International Journal of Gynecological Cancer, 2023, 33, 243-249.	1.2	3
1560	IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation. BMC Cancer, 2022, 22, .	1.1	0
1561	Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status. Journal of Ovarian Research, 2023, 16, .	1.3	8
1562	STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer. , 2023, 11, e005627.		17
1563	Cancer Therapyâ€“Related Hypertension: A Scientific Statement From the American Heart Association. Hypertension, 2023, 80, .	1.3	27
1564	The role of switch maintenance therapy in urothelial cancers. Therapeutic Advances in Urology, 2023, 15, 175628722211477.	0.9	2

#	Article	IF	Citations
1565	Real-World Efficacy and Safety of PARP Inhibitors in Recurrent Ovarian Cancer Patients With Somatic BRCA and Other Homologous Recombination Gene Mutations. Annals of Pharmacotherapy, 0, , 106002802211491.	0.9	0
1566	Prognostic relevance of HRDness gene expression signature in ovarian high-grade serous carcinoma; JGOG3025-TR2 study. British Journal of Cancer, 2023, 128, 1095-1104.	2.9	5
1567	Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM society. Tumori, 2023, 109, 490-495.	0.6	1
1568	Efficacy of chemotherapy according toBRCAstatus in patients with high-grade serous ovarian carcinoma at first platinum-sensitive relapse. International Journal of Gynecological Cancer, 2023, 33, 577-584.	1.2	0
1569	Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China. Frontiers in Pharmacology, 0, 13, .	1.6	5
1571	Multi-layered chromatin proteomics identifies cell vulnerabilities in DNA repair. Nucleic Acids Research, 2023, 51, 687-711.	6.5	4
1572	Systemic treatments for breast cancer brain metastasis. Frontiers in Oncology, 0, 12, .	1.3	0
1573	CD8Î±+â€‰dendritic cells potentiate antitumor and immune activities against murine ovarian cancers. Scientific Reports, 2023, 13, .	1.6	1
1574	Real-world applications of PARPi maintenance therapy for recurrent ovarian cancer: A single-center study in China. Gynecologic Oncology, 2023, 170, 25-31.	0.6	3
1575	Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme. European Journal of Cancer, 2023, 182, 3-14.	1.3	3
1576	Residual Disease Threshold After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 1: A Systematic Review and Network Meta-Analysis. American Journal of Therapeutics, 2023, 30, e36-e55.	0.5	4
1577	Ovarian Cancer in a Northern Italian Province and the Multidisciplinary Team. Cancers, 2023, 15, 299.	1.7	7
1579	Real-World Data on Olaparib in Relapsed BRCA-mutated Ovarian Cancer: A Multicenter GINECO RETROLA Cohort Study. Anticancer Research, 2023, 43, 653-662.	0.5	1
1580	PARP inhibitors: risk factors for toxicity and matching patients to the proper poly (ADP-ribose) polymerase inhibitor (PARPi) therapy. International Journal of Gynecological Cancer, 2023, 33, 812-822.	1.2	1
1581	Is Reflex Germline BRCA1/2 Testing Necessary in Women Diagnosed with Non-Mucinous High-Grade Epithelial Ovarian Cancer Aged 80 Years or Older?. Cancers, 2023, 15, 730.	1.7	1
1582	Incidence and risk of hypertension associated with PARP inhibitors in cancer patients: a systematic review and meta-analysis. BMC Cancer, 2023, 23, .	1.1	2
1583	Validation of multi-gene panel next-generation sequencing for the detection of BRCA mutation in formalin-fixed, paraffin-embedded epithelial ovarian cancer tissues. Taiwanese Journal of Obstetrics and Gynecology, 2023, 62, 66-70.	0.5	5
1584	Current status and future promise of next-generation poly (ADP-Ribose) polymerase 1-selective inhibitor AZD5305. Frontiers in Pharmacology, 0, 13, .	1.6	4

#	Article	IF	Citations
1585	Genetics, Genomics and Emerging Molecular Therapies of Pancreatic Cancer. Cancers, 2023, 15, 779.	1.7	4
1586	Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial. JCO Precision Oncology, 2023, , .	1.5	13
1587	Exploration of chemotherapy-free regimen after multi-line chemotherapy-induced renal impairment in recurrent ovarian cancer: Case report and literature review. Frontiers in Oncology, 0, 12, .	1.3	1
1588	Myeloid neoplasms post PARP inhibitors for ovarian cancer. International Journal of Gynecological Cancer, 2023, 33, 598-606.	1.2	5
1589	Homologous Recombination Deficiency in Ovarian Cancer: from the Biological Rationale to Current Diagnostic Approaches. Journal of Personalized Medicine, 2023, 13, 284.	1.1	5
1590	Safety and management of niraparib monotherapy in ovarian cancer clinical trials. International Journal of Gynecological Cancer, 2023, 33, 971-981.	1.2	4
1591	The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo. Gynecologic Oncology, 2023, 170, 172-178.	0.6	0
1592	3D-QSAR, molecular docking, and molecular dynamics analysis of dihydrodiazaindolone derivatives as PARP-1 inhibitors. Journal of Molecular Modeling, 2023, 29, .	0.8	2
1593	Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinoma. Translational Oncology, 2023, 31, 101638.	1.7	0
1594	The Role of PARP Inhibitors in the Treatment of Advanced Epithelial Ovarian Carcinoma. , 2022, , .		0
1595	Fallopian Tube Carcinoma. , 2022, , 357-361.		0
1596	Epithelial Ovarian Cancer. , 2022, , 291-323.		1
1597	The economic value of knowing BRCA status: BRCA testing for optimizing treatment in recurrent epithelial ovarian cancer. Expert Review of Pharmacoeconomics and Outcomes Research, 2023, 23, 317-325.	0.7	0
1598	Efficacy and safety of PARP inhibitors for maintenance treatment of ovarian cancer, regardless of BRCA or HRD status: a comprehensive updated meta-analysis. Journal of Obstetrics and Gynaecology, 2023, 43, .	0.4	4
1599	HÃmatologische Neoplasien und solide Tumore. , 2022, , 85-151.		0
1600	A Review of Labeling Based on Patient-Reported Outcome Endpoints for New Oncology Drugs Approved by the European Medicines Agency (2017-2021). Value in Health, 2023, , .	0.1	2
1601	Homologous recombination inquiry through ovarian malignancy investigations: <scp>JGOG3025</scp> Study. Cancer Science, 2023, 114, 2515-2523.	1.7	3
1602	BRCA1/2 Pathogenic Variants Are Not Common in Merkel Cell Carcinoma: Comprehensive Molecular Study of 30 Cases and Meta-Analysis of the Literature. Journal of Investigative Dermatology, 2023, 143, 1178-1186.	0.3	1

#	Article	IF	Citations
1603	Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study. Cancers, 2023, 15, 1032.	1.7	1
1604	Survival outcomes in patients withBRCAmutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors. International Journal of Gynecological Cancer, 2023, 33, 922-928.	1.2	2
1605	Established and Emerging Cancer Therapies and Cardiovascular System: Focus on Hypertensionâ€"Mechanisms and Mitigation. Hypertension, 2023, 80, 685-710.	1.3	7
1606	Homologous repair deficiency-associated genes in invasive breast cancer revealed by WGCNA co-expression network analysis and genetic perturbation similarity analysis. Cell Cycle, 2023, 22, 1077-1100.	1.3	2
1607	The role of urine and serum biomarkers in the early detection of ovarian epithelial tumours. Journal of Obstetrics and Gynaecology, 2022, 42, 3441-3449.	0.4	3
1608	Prognostic value and adverse events of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in primary advanced and platinum-sensitive recurrent epithelial ovarian cancer: a systematic review and meta-analysis. International Journal of Hyperthermia, 2023, 40, .	1.1	1
1609	Unravelling homologous recombination repair deficiency and therapeutic opportunities in soft tissue and bone sarcoma. EMBO Molecular Medicine, 2023, 15, .	3.3	5
1610	Patient Assessment and Therapy Planning Based on Homologous Recombination Repair Deficiency. Genomics, Proteomics and Bioinformatics, 2023, , .	3.0	2
1611	Current Evidence-Based Systemic Therapy for Advanced and Recurrent Endometrial Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2023, 21, 217-226.	2.3	9
1612	Rucaparib or Physicianâ€™s Choice in Metastatic Prostate Cancer. New England Journal of Medicine, 2023, 388, 719-732.	13.9	104
1613	Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial. Clinical Cancer Research, 2023, 29, 2602-2611.	3.2	4
1614	Venadaparib Is a Novel and Selective PARP Inhibitor with Improved Physicochemical Properties, Efficacy, and Safety. Molecular Cancer Therapeutics, 2023, 22, 333-342.	1.9	2
1615	Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes. Clinical Cancer Research, 2023, 29, 3110-3123.	3.2	6
1616	Amplified therapeutic targets in high-grade serous ovarian carcinoma â€“ a review of the literature with quantitative appraisal. Cancer Gene Therapy, 2023, 30, 955-963.	2.2	1
1617	PARP inhibitor-related haemorrhages: What does the real-world study say?. Frontiers in Oncology, 0, 13, .	1.3	2
1619	Molecular typing guiding treatment and prognosis of endometrial cancer. Gynecology and Obstetrics Clinical Medicine, 2023, 3, 7-17.	0.2	1
1620	Major adverse cardiac events and cardiovascular toxicity with PARP inhibitors-based therapy for solid tumors: a systematic review and safety meta-analysis. ESMO Open, 2023, 8, 101154.	2.0	2
1621	Personalized Systemic Therapies in Hereditary Cancer Syndromes. Genes, 2023, 14, 684.	1.0	4

#	Article	IF	Citations
1622	Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer: lessons learned and future directions. International Journal of Gynecological Cancer, 2023, 33, 431-443.	1.2	11
1623	Overcoming PARP inhibitor resistance in ovarian cancer. International Journal of Gynecological Cancer, 2023, 33, 364-376.	1.2	4
1624	Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival. Journal of Clinical Oncology, 2023, 41, 2706-2712.	0.8	22
1625	Targeting the BRCA1/2 deficient cancer with PARP inhibitors: Clinical outcomes and mechanistic insights. Frontiers in Cell and Developmental Biology, 0, 11, .	1.8	16
1626	Targeted therapy and immunotherapy: Diamonds in the rough in the treatment of epithelial ovarian cancer. Frontiers in Pharmacology, 0, 14, .	1.6	4
1627	Mechanism of PARP inhibitor resistance and potential overcoming strategies. Genes and Diseases, 2024, 11, 306-320.	1.5	7
1628	Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma. Journal of Ovarian Research, 2023, 16, .	1.3	2
1629	Overall survival after PARP maintenance treatment in platinum-sensitive relapsed ovarian cancer: opposing views of the US Food and Drug Administration and European Medicines Agency. International Journal of Gynecological Cancer, 0, , ijgc-2023-004478.	1.2	1
1630	Realâ€world outcomes of niraparib treatment in patients with ovarian cancer: a multicenter nonâ€interventional study in China. Cancer Communications, 0, , .	3.7	1
1631	Controversies in the treatment of advanced ovarian cancer in the PARP inhibitors era: a Delphi consensus. Journal of Gynecologic Oncology, 0, 34, .	1.0	0
1632	The Current Status of DNA-Repair-Directed Precision Oncology Strategies in Epithelial Ovarian Cancers. International Journal of Molecular Sciences, 2023, 24, 7293.	1.8	2
1633	Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOTâ€OV26/GOGâ€3012 trial. Cancer, 2023, 129, 1846-1855.	2.0	2
1634	Investigation of PARP Inhibitor Resistance Based on Serially Collected Circulating Tumor DNA in Patients With BRCA-Mutated Ovarian Cancer. Clinical Cancer Research, 2023, 29, 2725-2734.	3.2	2
1636	Kidney function in patients with ovarian cancer treated with poly (ADP-ribose) polymerase (PARP) inhibitors. Journal of the National Cancer Institute, 2023, 115, 831-837.	3.0	2
1637	PARP Inhibitors in Breast and Ovarian Cancer. Cancers, 2023, 15, 2357.	1.7	9
1638	Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study. International Journal of Gynecological Cancer, 2023, 33, 1253-1259.	1.2	2
1639	Impact of Age on Poly(ADP-Ribose) Polymerase Inhibitor (PARPi)-Induced Lymphopenia: A Scoping Review of the Literature and Internal Analysis of a Retrospective Database. Drugs and Aging, 2023, 40, 397-405.	1.3	1
1640	Targeted therapy. , 2023, , 205-411.		0

#	Article	IF	Citations
1641	An attempt to establish real-world databases of poly(ADP-ribose) polymerase inhibitors for advanced or recurrent epithelial ovarian cancer: the Japanese Gynecologic Oncology Group. Journal of Gynecologic Oncology, 2023, 34, .	1.0	0
1694	Managing Adverse Effects of Novel Therapeutic Agents in Gynecologic Malignancies. SN Comprehensive Clinical Medicine, 2023, 5, .	0.3	0
1702	A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-â^†11q splice variant. Oncogene, 0, , .	2.6	1
1712	Exploiting a living biobank to delineate mechanisms underlying disease-specific chromosome instability. Chromosome Research, 2023, 31, .	1.0	1
1721	A new wave of innovations within the DNA damage response. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	6
1722	Molecular Characterization of Single Circulating Tumor Cells in Breast and Ovarian Cancer. Current Cancer Research, 2023, , 327-358.	0.2	0
1725	Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options. Drugs, 2023, 83, 1365-1385.	4.9	0
1726	Heterogeneity and treatment landscape of ovarian carcinoma. Nature Reviews Clinical Oncology, 2023, 20, 820-842.	12.5	3
1727	Indazole as a privileged scaffold in drug discovery. , 2023, , 199-226.		0
1733	Molecular tumour boards â€" current and future considerations for precision oncology. Nature Reviews Clinical Oncology, 2023, 20, 843-863.	12.5	6
1759	Recurrent Ovarian Cancer. , 2023, , 53-63.		0
1763	Onco-Hypertension: Anticancer Therapy-Associated Hypertension. , 2024, , 456-465.		0
1780	Clinical Application of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Ovarian Cancer. Cancer Treatment and Research, 2023, , 71-89.	0.2	0
1781	Targeting Polymerase Theta (POLÎ¸) for Cancer Therapy. Cancer Treatment and Research, 2023, , 285-298.	0.2	0
1782	Shallow whole genome re-sequencing to precisely predict benefit from PARP inhibitor. Oncogene, 2023, 42, 3543-3544.	2.6	0
1786	Combining Poly (ADP-Ribose) Polymerase (PARP) Inhibitors with Chemotherapeutic Agents: Promise and Challenges. Cancer Treatment and Research, 2023, , 143-170.	0.2	0
1787	Mechanisms of PARP Inhibitor Resistance. Cancer Treatment and Research, 2023, , 25-42.	0.2	0
1788	Development of Homologous Recombination Functional Assays for Targeting the DDR. Cancer Treatment and Research, 2023, , 43-70.	0.2	0

#	Article	IF	Citations
1789	Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis. Targeted Oncology, 0, , .	1.7	1
1798	ROS, Redox Regulation, and Anticancer Therapy. , 2023, , 311-409.		0
1800	Mutual Feedback Between Gynecological HBOC Practice and Cancer Genomic Medicine. , 2023, , 47-56.		0
1801	Handling Germline Findings in Ovarian Cancer Cases. , 2023, , 129-141.		0
1814	New Concepts in Cardio-Oncology. Cancer Treatment and Research, 2023, , 303-341.	0.2	0
1842	HÃmatologische Neoplasien und solide Tumore. , 2023, , 99-174.		0
1843	Advances in the Medical Management of Ovarian Cancer. , 2023, , 345-396.		0
1848	Hypertension in Cancer Patients. Updates in Hypertension and Cardiovascular Protection, 2023, , 509-525.	0.1	0